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“Biologists are observing year by year and 
sometimes even day by day or hour by hour 
details of life’s unrolling and opening, right 
now.”  
Jonathan Weiner  
The Beak of the Finch, 1994 
 
 
 
“… the more you look the more you see.”  
Peter Grant 
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Summary 
The variability of the environment is a challenge for the flexibility of organisms. Temporal 
variation generates interesting optimization conflicts for evolution, which I investigated 
in this doctoral thesis for the example of Pseudomonas aeruginosa and the sequential 
treatment with antibiotics. This bacterium has remarkable metabolic and genetic 
versatility. P. aeruginosa expresses a range of efflux pumps for cell detoxification. 
Increasingly, this characteristic is transforming into a medical threat because it can 
convey antibiotic resistance. The spread of antibiotic resistance is a growing global 
challenge. The investigations of this thesis, may contribute to the design of new treatment 
strategies that inhibit the emergence of resistance. To achieve this aim, we integrated 
three principles from evolutionary ecology into drug treatments and tested them for their 
efficacy; we tested genetic conflicts, physiological conflicts, and environmental 
stochasticity for their ability to delay resistance evolution. 
The emergence of resistance can be countered with sequential treatments. Resistance 
mutations frequently cause hypersensitivity to other antibiotics. The targeted change of 
antibiotics may thus maintain treatment efficacy in spite of bacterial adaptation.  I 
measured the evolutionary stability of these genetic conflicts, and found that their 
stability depended on treatment order. 
The physiological response to antibiotic stress can temporarily increase the sensitivity 
against other antibiotics. The integration of such antibiotic hysteresis into sequential 
treatments could inhibit resistance evolution. Selection by hysteresis shifted adaptive 
priority towards physiological response optimization. My investigations indicate a new 
treatment strategy that is potentially promising, because it increases the immediate 
bactericidal effect and prolongs effective treatment by delaying resistance emergence.   
Unpredictable environmental variation can complicate evolutionary adaptation by 
limiting the spectrum of potential adaptive strategies. A decelerating effect was not 
generally observed in my experiments, but the strongest deceleration of adaptive 
response occurred in sequential treatments with irregular order of antibiotics. A 
mathematical model was developed based on these results. The model explained the 
observed variation between different environmental sequences and accurately predicted 
the rate of evolutionary adaptive response.   
Altogether my experiments emphasize the importance of cellular physiological balance 
for the evolution of bacteria. My findings may contribute to the development of novel 
treatment concepts that inhibit the emergence of antibiotic resistance.  
 
 
< Picture credit opening page:         Christian Urban, CAU Kiel, 2015 
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Deutsche Zusammenfassung 
Die Variabilität der Umwelt ist eine große Herausforderung für die Flexibilität der 
Lebewesen. Über lange Zeiträume entstehen interessante Optimierungskonflikte für die 
Evolution. Diese habe ich im Rahmen dieser Doktorarbeit beispielhaft am Bakterium 
Pseudomonas aeruginosa und mit sequentieller Antibiotikabehandlung untersucht. Die 
Besonderheit dieses Bakteriums ist seine metabolische und genetische Vielseitigkeit. P. 
aeruginosa besitzt zahlreiche Pumpsysteme zur Entgiftung der Zelle. Zunehmend wird 
diese Eigenschaft zu einer medizinischen Bedrohung, da durch sie Antibiotikaresistenz 
vermittelt werden kann. Die Verbreitung von Antibiotikaresistenzen ist eine dringliche 
globale Herausforderung. Die Untersuchungen dieser Dissertation tragen dazu bei, neue 
Behandlungsmethoden zu entwickeln, mit denen die Entstehung weiterer Resistenzen 
gehemmt werden kann. Hierzu wurden Prinzipien der Evolutionsökologie in 
Antibiotikabehandlungen integriert und auf ihre Wirksamkeit erprobt: Genetische 
Konflikte, physiologische Konflikte und Stochastizität. 
Der Entstehung von Antibiotikaresistenz kann durch sequentielle Behandlung begegnet 
werden. Viele Resistenzmutationen bewirken Hypersensitivität gegenüber anderen 
Antibiotika. Auf Grund dieser Tatsache kann durch einen gezielten Wechsel, der 
Antibiotika, die Wirksamkeit der Behandlung garantiert werden. Im Rahmen meiner 
Untersuchungen habe ich die evolutionäre Stabilität dieser genetischen Konflikte 
gemessen und dabei festgestellt, dass eine Abhängigkeit zur Behandlungsreihenfolge 
besteht. 
Die physiologische Einstellung auf Antibiotikastress kann die Empfindlichkeit gegenüber 
einem anderen Antibiotikum zeitweise erhöhen. Durch den Einbau solcher 
physiologischen Konflikte in Behandlungsprotokolle, das heißt durch die Berück-
sichtigung von Antibiotikahysterese, ließ sich die Resistenzentstehung hemmen, da sich 
die Priorität der evolutionären Anpassung zugunsten physiologischer Optimierung 
verschob. Mit diesen Untersuchungen habe ich einen neuen Behandlungsansatz 
aufgezeigt, der den unmittelbaren Behandlungserfolg steigern und die langfristige 
Wirksamkeit gewährleisten könnte. 
Unvorhersehbare Umweltvariationen erschweren die evolutionäre Anpassung, da diese 
das Anpassungsspektrum einschränken. Eine Hemmwirkung von Umweltstochastizität 
auf Resistenzevolution lag in meinen Untersuchungen nicht im Allgemeinen vor, aber die 
wirksamsten Behandlungssequenzen hatten unregelmäßige Abfolge. Darauf aufbauend 
wurde ein mathematisches Modell entwickelt, mit dem die Wirksamkeit verschiedenster 
Behandlungsabfolgen erklärt und vorhergesagt werden konnte. 
Insgesamt bestätigen meine Experimente die Wichtigkeit des physiologischen 
Gleichgewichts der Zelle für die Evolution von Bakterien. Auf Grundlage meiner 
Untersuchungen können neue Behandlungskonzepte abgeleitet werden, die die 
Entstehung von Antibiotikaresistenz hemmen.
10 
 
Introduction 
Natural environments are highly dynamic; they are ever-changing due to seasonal and circadian 
rhythms, day-to-day fluctuations and micro-scale gradients. The resulting environmental 
contrasts affect the fitness of organisms and thereby exert selection. Frequent disturbances 
interfere with offspring production, either directly through temporary resource availability, or 
indirectly by increasing resource demand through stress. Less frequent disturbances that span 
several generations, occasionally invert the direction of selection, potentially complicating 
adaptation. Thus, species face the challenge of keeping tune with their dynamic surroundings, for 
which some have evolved fascinatingly complex mechanisms. This dissertation presents the 
results of my investigations on how different aspects of temporal variation affect the evolutionary 
emergence of novel traits in the bacterium Pseudomonas aeruginosa. I was particularly interested 
in the importance of temporal regularity, and phenotypic memory for the rate and scope of 
adaptation, which I investigated with evolution experiments and artificial selection by sequential 
exposure to antibiotics. The approach was complemented by physiological characterization, 
genetic analyses, statistics, and mathematical modeling. 
In this first chapter, I provide background on fluctuating environments. I discuss the physiological 
responses of bacteria to sudden environmental contrasts and outline how recurrent change can 
be a potent selective force that drives, yet also complicates, evolutionary adaptation. For 
feasibility, the discussion is restricted to prokaryotes, especially bacteria. Nevertheless, many 
aspects are relevant for eukaryotes as well. I conclude this chapter by introducing the model 
system and indicating how my work may contribute to the design of evolution-robust antibiotic 
therapy. The potential applications of my findings are discussed in more detail in a separate 
chapter, at the end of the dissertation.  
 
Temporal variation 
Most microbial environments fluctuate on a daily basis. Because the fluctuations are often caused 
by the movements of the earth or moon, it is difficult to find a microbial habitat devoid of temporal 
structure. Perhaps the closest approximations are permafrost soils. The majority of microbial 
habitats are, however, characterized by frequent fluctuations. For example, tidal rhythms shift 
shoreline ecosystems between aquatic and terrestrial states, twice daily. Bacteria in mangrove 
sediments are thus exposed to rapid drops and increases of salinity (Barr et al., 2010). Further 
temporal contrasts arise from spatial variation and micro-scale gradients, which bacteria 
encounter during movement and translocation. Rapid transitions between environmental 
contrasts, thus, occur for gut symbionts that passage through a specific nutrient sequence along 
our digestive tract (Savageau, 1998), and for pathogens that switch between external and within-
host environments (Schild et al., 2007). In summary, temporal variation is a pervasive feature of 
bacterial habitats, and a systematic understanding of the ensuing ecological challenges is key to 
the understanding of bacterial evolution.  
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Table 1. Fine-scale temporal structure of natural environments of bacteria. 
Environment Fluctuating 
parameter 
Trigger Scale† Predictability¶ Reference 
Rainforest soil oxygen rain between days U Silver et al., 
1999 
Productive lake pH rain between days 
and diurnal 
U Maberly, 1996 
Ocean floor 
sediment 
marine snow light between days 
and diurnal 
U, structure 
within days 
Lampitt et al., 
1993 
Waste water antibiotics human 
activity 
diurnal mostly P Coutu et al., 
2013 
Mangrove 
sediment 
salinity tides tidal P Barr et al., 
2010 
Wetland plant 
rhizophere 
redox light diurnal P Nikolausz et 
al., 2008 
Seagras 
rhizosphere 
redox: iron 
(II), sulfide 
light diurnal P Pagès et al., 
2012 
Salt marsh redox: iron 
(II), sulfide 
light diurnal P Luther & 
Church, 1988 
Hypersaline 
microbial mat 
redox: iron 
(II), sulfide 
light diurnal P Pages et al., 
2014 
Hypersaline lake 
cyanobacterial 
mat  
oxygen, 
redox, H2S 
light diurnal P Jørgensen et 
al., 1979 
Hot spring 
microbial mat 
oxygen light diurnal P Steunou et al., 
2008 
Hyperventilating 
shallow estuary 
oxygen light diurnal P Beck & 
Bruland, 2000 
Streambed during 
algal bloom 
acetate light diurnal P Kaplan & Bott, 
1989 
Cobble-bed river 
close to mine 
dissolved 
metal ions, 
nitrate 
microbial 
respiration 
diurnal P Brick & Moore, 
1996 
Polluted high 
altitude lake 
mercury unclear diurnal P Alanoca et al., 
2016 
Host colonization oxygen, 
temperature 
spatial 
variation 
sudden P Schild et al., 
2007; 
Tagkopoulos et 
al., 2008 
Mammalian gut nutrients 
(sugars) 
digestion hours P Savageau, 
1998 
† Seasonal variation excluded. ¶ Temporal regularity of fluctuations: P, predictable; U, 
unpredictable. 
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An important parameter governing adaptation to fluctuating parameters may be their 
predictability (Kashtan, Noor, & Alon, 2007; Mitchell & Pilpel, 2011; Botero et al., 2015), because 
it provides opportunity for the evolution of pre-adaptation. Predictable periodic fluctuations are 
often triggered by oscillating external factors, most notably light. The light-dependent metabolic 
activity of plants, animals, and bacteria generates diurnal structure in environments ranging from 
the deep-sea to rainforest soil (Table 1). Diurnal variation can occur in any abiotic parameter 
relevant to the ecology of organisms, including resource supply, toxicity, pH, and redox levels 
(Table 1). Some diurnal variations are caused by the activity patterns of humans; drug 
concentrations in waste water have a morning peak (and somewhat smaller evening peak) 
corresponding to the times of typical toilet use (Coutu et al., 2013). The progression of many 
diurnal fluctuations can be regarded as a fixed sequence of events. Any single event can potentially 
serve as a cue for organisms to prepare for following events. Fixed sequential orders are indeed 
exploited by gut bacteria. Wildtype Escherichia coli show lactose-triggered upregulation of 
maltose genes – in anticipation of maltose rich conditions encountered three hours later 
(Savageau, 1998; Mitchell et al., 2009). Similarly, E. coli prepare for anoxia following rapid 
temperature increases (Tagkopoulos, Liu, & Tavazoie, 2008), a predictive behavior that reflects 
their natural coincidence when entering the gut. Anticipatory gene regulation is common in 
pathogenic bacteria (Brunke & Hube, 2014) yet the costs associated to preparation, restrict its 
evolution to highly predictable environments (Mitchell & Pilpel, 2011).  
The timing of other environmental contrasts is stochastic and thereby devoid of reliable cues. 
Stochastic fluctuations can be a consequence of unpredictable precipitation (Table 1), which, for 
example, causes fluctuations of soil oxygen levels by several orders of magnitude (Silver, Lugo, & 
Keller, 1999). In other cases the occurrence of fluctuations is unpredictable, but their progression 
is structured. There is unpredictable day-to-day variation in the amount of marine snow in the 
deep sea, yet morning supply is larger than evening supply (Lampitt, Hillier, & Challenor, 1993). 
Although unpredictable environmental variation is likely important in the natural ecology of 
bacteria, its effect on local adaptation is unclear. 
 
Physiological response 
Environmental contrasts require specific changes in cellular physiology. Bacteria cannot express 
their whole genome simultaneously, because many functions are biochemically incompatible, and 
gene expression is associated with fitness costs. Instead, bacteria selectively express parts of their 
functional repertoire in response to the current ecological needs. Upon encountering sudden 
change in environment, they typically reduce growth and enter a temporary lag phase during 
which there is no increase in cell number (Monod, 1949). The duration of lag phase, i.e. the time 
for the first generation in the new environment, depends on the disparity of the environmental 
contrast. For example, growth lagged for 2h after a switch from glucose-depleted media to fresh 
glucose media, and 8h when cells were switched to arabinose instead (Madar et al., 2013). The 
seeming inertia is deceiving, as the lag phase is a first and specific step of bacterial response. A 
switch of carbon sources in the example (glucose -> arabinose) was followed by an immediate 
exponential increase in the expression of arabinose utilization genes (Madar et al., 2013), 
initiating the acclimatization of bacterial physiology to the new conditions. The subsequent 
acceleration of growth is mediated by changes in the amount of active proteins, which is highly 
regulated. Crucial processes are the production of new proteins, rapid post-transcriptional 
regulation via mRNA or protein modification, proteolysis and the dilution of old proteins through 
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cell division (Alon, 2006). Many bacterial proteins are stable i.e. that ½ of their activity is available 
to the next generation. Stable proteins thereby provide a phenotype memory of past environments, 
which has interesting consequences for rapidly fluctuating environments.  
Memory in bacteria 
A detailed investigation of cellular memory was performed by Lambert and Kussel for the model-
system of lactose utilization in E. coli (Jacob & Monod, 1961). Lactose utilization requires 
expression of the lac operon (yielding LacZ, LacY and LacA), which is repressed by LacI in the 
absence of lactose (Madigan et al., 2014). Addition of lactose relieves repression via the isomer 
allolactose that sequesters LacI. The formed lactose utilization proteins are very stable with 
degradation rates < 0.6% h-1 (Mandelstam, 1958; McKenna et al., 1991) so that their 
concentrations decay mainly by dilution from cell division. Lambert and Kussel induced 
expression of the lac operon in E. coli by growing cells with lactose in a microfluidic device for 4h 
(Lambert & Kussell, 2014). Thereafter, cells were shifted to glucose for varying amounts of time, 
before being shifted back to lactose (Figure 1A). Glucose exposure stops expression of the lac 
operon via cAMP (catabolite repression). Non-induced cells had a lag-time of 38 min, but pre-
induced cells continued growth with shorter interruptions (Figure 1B). No lag occurred for 
intervals ≤ 4h and significantly shorter lags were measured for intervals up to 12h (Figure 1B), 
corresponding to 10-12 generations (Lambert & Kussell, 2014). This example is an impressive 
demonstration of phenotype memory that is mediated by stable proteins and can prevent growth 
delays in fluctuating environments. 
 
 
Figure 1. Cellular memory in the lactose response of E. coli. (A) Schematic of experiment to measure 
cellular memory. Two lactose exposures are interrupted by the presence of glucose. (B) Protein stability 
accelerates response upon second encounter of lactose. (C) Hysteretic response continuation in the absence 
of lactose. Modified from Lambert & Kussell, 2014. 
 
In the same study system, a second type a memory occurs on finer time scales, i.e. within one 
generation time: response memory, which refers to the hysteretic continuation of response after 
removal of the stimulus (Lambert & Kussell, 2014). In this example, LacY concentrations continue 
to increase after a switch to glucose. Decay of protein levels starts 40 -50 min after removal of the 
inducer (Figure 1C). The overshoot is explained primarily by residual intracellular inducer 
14 
 
(explains 50% of overshoot), but also by binding dynamics of LacI and mRNA stability (Lambert 
& Kussell, 2014). Response memory protects cellular responses from transient loss of stimulus. 
In summary, bacteria physiologically respond to environmental contrasts and responses are 
stabilized within and between generations. The cellular memory can ensure steady growth in 
environments with fluctuating resource levels and may further have interesting consequences for 
the survival in stressful conditions (Lin & Kussell, 2016). 
Stress response 
Bacteria respond to stress by triggering one or multiple stress-response systems. There are 
general and specific stress response systems (Storz & Hengge, 2010). General stress response 
systems target the transcription of a large number of genes via transcription factors and thereby 
improve survival in many stressful conditions. In E. coli the general stress response is regulated 
by the alternative sigma factor RpoS (sigma 38), which controls the expression of ~ 500 genes 
(Battesti, Majdalani, & Gottesman, 2011). The expression of RpoS is induced by reduced growth 
as caused by nutrient limitation, but can also be triggered by rapid changes in acidity, osmolarity, 
and temperature (Storz & Hengge, 2010). There are a variety of specific stress response systems. 
E. coli, for example, has specific responses against heat shock (36 genes regulated by sigma factors 
RpoE and RpoH), oxidative stress (~30 genes regulated by activator OxyR), DNA damage (SOS 
response; ~20 genes regulated by repressor LexA), and several other stressors (Storz & Hengge, 
2010; Madigan et al., 2014). There is significant overlap among the targets of stress response 
systems and their induction signals. Consequently, alternative response systems compete for 
their activation upon encounter of stress. In E. coli, gradual increase of stress induces specific 
responses, but sudden stress induces general stress response via RpoS (Young, Locke, & Elowitz, 
2013). The specificity of the mounted response produces varying degrees of cross-stress 
protection in fluctuating environments.  
In many cases the regulatory overlap of response systems enhances cross-stress survival. For 
example, heat-shocked E. coli had 10-100x higher survival during subsequent acid stress (Wang 
& Doyle, 1998). Acid survival was likewise increased by previous short pulse of antibiotic 
treatment as provided by trimethoprim (Mitosch, Rieckh, & Bollenbach, 2017). Cross-stress 
protection can also be mediated by the expression of individual protein complexes. For example, 
low concentrations of specific antibiotics induce the expression of broad spectrum drug efflux-
pumps that transport a wide range of antibiotics and other toxic natural substances (Li, Elkins, & 
Zgurskaya, 2016). These examples show that pre-adaptation for future environmental stress can 
be provided by past stress response. 
Intriguingly there are opposite cases, where historic stress decreases survival in current stress, a 
phenomenon called cross-stress sensitivity. A well understood example is the NaCl-induced acid 
sensitivity of E. coli that is mediated by expression of the porin PhoE (Rowbury, Goodson, & 
Humphrey, 1994; Lazim, Humphrey, & Rowbury, 1996). Furthermore, there may be less specific 
cross-sensitivity interactions as caused by metabolic costs of response memory or even damage 
from previous stressors. There is comparatively little research on cross-sensitivity, possibly 
because its existence suggests the infrequency and thus ecological irrelevance of certain 
transitions in the natural bacterial habitats. 
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Adaptive response 
In addition to active physiological acclimatization, bacteria are also passively adapted to their 
dynamic environments by the process of natural selection, as originally described by Darwin and 
Wallace in their joint paper to the Linnean Society in 1858 (Darwin & Wallace, 1858). Due to 
errors during genome replication, partial genome duplications and lateral gene transfer, genomes 
are continuously changing (Knöppel, 2016). The genetic variation is linked to variation in fitness, 
the ability of organisms for translating resources to reproduction. Natural selection optimizes 
fitness across generations through an ecological sampling process, thereby gradually tuning 
organisms to their environment (Via & Lande, 1985). Although mechanistically simple, adaptation 
is a complex process in nature.  
Temporal variation broadly selects for reproductive success in the various temporal states of the 
environment, and the transitions between them. Fitness improvements to the selective 
components need not be genetically correlated, such that distinct sets of mutations are 
consecutively selected (e.g. Leroi, Lenski, & Bennett, 1994; Jasmin & Kassen, 2007; Kim, 
Lieberman, & Kishony, 2014). The individually selected mutations can have pleiotropic effects, i.e. 
that they affect the expression of multiple traits. As a consequence of protein interactions and 
resource limitations, mutations are nearly always pleiotropic (Wright, 1968; Kacser & Burns, 
1981), and a good example for pleiotropy is the evolution of antibiotic resistance in the absence 
of antibiotics (Rodríguez-Verdugo, Gaut, & Tenaillon, 2013; Katz & Hershberg, 2013; Knöppel, 
Näsvall, & Andersson, 2017). Pleiotropy can generally either cause positive, or negative fitness 
effects in future environmental states. An example of negative, antagonistic pleiotropy is the 
generally reduced physiological growth rate of antibiotic resistant bacteria (Andersson & Levin, 
1999). In the absence of antibiotic, non-resistant cells outgrow the resistant ones, which can limit 
the maintenance of resistance after end of treatment (Andersson & Hughes, 2010). Similarly, more 
frequent environmental fluctuation can interfere with selective sweeps, increase clonal 
interference, and thereby altogether delay evolutionary dynamics (Harrison et al., 2013). 
Adaptive response may further be delayed by competing selective pressures, arising from the 
transitions between environmental states. When transitions entail cross-stress sensitivity, 
frequent changes may select for optimized shifting. The ensuing competing adaptive priorities are 
difficult to observe in the wild, but they can be studied efficiently in laboratory. 
Evolution experiments 
The short generation time and small size of microorganisms enable experimental studies of 
evolutionary adaptation, on feasible time scales and in controlled laboratory settings. Evolution 
experiments are easily set up with bacteria. The classic protocol is to grow batch cultures, apply 
selection during incubation, and serially propagate populations by dilution into fresh media 
(Kassen, 2014). Samples of the evolving population can be regularly preserved by freezing, to 
produce a “fossil record” for subsequent characterization. Through measurements of fitness one 
can infer the rate of adaptive response to selection, as provided by the experimental procedure. 
In contrast to evolution in the wild, this setup allows for replication and thereby enables the 
statistical evaluation of pre-formulated hypotheses regarding the dynamics of adaptation 
(Garland & Rose, 2009). These experiments can test evolutionary theory by asking fundamental 
questions, such as the following: Does fitness increase indefinitely? Is adaption gradual or saltatory? 
Do new functions evolve from random DNA sequences? Does temporal variation affect the rate of 
adaptation? 
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The precise setup of evolutionary experiments is tailored to the questions they address, as 
illustrated by three examples that take different approaches: 
i) Parallel adaptation experiments test whether or not a difference in selection 
pressure causes distinct adaptive responses in evolving treatment groups. This 
approach is focused on contemporary comparisons. For example, Lindsey et al. 
investigated how the rate of environmental deterioration affects the dynamics of 
evolutionary rescue by experimentally treating replicate populations of E. coli with 
increasing concentrations of antibiotic (Lindsey et al., 2013). Treatment groups 
differed by the rates of concentration increase. Fast increases produced higher 
extinction and adapted populations had lower genetic diversity, demonstrating 
that evolution is contingent on the rate of environmental change (Lindsey et al., 
2013).  
 
ii) Comparative evolution experiments test the impact of genetic background on the 
adaptive response to identical selection. For example, Vogwill et al. measured 
parallelism of antibiotic resistance evolution in the Pseudomonas clade by 
subjecting eight species of Pseudomonas to selection with rifampin (Vogwill et al., 
2014). They discovered that adaptation had pronounced parallelism on the 
nucleotide level, but that pleiotropic fitness-costs were significantly different 
between species (Vogwill et al., 2014). 
 
iii) Single group evolution experiments ask fundamental questions concerning 
adaptation by longitudinal comparisons to the ancestor. The prime example is the 
long-term evolution experiment that was started by Lenski in 1988 and has lasted 
> 60 000 bacterial generations (Good et al., 2017). The experiment consists of E. 
coli grown in media containing glucose and citrate. The ancestral strain from 1988 
cannot utilize citrate. This experiment has demonstrated that the evolution of key 
innovations – in this case citrate utilization – requires previous potentiating 
mutations (Blount, Borland, & Lenski, 2008; Blount et al., 2012), that adaptive 
specialization frequently involves fitness trade-offs (Travisano & Lenski, 1996), 
and that the overall adaptive dynamics are characterized by ever-smaller 
increases in fitness, although they do not plateau (Wiser, Ribeck, & Lenski, 2013).  
Experimental evolution contributes to a mechanistic understanding of evolution, as it often 
focusses on dissecting the underlying constraints that ultimately determine the likely range of 
evolutionary trajectories.  
 
Adaptive strategies 
There are a variety of eco-evolutionary strategies for adaptation to fluctuating selection. In the 
discussion of potential adaptive responses, I will focus on the early steps of adaptation, as 
potentially observed in evolution experiments. Two contrasting main strategies are discussed the 
most by the literature, the emergence of generalist or specialist genotypes, yet there are further 
adaptive strategies.  
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Generalists and specialists 
A generalist is defined by the expression of one or several traits that increase fitness to multiple 
temporal states of the environment. The idealized case has equal fitness on all temporal states, 
which I call a balanced fitness array. A specialist is the opposite strategy, in that a specialist has 
an unbalanced fitness array being specifically adapted to a single or few temporal states. It is 
important to note that both definitions are relative to a specific environment; a generalist may be 
a specialist in other fluctuating environments.  
The evolution of generalists is a common adaptive response in rapid and regularly fluctuating 
environments (Kassen, 2002). Generalists can emerge from single mutations that have positive 
pleiotropy, or by a combination of mutations. Generalists rapidly evolve in a wide range of 
fluctuating conditions, as illustrated by an experiment with P. fluorescens and selection for growth 
rate in environments alternating between poor and rich media (Buckling et al., 2007). The study 
investigated fitness changes during growth in alternating environments with different scales of 
temporal variation (intervals ranging from 7 to 350 generations), in comparison to control 
populations evolving in either of the media. Control populations only improved local fitness, and 
had up to 20% lower fitness in the other media (Buckling et al., 2007). Populations that cycled 
between media increased fitness in both conditions (Buckling et al., 2007), demonstrating the 
emergence of cost-free generalists, under a wide-range of temporal scales. There are many more, 
albeit less systematic, accounts for the rapid evolution of generalists in fluctuating environments 
(Leroi et al., 1994; Hughes, Cullum, & Bennett, 2007; Ketola et al., 2013; Schenk et al., 2015).  
The emergence of specialists is more characteristic for stable environments (Futuyma & Moreno, 
1988), yet they may also be selected in fluctuating environments that meet certain criteria. 
Temporal variation produces niche multiplicity and may thus contribute to the emergence and 
maintenance of biodiversity (Kassen, 2002), which implies the evolution of specialists due to 
Gause’s law; “Complete competitors cannot coexist” (Gause, 1934; Hardin, 1960). Multiplicity of 
adaptive peaks could be shown for E. coli in alternating resource environments, as reflected by 
increased divergence among replicates, compared to stable environments with either resource or 
their mixture (Cooper & Lenski, 2010). Yet evidence for the selection of specialists in response to 
fluctuating selection is rare, and has only been demonstrated for adaptation to targeted selective 
pressures, as provided by the alternation of the sugars mannose and xylose (Jasmin & Kassen, 
2007) or specific pairs of antibiotics (Yoshida et al., 2017). The mechanisms for the selection of 
single-sided adaptation are not entirely clear, but may result from evolutionary genetic 
constraints, for which there are indications in both cases.  
Reduced responsiveness 
Fluctuating environments can also select for altered regulation of cellular responses (i.e. change 
of phenotypic plasticity). For example, fluctuation may favor the change from inducible responses 
to their constitutive expression, such that cells effectively skip lag-time – they are pre-adapted 
(strictly speaking, pre-acclimated would be a better term). Such response was selected in E. coli, 
growing in alternating resource environments with glucose and lactose (Cooper & Lenski, 2010; 
Quan et al., 2012). Constitutive regulation evolved in all replicates (6/6), and had a total frequency 
of 99.7% among the isolated clones. Constitutive expression also evolved in some replicates, 
adapting in constant lactose or the mixed environment, yet to a significantly smaller degree (2 or 
3/6 replicates; <50% of isolated clones; (Quan et al., 2012). The parallel evolution of pre-
adaptation in this setting is likely a special case, because glucose protected from the potential 
metabolic burden of constitutive lacZYA expression – via catabolite repression.  
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Bet-hedging 
Unpredictably changing environments with strong selective pressures may favor the evolution of 
bet-hedging strategies. Bet-hedging refers to adaptive strategies that ensure the survival of 
populations, by the stochastic production of alternative phenotypes. Although, bet-hedging is a 
complex phenotype, it can evolve by few genetic changes, as demonstrated in an evolution 
experiment P. fluorescens (Beaumont et al., 2009). Alternating selection for capsulated and non-
capsulated cells, selected for novel bistability in the capsule pathway (Gallie et al., 2015); the 
evolved bet-hedging genotype stochastically produced both cell types, in sectored colonies 
(Beaumont et al., 2009). Bistability is common in bacteria; growing cultures naturally produce a 
fraction of dormant cells, due to stochastic levels of ppGpp (Maisonneuve, Castro-Camargo, & 
Gerdes, 2013). The dormant sub-population can ensure population survival in stressful 
environments, e.g. because non-growing cells survive antibiotic treatments that are lethal to 
active cells (Lee, Foley, & Epstein, 1944; Tuomanen et al., 1986). The persisters (Bigger, 1944) 
stochastically revert to normal growth (Balaban, 2004). The frequency of persister cells formation 
is genetically controlled (Moyed & Bertrand, 1983; Balaban, 2004), but has not been explored 
using evolutionary experiments. 
Elevated mutation 
A temporary solution to complex adaptive challenges is the elevation of mutation supply. Elevated 
mutation rates come at a large cost, because of the rapid accumulation of deleterious mutations. 
Accordingly, the adaptive benefits of hypermutation are temporary, and there is strong selection 
for mutation rates to decrease after successful adaptation, as captured by in vivo evolutionary 
experiments of E. coli in the mouse gut (Giraud et al., 2001). Interestingly, mutation rate is not 
equal across the genome, which may be the adaptive solution to this conundrum. There are hyper-
variable loci, e.g. long stretches of tandem repeats that are prone to frameshift mutations, as 
caused by slipped strand mispairing (Levinson & Gutman, 1987). It has been postulated that the 
variation in mutation rate is adaptive, because the mutation hotspots predominately occur in 
genes that interact with the environment in unpredictable ways (Moxon et al., 1994). These sites 
were called contingency loci (Moxon et al., 1994), due to their putative adaptive value in variable 
environments. A textbook example is the ahpC gene from the oxidative stress response of E. coli. 
AhpC contains 4 repeats of TCT in the wildtype (Ritz et al., 2001). Peroxidase function is frequently 
lost, due to the reversible addition of a 5th TCT repeat. The extra repeat is a gain-of function 
mutation that converts enzyme function from peroxidase to a disulfide reductase (Ritz et al., 
2001). A genetic switch reminiscent of a contingency locus, was experimentally selected in P. 
fluorescens by selection for alternating production of biofilm (Hammerschmidt et al., 2014). The 
most successful genotype had a mutS mutation that generally elevated mutation rate, yet as one 
of the genes controlling biofilm formation had a tract of 7 Gs in the active site, the mutS mutation 
actually converted that gene into a genetic switch. Reversible addition of a single G resulted in 
reliable phenotype switching (Hammerschmidt et al., 2014). 
Altogether, the evolution of generalists seems to be ultimate adaptive response to fluctuating 
selection. Specialists and other more complex strategies are only maintained under specific 
conditions. Their emergence and maintenance may, therefore, be indicative of stronger adaptive 
constraints that prevent the evolutionary modification of traits from reaching an adaptive 
optimum; they either slow the approach of the optimum, or shift adaptation away from the 
optimum (Hansen, 2015). Initially selected strategies may eventually be outcompeted by others, 
or even transform. For example, a specialist can turn into a generalist by additional mutation. 
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Finally, adaptation to fluctuating environments may proceed via unknown adaptive strategies, 
adding elements of suspense and surprise to every evolutionary experiment. 
 
Objectives 
In this thesis I experimentally study, how temporal variation affects the adaptive response of 
bacteria in a novel fluctuating environment. My general aim is to contribute to the understanding 
of adaptive constraints in changing environments. I approach this aim with laboratory evolution 
experiments that investigate the following specific aims: 
Influence of different fluctuation characteristics on adaptive dynamics 
We are only beginning to understand how different flavors of temporal variation affect 
evolutionary dynamics. With the approach of parallel evolution I investigate the 
quantitative impacts of temporal regularity, fluctuation interval, breadth of selective 
pressure, and fluctuation order on rates of adaptation.  
Evolutionary stability of adaptive constraints  
Antagonistic pleiotropy frequently emerges as a result of directional selection. Evolution 
in fluctuating environments may be limited by these genetic fitness trade-offs. This opens 
the question as for their stability, i.e. whether they preclude the reaching of an adaptive 
optimum, or whether populations can escape the constraint via alternative evolutionary 
trajectories. Using the approach of comparative evolution, I test the evolutionary stability 
of reciprocal genetic trade-offs. 
Importance of phenotypic memory  
The impact of bacterial phenotypic memory for fitness optimization in rapidly fluctuating 
environments has hardly been investigated. I hypothesize that phenotypic memory can 
facilitate, or constrain adaptation, by changing selection pressure at environmental 
transitions. Cross-stress protection may buffer the fitness effects of antagonistic 
pleiotropy. Cross-stress sensitivity may itself be a competing selective force. I investigate 
how changes in fluctuation frequency, and thus the occurrence of phenotypic memory, 
affect evolutionary adaptive dynamics.  
Application of findings to limit resistance evolution 
Evolution is not a historic account, but an active process that increasingly affects our 
society. The prime example is the spread of antibiotic resistance in response to the use of 
antibiotics. A key motivation for this thesis is to test, whether we can apply evolutionary 
principles to limit the emergence of antibiotic resistance. The model system is carefully 
selected to facilitate translation of findings to applications in antibiotic therapy. 
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Model system 
The model system for my evolutionary investigations is the bacterium Pseudomonas aeruginosa 
and fluctuating selection, as provided by the sequential exposure to antibiotics. Antibiotics 
provide focused selective pressure with described mechanisms of action. Moreover, the genetics 
of the adaptive response – antibiotic resistance – are well studied. The identification of selection 
regimes that inhibit resistance evolution implies ways to stabilize effective antibiotic therapy. 
This aim is supported by the choice of P. aeruginosa as a model organism, due to of its 
pathogenicity and high potential for resistance evolution. 
Antibiotics 
Antibiotics are molecules that kill or inhibit the growth of bacteria and fungi. The antibiotics used 
for therapy today are mostly derived from naturally occurring bioactive compounds that are 
produced by certain fungi and bacteria, most notably actinomycetes. Many antibiotics, therefore, 
have natural functions in the ecology of bacteria, notably microbial antagonism (Roberts, 1874; 
Tyndall, 1876; Waksman & Woodruff, 1940; Currie et al., 1999) and signaling (Hopwood, 1981; 
Linares et al., 2006). Other antibiotics are of synthetic origin. The discovery of antibiotics (Ehrlich, 
1911; Fleming, 1929; Klee & Römer, 1935) transformed medicine, as they enabled treatments for 
previously untreatable infections. Extensive research efforts in the 1940s and 1950s – motivated 
by treatment success and the political situation – yielded an impressive arsenal of antibiotics.  
 
Figure 2. Cellular targets of antibiotics in Gram-negative bacteria. DHPS, dihydropteroate synthase; 
DHFR, dihydrofolate reductase; DHP, dihydropteroate; LPS, lipopolysaccharide; PABA, para-aminobenzoic 
acid; dTMP, deoxythymidine monophosphate; dTTP, deoxythymidine triphosphate; dUMP, deoxyuridine 
monophosphate; UDP, uridine diphosphate. Modified from Walsh, 2003. 
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Antibiotics are grouped into functional classes according to their cellular targets. Antibiotics of 
the same class have similar chemical structures (Walsh, 2003). Most antibiotics target one of 
several major targets (Figure 3), notably: cell-wall synthesis (β-lactams), protein synthesis 
(aminoglycosides, macrolides, tetracyclins), DNA or RNA synthesis (quinolones, rifampin), or the 
folate biosynthesis pathway that synthesizes precursors for DNA and RNA synthesis 
(trimethoprim, sulfamethoxazole) (Walsh, 2003). The most relevant minor targets are 
membranes (daptomycin, polymyxin) and mycolic acid synthesis (isoniazid). It is increasingly 
clear that some compounds have multiple targets, as is the case for aminoglycosides (Davis, 1987) 
and certain antimicrobial peptides (Andersson, Hughes, & Kubicek-Sutherland, 2016). 
Antibiotic resistance 
The success of antibiotics prompts their lavish use, causing massive leakage into natural 
environments via waste water from the pharmaceutic industry, hospitals, homes and, most 
regrettably, agriculture. Low concentration of antibiotics elicit multitudinous responses in 
microorganisms (Andersson & Hughes, 2014) and can select for the emergence of clinically 
relevant resistance mutations (Gullberg et al., 2011). There are also pre-existing, ancient 
resistance genes in the bacterial pangenome (e.g. the vancomycin operon vanHAX), whose natural 
function we do not know, but that are now causing major challenges for therapy due to their 
dispersal on mobile genetic elements (D’Costa et al., 2011). Consequently, in a worrying analogy 
to an evolution experiment, antibiotic resistance is emerging and spreading globally 
(Laxminarayan et al., 2013).  
Antibiotic resistance can be achieved by three general mechanisms (Walsh, 2003): 
i) modification of target structures that affect antibiotic binding dynamics, 
ii) modification of target access by changing antibiotic entry or expulsion, 
iii) enzymatic breakdown of the antibiotic. 
Target modifications and de-repression of efflux pumps of β-lactamases is often mediated by 
single nucleotide changes called SNPs (single nucleotide polymorphisms) in the DNA that mostly 
occur due to errors in DNA replication. In most bacteria, per generation mutation rates are in the 
range of 10-10 - 10-9 per site (Lynch et al., 2016), translating to 10-8 to 10-7 per gene. An approach 
to thwart resistance evolution is to decrease population size to level at which de-novo evolution 
of resistance is highly unlikely. However, there are alternative mechanisms that may serve as 
stepping-stones to resistance, such as gene amplification, and tolerance. Partial genome 
amplifications that increase the copy number of genomic regions can be very frequent in 
populations of particular pathogens, in the range of 10-5 to 10-2 per gene and generation as 
measured in Salmonella enterica (Anderson & Roth, 1981). For example, the partial genome 
duplication spanning the drug efflux pump AcrAB conferred rapid adaptive response to 
combination treatment with the antibiotics erythromycin and doxycycline in E. coli (Pena-Miller 
et al., 2013). The amplifications are highly unstable and are rapidly lost upon removal of selective 
pressure (Laehnemann et al., 2014). It is likely that partial genome duplications frequently occur 
during antibiotic therapy, as they are a molecular mechanism for heteroresistance (Hjort, Nicoloff, 
& Andersson, 2016), the commonly observed microbiological phenomenon of mixed resistance 
profiles in clinical isolates.  
Antibiotic tolerance is a bacterial survival strategy that relies on the reduced bactericidal activity 
of antibiotics, against slowly growing cells (Lee et al., 1944; Tuomanen et al., 1986). Tolerant 
mutants do not have increased resistance, as reflected in unchanged minimal inhibitors 
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concentrations (MIC), but their low physiological growth rate decreases the killing rate of 
antibiotics compared to susceptible strains (Brauner et al., 2016). Tolerant strains can be selected 
by short exposures to high drug concentrations (Fridman et al., 2014; Levin-Reisman et al., 2017). 
Importantly, the expression of resistance is modulated by environmental and physiological 
contexts, as recently reviewed (Hughes & Andersson, 2017). An illustrative example is the 
expression of mecillinam resistance as caused by cysB mutation in E. coli. The addition of cysteine 
completely suppresses the expression of resistance from cysB mutations, which otherwise cause 
>100-fold increase in resistance (Thulin, Sundqvist, & Andersson, 2015). The expression of 
resistance by the same mutation is also modulated by the osmolarity in urine, suggesting a 
possibility to influence treatment success by drinking more water or supplementing nutrition 
with cystein (Thulin, Thulin, & Andersson, 2017).  
Antibiotic resistance is a pleiotropic trait. Bacteria selected for resistance against single 
antibiotics usually display cross-resistance to antibiotics of the same class (Szybalski & Bryson, 
1952; Imamovic & Sommer, 2013; Lazar et al., 2014; Barbosa et al., 2017; Imamovic et al., 2018), 
which would translate to fitness benefits at sequential encounters of these drugs. The same 
resistance mutations can also have negative fitness effects, so called collateral sensitivity, during 
treatment with other antibiotics. It remains to be tested how these trade-offs affect the 
maintenance of antibiotic resistance in clinical and natural environments. 
Pseudomonas aeruginosa 
P. aeruginosa is a motile, rod-shaped ɣ-proteobacterium (Gram-negative) that characteristically 
produces green pigments in liquid culture (Madigan et al., 2014). Its metabolic versatility enables 
growth on unusual carbon sources and P. aeruginosa can be easily isolated from soil and water 
(Ramos, 2004). Importantly, P. aeruginosa is also an opportunistic pathogen with broad host 
range causing virulence in plants, invertebrates but also in humans (Rahme et al., 1995).   
Infections by P. aeruginosa frequently occur in the lungs of cystic fibrosis (CF) patients, where the 
bacteria dwell in sticky mucus. The mucus is a consequence of a dysfunctional ion-transport in 
the lung epithelium of the patients as caused by mutations in the cystic fibrosis transmembrane 
regulator CFTR (Winstanley, O’Brien, & Brockhurst, 2016). Bacterial infections are the primary 
cause of mortality in CF patients and extensive chemotherapy is employed to prevent 
exacerbations in bacterial density. Therapy is usually focused on P. aeruginosa and involves more 
or less constant selective pressure by antibiotics (Döring et al., 2012), as illustrated by a cohort of 
chronically Pseudomonas-positive patients that receive regular prophylactic treatments at the 
Universitätsklinikum Schleswig-Holstein in Kiel. Patients in this cohort regularly inhale 
tobramycin, colistin or aztreonam at home (Tüffers, 2018). They occasionally receive 2-week 
courses of prophylactic intravenous treatment with combinations of two, sometimes three drugs, 
during which some patients choose to continue their inhalations (Tüffers, 2018). The constant 
antibiotic exposure is a potent selective pressure and P. aeruginosa undergoes rapid adaptive 
evolution within patients, in response to drug treatment (Winstanley et al., 2016). Phenotypic 
changes between longitudinal isolates are commonly the evolution of mucoid phenotypes and 
increases in antibiotic resistance (Damkiær et al., 2013; Marvig et al., 2015). P. aeruginosa has an 
impressive array of chromosomally encoded efflux pumps (Li et al., 2016) enabling rapid 
evolution of multidrug resistance via regulatory changes, such as mutational inactivation of efflux 
repressors (Breidenstein, de la Fuente-Núñez, & Hancock, 2011). It is, therefore, not surprising 
that certain strains of P. aeruginosa were recently ranked as the second most critical resistance 
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threat by the World Health Organization (World Health Organization, 2017). Altogether, P. 
aeruginosa is a good model for the development of new antibiotic treatment strategies. 
 
Thesis content 
Chapter 1: Evolutionary ecology meets the antibiotic crisis: Can we control evolution? 
Roderich Römhild and Hinrich Schulenburg. – Manuscript submitted for publication  
In this opinion paper, we reviewed common antibiotic treatment practices, from the perspective 
of evolutionary ecology. We argued that principles from ecology and evolution may contribute to 
the design of more sustainable treatments that inhibit the emergence of resistance. Recent and 
neglected older investigations supported a re-consideration of sequential treatments. We 
proposed evolution experiments as an efficient tool for the investigation of new treatment 
strategies. We further discussed the advantages of antibiotics as a laboratory model system for 
the study of evolutionary dynamics. 
Chapter 2: Adaptive paths to escape collateral sensitivity cycling.  Roderich Römhild*, Camilo 
Barbosa*, Philip Rosenstiel, and Hinrich Schulenburg. – Manuscript 
We investigated the evolutionary stability of genetic constraints, as provided by two cases of 
reciprocal collateral sensitivity. We performed comparative evolution starting with characterized 
resistant clones, which were subjected to increasing concentrations of antibiotics. We specifically 
investigated how new mutations selected by the second antibiotic affected the expression of 
previous resistance phenotypes. The main finding was that reciprocal collateral sensitivity 
generally constrains the evolution of dual resistance, but that rare mutations can enable bacteria 
to escape the genetic trade-off. The probability of escape was dependent on the order of antibiotic 
selection. To our knowledge, this is the first experimental test for the efficacy of collateral 
sensitivity cycling. *This manuscript has joint first-authors. 
Chapter 3: Negative hysteresis improves antibiotic cycling efficacy. Roderich Römhild, 
Chaitanya S. Gokhale, Christopher Blake, Philip Rosenstiel, Arne Traulsen, Dan I. Andersson, and 
Hinrich Schulenburg. – Manuscript submitted for publication 
The overall aim of this study was to gain a systematic insight into fitness optimization and 
adaptive priorities in fluctuating environments. We performed parallel evolution experiments 
with selection by 16 different sequences of three bactericidal antibiotics (ciprofloxacin, 
gentamicin, and carbenicillin). The sequences differed with respect to drug order, switching rate, 
and temporal regularity. The antibiotics were chosen for their association with collateral 
sensitivity and cross-stress sensitivity (so-called negative antibiotic hysteresis). The main finding 
was that physiological balance is an important driving force in bacterial evolution.  
The cumulative influence of negative hysteresis accurately predicted rates of resistance evolution, 
across the treatment sequences. The correlation was explained by a genetic trade-off between 
resistance and a novel response, insensitivity to hysteresis, which was mediated by mutations in 
cpxS (formerly known as PA3206 or PA14_22730). Experimental change of hysteresis levels in 
follow-up experiments predictably altered rates of resistance evolution, as evaluated by 
population extinction and resistance gains. Our results indicate new ways to improve treatment 
efficacy – sequential protocols with high hysteresis density that select for physiological balance 
and thus inhibit the evolution of resistance.  
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Chapter 4: Sequential treatment with three β-lactams in Pseudomonas aeruginosa and the 
evolution of resistance. Roderich Römhild and Hinrich Schulenburg. – Manuscript 
The aim of this study was to investigate the dynamics of resistance evolution during treatment 
with antibiotic that individually inhibit cell wall synthesis (carbenicillin, cefsulodin, and 
doripenem). The performed parallel evolution experiment had identical setup to the main 
experiment of Chapter 3, but the antibiotics displayed cross-stress protection. As a result, 
populations evolved resistance more rapidly. However, fast-switching treatments significantly 
increased the likelihood of population extinction. The observation seemed to be explained by 
uncorrelated genetic responses and the evolution of collateral sensitivity within β-lactams. Our 
observations challenge the notion that multidrug treatments with similar antibiotics are 
ineffectual.  
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Abstract 
The spread of antibiotic resistance is a global challenge that is fueled by evolution and ecological 
processes. We here argue that principles from evolutionary ecology can be applied to control the 
emergence and spread of resistance. We specifically propose that pathogen adaptation can 
effectively be constrained by temporal variation, especially when changes are fast and/or 
irregular and combined with genetic and physiological trade-offs in the evolving organisms. We 
then outline how work on antibiotic resistance can simultaneously advance a mechanistic 
understanding of evolution, as it often focusses on dissecting the underlying constraints that 
ultimately determine the likely range of evolutionary trajectories. We conclude that it is high time 
for more evolutionary ecologists to get involved in antibiotic research.  
Main text 
Antibiotics and antibiotic resistance are an ancient part of bacterial ecology [1–3]. In the face of 
the current antibiotic crisis, we should therefore remember that antibiotic resistance is a 
pleiotropic trait that usually entails ecological trade-offs [4] (see Glossary). As a consequence, we 
can apply principles from evolutionary ecology to improve our treatment protocols with the aim 
to constrain the emergence of drug resistances. At the same time, resistance evolution shows very 
high potential to enhance our general understanding of adaptation, because it can be easily 
studied with controlled laboratory-based evolution experiments, because comprehensive 
reference data sets are already available from in vitro and also in vivo studies, and because it 
allows us to connect ecological factors to evolutionary processes and also the underlying 
molecular and genetic mechanisms. The selective pressure (antibiotics), the evolving organisms 
(bacteria) and the evolutionary genetics of adaptation (space of resistance mutations and the 
distribution of their fitness effects) are often well characterized in this system. Intriguingly the 
eco-evolutionary feedbacks, which may drive resistance evolution, are not always well 
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understood and are usually neglected in this field of research – in spite of their potential 
importance. 
With this opinion paper, we highlight how concepts based in evolutionary ecology may yield novel 
ideas for antibiotic therapy. We identify sequential antibiotic treatments as a highly potent 
treatment option, which we believe should make it difficult for bacteria to adapt because of the 
continuously changing selective challenge and which is usually not considered for therapy. 
Surprisingly, we currently possess only comparatively little detailed knowledge on how 
organisms adapt to such rapidly fluctuating environments. Therefore, the research that we 
propose should also help to enhance our general understanding of the processes and mechanisms 
that underlie adaptation to temporarily variable conditions. In the following, we will show that 
current procedures of antibiotic treatment are sub-optimal from the view of evolutionary ecology 
(Section 1). We then discuss ecological principles that may improve treatment sustainability 
(Section 2). We conclude the paper, by outlining how selection experiments with antibiotics 
enable evolutionary ecologists to gain a mechanistic understanding of adaptation (Section 3). 
 
Section 1: Sub-optimality of common treatments 
Historically, the first strategy for antibiotic therapy was to treat patients for several days with an 
antibiotic, typically of broad-range activity, such as penicillin. Such monotherapies are still the 
main treatment form today, yet resistance to the single drugs can evolve rapidly through natural 
selection [5]. Fast adaptation to individual antibiotics is usually caused by three main non-
exclusive factors: (i) a high number of different mutations can confer resistance and these may 
easily arise due to usually large bacterial population sizes and/or horizontal gene transfer, (ii) the 
selective advantage of any resistance mutations is large, even if originally rare, and thus they can 
spread fast through the population; and (iii) non-resistant competitors are excluded by the action 
of the antibiotic, further enhancing proliferation of the resistant varieties (i.e., competitive 
release). Evolutionary biologists seek ways to prevent the rapid fixation of resistance mutations 
by limiting these processes. One approach is to increase the complexity of the environments – and 
their adaptive landscapes – by applying several different drugs within a single treatment [6]. It is 
more likely for bacteria to become resistant to a single drug than to several drugs, because there 
are fewer mutations that provide cross-resistance. These drugs can be deployed simultaneously 
or consecutively (Fig. 1). It is important to differentiate the hierarchical level at which multidrug 
treatments are implemented, i.e. with focus on patient groups or individuals (Fig. 1). The 
approaches have different rationales: Group level application (hospital, cohort, intensive care 
unit) aims at limiting the spread of resistance caused by cross-infection. Application in single 
patients aims at the prevention of the emergence of resistance during treatment. 
Simultaneous multidrug treatment of patient groups is termed mixing therapy [7]. Within an 
intensive care unit (ICU) multiple antibiotics are applied the same day, but patients individually 
only receive a single drug (Fig. 1A). Throughout the whole treatment, medication of a patient 
remains constant, such that each patient effectively receives monotherapy. This strategy produces 
a patchy selective environment and thus increases spatial but not temporal variation. Therefore 
the likelihood of de-novo resistance evolution in a single patient is not decreased over 
monotherapy.  
Combinations of two or more drugs within the same patient (Fig. 1B) produce more complex 
adaptive landscapes due to drug interaction. Drug interaction can provide immediate advantage 
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if drugs synergistically enhance their inhibitory effect on bacterial growth. Certain antibiotic 
combinations have therefore been used to combat infections fast and efficiently [8] and 
combination treatment is now the standard for several bacterial infections [9,10]. However, 
simultaneous drug deployment was repeatedly observed to accelerate evolutionary rescue in 
vitro [11–13]. Resistance evolved earlier in experimental populations treated with combinations 
than in populations treated with monotherapy, because aggressive treatments release rare 
multidrug resistant variants from competition with non-resistant cells. Simultaneous treatments 
may therefore rather obstruct the intended clearance of pathogens. This may explain, why clinical 
trials failed to show a general advantage in patient recovery and survival after combination 
therapy as compared to monotherapy [14]. The continued interest in combination therapy is 
partly due to discoveries of special drug combinations with suppressive interaction [15,16]. These 
combinations can limit bacterial resistance evolution by selecting against mono-resistant mutants 
in a specific concentration window. Yet, these drug pairs need to be applied in higher doses than 
in monotherapies, potentially causing stronger side-effects [6]. Altogether, we suggest to 
reconsider sequential drug protocols as an alternative treatment strategy, as it may unite the 
benefits of combination therapy with sustainability, due to additional adaptive constraints caused 
by the temporal complexity. 
 
 
Figure 1. Strategies for multidrug treatments. Multidrug treatments can be designed in different ways, 
depending on the temporal structure and the application level. Colours represent different drugs. 
 
To date, the idea of sequential treatment has been applied mostly on the group level. In rotation 
or cycling therapy the whole ICU is treated with the same antibiotic, which is periodically switched 
for a new antibiotic after several weeks (Fig. 1C). As switching interval is longer than hospital stay, 
the likelihood of resistance emergence is not reduced compared to monotherapy. A recent meta-
analysis of clinical trials for cycling therapy could show an overall benefit compared to mixing 
[17] but this effect was due to a reduced number of hospital acquired infections and not because 
selection for resistance was minimized [18]. We argue that sequential therapy can minimize 
resistance evolution, but not when it is carried out with the currently used unit-wide approach 
and the long switching intervals. Drug resistance evolves within single patients (e.g. 
Mycobacterium tuberculosis [5], Pseudomonas aeruginosa [19]). To limit the emergence of 
resistance, multidrug treatments have to be applied to one patient, such that they potentially 
affect a single population of pathogen. To achieve this aim, drugs need to be rotated more rapidly 
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than in the unit-wide protocol, i.e. each day (Fig. 1D) or more often. Frequent switching produces 
fluctuating selection to which adaptation is more difficult. Any particular switch of antibiotics 
during treatment may improve treatment outcome by curing strains resistant to the preceding 
antibiotic [17]. Clinical trials on fast sequential treatments proved effective against Helicobacter 
pylori infections [20]. Likewise,  sequential therapy increased eradication of P. aeruginosa in a 
small cohort of cystic fibrosis (CF) patients [21]. Intriguingly, the latter study was already 
published 30 years ago in the Lancet, but did not receive any attention (less than 10 citations 
within the 30 years according to Web of Science).  
 
Section 2: Controlling resistance emergence by temporal variation 
Sequential treatments complicate adaptation because they produce dynamically changing 
adaptive landscapes for pathogen populations. The selection dynamics can be optimized 
according to eco-evolutionary principles. We argue that the full potential of sequential treatments 
can be achieved by considering a) pleiotropic fitness effects of resistance mutations, b) 
physiological interactions that occur at switches between drugs, c) a sufficient rate of 
environmental change, and d) sequence stochasticity. 
a) Antagonistic pleiotropy 
Most proteins are part of interconnected biological networks. As a consequence, adaptive 
mutations nearly always affect the expression of multiple traits (i.e., pleiotropic effects; [22,23]). 
Adaptive mutations are therefore often associated with fitness trade-offs in distinct environments 
[24–27]. In the context of antibiotic treatment, switching drugs in a certain way can potentiate 
treatment and re-sensitize bacteria due to the antagonistic pleiotropy of previous resistance 
mutations. 
The importance of pleiotropy for the evolution of resistance has recently been reinforced by the 
rediscovery of the concept of collateral sensitivity, originally introduced more than 60 years ago 
(Box 1). The evolution of resistance to one antibiotic can increase susceptibility to antibiotics of 
other classes. The published sensitivity maps [28–32] show antibiotic class specific patterns, 
which indicates that collateral sensitivity originates from constraints caused by the general 
Bauplan, i.e. structural architecture [33] of the cell. Indeed, genetic investigations confirmed that 
collateral sensitivity can result from resistance mutations against a first drug that simultaneously 
enhances uptake of a second antibiotic. For example, collateral-sensitivity was found for strains 
of Escherichia coli adapted to aminoglycoside antibiotics [28–30]. Resistance against 
aminoglycosides is often caused by mutations that decrease membrane potential, for example by 
targeting the K+-ion-transporter TrkH [29,30,34]. This reduces the uptake of aminoglycosides 
[35] but also impedes the efficacy of drug efflux pumps such as AcrAB [29], thereby constraining 
the cellular removal of other drugs, causing hyper-sensitivity. A similar phenotype is achieved by 
alternative mechanisms in P. aeruginosa. Fluoroquinolone-resistant strains of P. aeruginosa 
frequently show collateral sensitivity to aminoglycosides and β-lactams [31,32,36], which is 
caused by mutations that alter the expression of efflux pumps, e.g. via mutation of nfxB [37], the 
major transcriptional repressor of the multidrug efflux pump MexCD-OprJ [38], or other efflux 
regulators such as mexZ or nalC [31]. The resulting changes in expression of particular efflux 
pumps however affects expression of alternative pumps [38], suggesting that collateral sensitivity 
is caused in these cases by a deviation from natural efflux balance. 
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Recent experimental tests of sequential treatments that involve collateral sensitivity highlight 
their potential application in therapy. Evolved P. aeruginosa strains that acquired resistance 
against the β-lactam piperacillin during treatment, could be re-sensitized by switching to 
ciprofloxacin [36], possibly due to nfxB-mediated changes in pump expression. Rapid alternating 
treatments of E. coli with drug pairs involving the antibiotic polymyxin resulted in one-sided 
adaptation and thus the suppression of resistance emergence to one of the drugs [39]. Although 
the mechanism is not entirely clear, it is likely associated with collateral sensitivity. 
A second, more general case of pleiotropy is the usually reduced growth rate of antibiotic resistant 
mutants, which can result from sub-optimal metabolic flux. The reduced growth rate of resistant 
mutants is often called a fitness cost [40] because it increases competition with non-resistant types 
and this clonal interference can decelerate adaptation [41].  
b) Negative physiological interactions 
Bacteria physiologically respond to stress, as caused by antibiotics, by activating stress-response 
systems that alter transcription of a large number of genes and thereby improve survival for the 
current conditions [42]. Because many bacterial proteins are stable, induced responses can be 
phenotypically inherited [43] and may thereby provide cross-stress protection to new conditions 
. Intriguingly, there are also cases where the previously experienced stressor decreases survival 
in new stressful environment, a phenomenon called cross-stress sensitivity. A comparatively well 
understood example is NaCl-induced acid sensitivity in E. coli, which is mediated by expression of 
the porin PhoE [44,45]. Furthermore, there may be less specific cross-sensitivity  caused by a 
metabolic cost of hysteretic response memory [46] or directly by stress-induced damage. 
Antibiotics themselves can induce responses that entail fitness disadvantages when drugs are 
switched in sequential treatments. Again, the ecological phenomenon itself was already studied 
50 years ago, but has since received negligible attention: Sub-lethal pre-treatments with β-lactam 
antibiotics potentiate killing on aminoglycoside antibiotics in several species of bacteria [47,48] 
(Box 2). Such physiological potentiation can help to eradicate chronic infections, as demonstrated 
experimentally (Box 2) or indicated by the high efficacy of sequential protocols in the treatment 
of biofilms [49]. It remains to be seen whether or not physiological interactions, in addition to 
their immediate therapeutic benefits, influence resistance evolution, for instance by shifting the 
priority of adaptation from resistance towards overcoming the physiological transitions. 
c) Frequency of change 
Fluctuating selection can delay adaptation, because it interrupts selective sweeps. For example, 
rapid but not slow fluctuation in media quality prevented co-evolution between bacteria and 
phage [50]. Likewise, switching rate determines the evolvability in the case of antibiotics. If 
antibiotics are switched too slowly in a sequential protocol, resistance mutations spread through 
the population, as in monotherapy. In contrast, more rapid fluctuations, such as switching 
antibiotics every 12 h or 24 h, can limit resistance evolution, as recently demonstrated for the 
pathogens P. aeruginosa [51] and Staphylococcus aureus [52] using experimental evolution. 
Interestingly, these experiments used sub-lethal antibiotic concentrations and achieved both a 
deceleration of adaptation and also increased population extinction [51]. The latter is likely 
explained by the increased occurrence of selection pulses as caused by physiological interactions 
and genetic trade-offs.  
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d) Stochasticity 
Unpredictably occurring environmental disturbances are more difficult to adapt to than regularly 
occurring selective pressures [53,54]. According to the hypothesis of environmental adaptive 
conditioning [55] – the terminology is an analogy to associative learning [56] – evolution adjusts 
gene expression to regular patterns of stimuli. Correlated environmental factors are a common 
feature of microbial habitats and several microbes exhibit anticipatory gene regulation [57,58]. 
These organisms use trigger molecules in their environment to adjust gene regulation for future 
challenges. One example is Vibrio cholera, which during the last phase of the infection of the 
human intestine already induces genes necessary for survival in the aquatic environment outside 
the host [59]. Anticipation was likewise selected by the fixed sequential contrasts in the human 
gut. Following transmission, E. coli encounters lactose in the proximal part of the intestine, 
followed by maltose in the distal part three hours later [60]. In the scramble for nutrients, E. coli 
benefits from up-regulating maltose-metabolizing genes ahead of time (lactose induces 
expression of the maltose operon), thereby skipping the lag-phase associated with the shift in 
carbon sources [55]. The anticipatory regulation and its fitness advantage are lost when wildtype 
E. coli were grown in constant lactose environment in the lab, indicating a cost of the anticipation 
behavior [55]. A mathematical model predicts the evolution of anticipation under certain 
conditions: strong temporal correlation of stimuli, short time between stimuli, and high benefit of 
the anticipation [57]. These examples illustrate that predictable patterns in sequential antibiotic 
therapy are potentially dangerous, because they generate the parameter space for the evolution 
of anticipation. The ensuing adaptive response may be circumvented by irregular drug orders.  
Aside from limiting fitness benefits of anticipation, stochasticity in fluctuations can also directly 
decelerate adaptation. This was demonstrated with populations of viruses, which were exposed 
to regularly alternating and randomly changing temperatures [61]. In contrast to the observed 
fitness increases in regularly alternating environments, unpredictable temperature fluctuations 
led to a significant decrease of fitness [61]. Similarly, fitness returns of bacteria adapting to 
randomly fluctuating pH were lower than those attained in regularly alternating sequences of pH 
[62]. The incorporation of temporal stochasticity in sequential protocols may thus additionally 
restrict resistance evolution in the long-term. We expect the decelerating effect of randomness to 
increase with the total number of drugs, because of the exponential increase in the number of 
possible switching directions (N = x!). The potential for stochastic orders to decelerate adaptation 
is mostly unexplored, as trials for sequential treatments with random orders have focused on drug 
pairs [13,51].  
Altogether, principles from evolutionary ecology can be tested for their ability to slow down the 
emergence of resistance using laboratory experiments. The data thus far generated indicate that 
complex treatments such as combination or sequential treatments limit resistance evolution. 
Nevertheless, bacteria may ultimately be able to adapt to treatment by their enormous 
evolutionary potential, even if only rare evolutionary trajectories are available [63]. Bacteria use 
genetic loop holes, notably cross-resistance and phenotypic heterogeneity, to escape treatment. 
The likelihood of cross-resistance strongly depends on the choice of antibiotics. Ideally, the 
antibiotics select from distinct sets of beneficial mutations. A first step towards this goal is to 
choose drugs that target different cellular functions, because cross-resistance is particularly 
common within drug classes, although there are noteworthy exceptions due to epistasis, in 
particular with -lactams [64,65]. Bacteria can also adapt to unpredictable disturbances by 
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increasing phenotypic heterogeneity [66], which is produced by stochastic noise in gene 
expression [66,67]. The variability in gene expression is often linked to variability in antibiotic 
tolerance [68–70], which is explained by growth rate dependent killing [71,72]. A certain 
frequency of dormant cells, so called persisters, is naturally produced by stochastic partitioning 
of proteins after cell division [73,74] and represents an ancient evolutionary survival strategy; 
bet-hedging. Rather than relying on the phenotype of highest fitness in the current environment, 
bacteria spread their eggs (resources) across several baskets (phenotypes) to reduce the risk of 
losing them all at once. Phenotypic heterogeneity may thus be an adaptive strategy for 
unpredictable antibiotic treatments. 
 
Section 3: Opportunities for ecologists in antibiotic research 
Opportunities for ecologists arise from the well-studied genetics of antibiotic resistance to learn 
about evolution. Antibiotics can be used to test evolutionary theory in evolution experiments 
across short time frames – because antibiotics can provide strong selective pressure – and well-
controlled selective conditions – because antibiotic selection precisely targets certain cellular 
functions and inhibition levels are controlled by concentration. We argue that more can be learned 
about evolution through the study of adaptive constraints rather than the adaptations themselves. 
For example, experiments with antibiotics have helped to understand the ecological parameter 
space that favours the evolution of specialists over generalists in fluctuating environments. 
Theory predicts the evolution of broad niche width in response to fluctuation [75] and this has 
been observed in many cases [76], making it mechanistically interesting to see cases for the 
evolution of specialists. In the experiments, specialists evolved in response to targeted selection 
and when adaptation invokes pleiotropic trade-offs [39,77], as provided by specific sugars or 
antibiotics. This contrasts with the experimental evolution of generalists in response to less 
specific selective pressures, such as temperature fluctuations or patch quality that select towards 
general stress-response and associated pre-adaptation to other stressors  [78,79]. Similarly, a 
whole suite of questions that would be hard to tackle using less controllable or less studied 
systems, can be addressed using antibiotic selection. Some intriguing questions arise from the 
points presented in this paper (Box 3). We conclude that antibiotics are a practical toolbox for 
evolutionary research. 
In this paper, we outlined how eco-evolutionary research can guide clinicians in the design of 
sustainable antibiotic treatments. We argue that current cycling treatments do not yet reach their 
full potential to eliminate bacteria and simultaneously minimize resistance evolution. Using eco-
evolutionary principles, we identify fast sequential treatment of individual patients as a hard-to-
adapt treatment option that warrants further exploration as a weapon against antibiotic 
resistances. By studying the emergence of resistance, evolutionary ecologists can contribute to 
the management of a growing global problem. Antibiotic resistance is an ancient ecological trait 
and its spread and rapid emergence are evolutionary processes. Clearly, evolutionary ecologists 
should get involved!  
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Box 1. The discovery of collateral sensitivity. 
Collateral sensitivity is the specific term for trade-offs in antibiotic resistance, in which genetic 
changes that increase resistance to one antibiotic simultaneously increase susceptibility to other 
antibiotics. Collateral sensitivity was originally discovered and studied by Waclaw Szybalski at 
Cold Spring Harbor in the 1950s. Szybalski selected bacteria resistant to a wide array of antibiotics 
and toxic agents and screened them for cross-resistance against other antibiotics [80–82]. He 
discovered class-specific patterns in cross-resistance but also collateral sensitivity, and proposed 
to exploit these observations in chemotherapy [80]: “Whenever one antibiotic can be found that is 
particularly effective against bacteria resistant to another, it might be proved useful in combating 
disease and in permitting the application of antibiotics in a rational sequence when more than one 
is to be employed. Thus, the exact study of both collateral sensitivity and cross resistance may help 
in designing a proper program of multiple chemotherapy.” However, at the time, antibiotic 
resistance was not common and research did not follow up on his ideas. Instead, his findings were 
mainly applied in the search for novel antibiotics [83]. Candidate substances were used to select 
for resistant mutants, which were screened for their collateral sensitivity profiles. A deviation of 
the mutant profiles from established profiles was taken as indication of a new class of antibiotic. 
In the following years, the term collateral sensitivity disappeared from the field of antibiotics 
research, although studies continued to accumulate evidence of sensitivity trade-offs in antibiotic 
resistance [4,37,84,85]. Only now – in the light of the antibiotic crisis – has this concept been re-
connected to antibiotic therapy [28], as originally proposed by Szybalski. Matrices of evolved 
collateral effects have now been inferred for E. coli and P. aeruginosa under laboratory, 
highlighting a high frequency of collateral sensitivities involving aminoglycosides, although their 
direction can vary among bacteria [28,29,31,86] and between evolved replicates of the same 
strain [31] depending on the precise genetic changes. The obtained insights are currently being 
explored for clinical application of collateral sensitivity in sequential treatment regimens.  
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Box 2. Sequential application potentiates treatment due to physiological interactions. 
Short exposures to sub-lethal concentrations of antibiotic can potentiate subsequent antibiotic 
treatment. This phenomenon was first described in 1962 for E. coli. Pre-treatments of bacterial 
cultures with -lactams for 15 minutes increased the bactericidal activity of aminoglycosides (AG, 
Fig. panel A, modified from [47]) by accelerating their cellular uptake (Figure panel B, modified 
from [47]). Such physiological effects are likely important in a clinical study on a cohort of cystic 
fibrosis (CF) patients with chronic P. aeruginosa lung infections, published in 1988 and 
representing one of the very few clinical applications of fast sequential therapy (i.e., including 
drug changes within a patient in less than a day). This study evaluated the potency of a specific 
form of sequential treatment, where a second antibiotic is added while the first antibiotic 
administered four hours earlier is still present in the patient at decreasing serum levels. 
Physiological interactions should influence treatment outcome, even if not known by the authors, 
because they switched between aminoglycosides and β-lactams, thus recapitulating the above 
described conditions. The test was unexpectedly successful, substantially reducing bacterial load 
upon sequential treatment (Fig. panel C, modified from  [21]): “Between 1983 and 1987, 36 
episodes of pseudomonas infections in thirty-two patients with CF have been treated with a 
combination of a 𝛽-lactam (azlocillin, piperacillin, ticarcillin 120 mg/kg) and an aminoglycoside 
(gentamicin or tobramycin 12 mg/kg) with doses 4 hours apart. In 16 episodes P. aeruginosa was 
eradicated from sputum for at least 3 weeks and sometimes for up to a year. In all other patients the 
number of colony forming units in sputum fell 1000-10000-fold. Clinical improvement, as judged by 
fever, amount of sputum, and laboratory findings (e.g. erythrocyte sedimentation) was seen in every 
patient.“ [21] This strikingly contrasts with simultaneous dosing: “Between 1972 and 1978 we 
treated 66 episodes of infection due to P. aeruginosa in fifty-two patients with CF. We used a 
combination of carbenicillin (500 mg/kg) and an aminoglycoside (5 mg/kg) given simultaneously 
every 8h. In none of these 66 episodes was the pathogen eradicated.” [21] It is fascinating to see that 
this highly effective application of fast sequential therapy was not expanded and more widely 
explored. 
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Box 3. Outstanding questions. 
With this paper we would like to stimulate research on evolution in complex drug environments. 
Many points warrant further exploration and some of these could be tackled with experimental 
evolution. 
Main topic 1: Evolutionary questions 
 What is the evolutionary robustness of adaptive constraints, such as collateral sensitivity 
or cross-stress sensitivity?  
 How does evolution manage competing adaptive constraints? Specifically, when does 
evolution prioritize adaptation to physiological interactions or genetic trade-offs? How 
does phenotypic memory affect the emergence of resistance mutations? 
 What is the mechanistic explanation for decreased fitness gains after stochastic compared 
to periodic selection? 
 What is the optimal switching rate and treatment duration in sequential therapy? To what 
extent is the switching-rate optimum influenced by drug dose (i.e., selection coefficient), 
physiological interactions, or trade-offs? 
 How does anticipatory gene regulation evolve? Although the parameter space is 
described, we lack an experimental demonstration for the evolution of anticipatory gene 
regulation. 
 Which selective conditions favor the evolution of bet-hedging strategies such as 
phenotypic heterogeneity? Is this dependent on switching rate, stochasticity, or genetic 
trade-offs? 
Main topic 2: Treatment-related questions 
 What are the dynamics and likelihood for resistance emergence in multidrug-treatments 
with 3 or more antibiotics? Can the rate of adaptation be decreased by unpredictable order 
of antibiotics? 
 How do bacteria evolve under sequential treatment which responds to evolution in real 
time? So far experiments assessed evolution in pre-defined scheduled protocols with 
balanced proportions of drugs. What happens when the replacement of antibiotics is 
directly coupled to real-time diagnostics by feedback loops? 
 What are the molecular mechanisms for cross-stress sensitivity?  
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Highlights. 
 Eco-evolutionary processes determine the rise in antibiotic resistance, yet are largely 
ignored in the current antibiotic crisis  
 Eco-evolutionary principles can thus help the design of sustainable treatments, such as 
fast sequential therapy 
 Fast sequential therapy creates temporal selective constraints that are difficult to adapt 
to, especially if combined with physiological effects, genetic trade-offs, or stochasticity 
 Exploration of adaptation to fluctuating antibiotic environments should simultaneously 
enhance our understanding of the process of evolution, taking advantage of the 
comprehensive database on antibiotic resistance mechanisms and established 
experimental tools for pathogens 
 Such work will further close the gap in our understanding of adaptation to stochastically 
fluctuating environments, which are widespread in nature but neglected in experimental 
studies 
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Glossary 
Antagonistic pleiotropy: a mutation that influences several traits improves one trait and 
compromises other traits 
Bet-hedging: constitutive or inducible expression of distinct phenotypes in isogenic populations 
as an adaptive strategy to persist in environments with unpredictable change 
Clonal interference: competition between clones in asexual organisms, as determined by the 
complex of mutations contained in each of the clonal organisms, potentially leading to loss of 
advantageous mutations from the population 
Collateral sensitivity: the phenomenon that a mutation conferring resistance to a specific 
antibiotic causes increased susceptibility to other antibiotics 
Evolution experiment: experimental selection of a particular phenotype over many successive 
generations of an organism; derived and ancestral phenotypic states are usually compared using 
common-garden experiments 
Fitness cost of resistance: reduction of the maximum growth rate achieved in drug-free 
environments of a resistant mutant compared to wild-type cells 
Stochasticity: lack of predictable order 
Trade-off: concept of traits being mutually restricted by a common resource or a common genetic 
mechanism 
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Abstract 
Evolution is at the core of the impending antibiotic crisis. Sustainable therapy must account for 
the adaptive potential of pathogens, e.g., by exploiting genetic trade-offs of resistance mutations, 
which can produce hypersensitivity to other drugs (so-called collateral sensitivity). To date, the 
evolutionary stability and thus therapeutic applicability of reciprocal collateral-sensitivity 
remains unclear. Here we demonstrate experimentally that the model pathogen Pseudomonas 
aeruginosa cannot easily overcome collateral sensitivity, yet escape is occasionally possible via 
rare mutations. We further show that the application of the phenomenon can have three 
evolutionary outcomes: (i) population extinction, when bacteria fail to counter sensitivity to the 
second drug; (ii) maintenance of the double-bind, because gain of resistance causes reliable re-
sensitization to previous drugs; or (iii) conversion of hypersensitivity into multidrug-resistance 
by the fixation of rare mutations. The prioritized adaptive path depends on drug order. Our 
identification of robust genetic trade-offs will contribute to novel antibiotic therapy. 
Main text 
Treatment of cancer and infectious diseases often fail because of the rapid evolution of drug 
resistance1–3. Optimal therapy should thus anticipate emerging resistant variants and exploit their 
characteristics to improve treatment4–6. Thereby, the applied therapy may be one step ahead of 
evolution. In bacteria, and similarly in cancer7,8, mutations that confer resistance to one drug can 
cause hypersensitivity to other drugs (i.e., collateral sensitivity)6,9–12. Antibiotic cycling with drug 
pairs, for which this relation is reciprocal, has been proposed as a sustainable treatment strategy, 
because – in theory – it traps bacteria in a double bind6,13,14. It is argued that inversion of selection 
causes serial re-sensitization during adaptation to either drugs, reminiscent of a flip-flop 
mechanism. The validity of this argument lacks a thorough experimental test, and may generally 
be questioned because evolution is not a deterministic process. Recent work with non-reciprocal 
collateral sensitivity15 indicates that re-sensitization is contingent on history, but the genetic 
mechanisms are unclear. Here we use two-step experimental evolution (Fig. 1a) and genomic 
analyses of the pathogen Pseudomonas aeruginosa to measure the evolutionary stability of 
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reciprocal collateral sensitivity. In particular, we previously evolved P. aeruginosa to high levels 
of resistance against several antibiotics11 and identified two cases of strong reciprocal collateral 
sensitivity, between (i) carbenicillin (CAR) and gentamicin (GEN), and also (ii) 
piperacillin/tazobactam (PIT) and streptomycin (STR), which we here validated through dose 
response analyses (Fig. 1b, 1c). To assess whether or not switching drugs reliably selects for re-
sensitization, we here challenged four clones from each of four resistant populations in a 12-day 
evolution experiment with increasing concentrations of the hypersensitive drug under the 
following four conditions: presence or absence of the antibiotic against which bacteria originally 
evolved resistance, and fast or slow increase of the second drug (Fig. 1a). Concentrations were 
increased using linear ramps, to facilitate evolutionary rescue (Supplementary Table 1). Our 
results thereby yield a conservative measure for the applicability of collateral sensitivity cycling. 
 
 
Figure 1. Reciprocal collateral sensitivity and experimental design. (a) Two-step experimental 
evolution: resistant populations of P. aeruginosa were experimentally selected with increasing 
concentrations of a particular drug (here labelled A) and resulting populations were hypersensitive to other 
drugs (here labelled B). In a second step, selection was inverted by switching treatment to drug B, with four 
selection regimes: (i) mild dose increase of drug B; (ii) strong dose increase B; (iii) strong dose increase B 
plus presence of drug A; and (iv) mild dose increase B plus presence A. Reciprocal collateral sensitivity for 
drug pairs (b) GEN/CAR and (c) STR/PIT. Mean ± CI95, 8 technical replicates. CAR, carbenicillin; GEN, 
gentamicin; STR, streptomycin; PIT, piperacillin with tazobactam; wt, wildtype; superscript R denotes 
resistance. 
 
Evolutionary dynamics 
Although, concentrations increased with small slopes (starting with IC50 and ending at IC95 of the 
hypersensitive or wildtype strains for fast and slow increases, respectively), experimental 
populations frequently went extinct, indicating strong genetic constraints for the evolution of 
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dual-resistance (Fig. 2). In particular, extinction was common when selection for the original 
resistance was maintained by the presence of both drugs (i.e., bound treatments), as compared to 
unbound evolution during sequential treatment (extinction events in bound vs. unbound 
treatments, χ2-test, χ2=12.9, df=1, P<0.0001; Fig. 2, Supplementary Table 2). During such unbound 
evolution, extinction only occurred under fast but not slow concentration increases. Throughout 
treatment, we monitored bacterial growth, using continuous absorbance measurements (optical 
density, OD600). Relative biomass, as calculated from the areas under the obtained growth curves 
(AUC) relative to those from untreated controls, increased in surviving populations, indicating 
evolutionary adaptation. Adaptive increases in relative biomass were significantly slower for fast 
compared to slow increases, except for selection by STR (Figs. 2a, 2b, Supplementary Table 3). 
The simultaneous presence of both drugs significantly lowered growth across time, except for 
selection with PIT+STR (Fig. 2d; Supplementary Table 3). We conclude that adaptation to the 
second drug occurred in our experiments, although with varying degrees of difficulty. Adaptation 
was less rapid in the presence of both drugs, and for fast increases. These results are in agreement 
with previous studies that observed elevated extinction upon fast environmental deterioration as 
a consequence of narrowed mutation space16,17. Interestingly, growth improvements appear to be 
facilitated when sequential treatments begin with the aminoglycosides rather than the β-lactam 
antibiotic of the pair (left panels versus the right panels in Fig. 2), possibly suggesting a drug order 
effect determining the dynamics of resistance evolution. 
 
 
Figure 2. Growth dynamics and extinction events during second step of experimental evolution.  
Extinction events and changes in relative biomass of surviving populations for (a) CARR-populations 
adapting to GEN, (b) GENR-populations adapting to CAR, (c) PITR populations adapting to STR and (d) STRR-
populations adapting to PIT. The dotted horizontal line indicates growth equal to untreated controls. Mean 
± CI95, number of biological replicates differs due to extinction (Supplementary Table 2). Statistical 
evaluation of the differences among treatments is given in Supplementary Table 3. 
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Figure 3. Changes in antibiotic resistance after one treatment cycle. Surviving populations from the 
various treatments (different panels and colors) were evaluated for changes in their resistance against the 
two antibiotics of a pair, which they experienced originally (OLD) or in the subsequent evolution 
experiment (NEW). The change is measured by cumulative differences in dose-response before and after 
the second round of evolution (i.e., the original antibiotic resistant clone versus its evolved descendants). 
Mean ± CI95, number of biological replicates differs due to extinction (Supplementary Table 2). Asterisks 
indicate significant changes in resistance (one-sample t-test, µ=0 per treatment and antibiotic; FDR-
adjusted probabilities). 
 
Evolution of re-sensitization 
To evaluate whether selection by the second antibiotic re-sensitized bacteria to the original first 
drug or caused multi-drug resistance, we measured dose-response curves for the evolved 
populations against both antibiotics. In agreement with the recorded adaptive dynamics during 
treatment (Fig. 2), all surviving populations significantly increased resistance against the drug, 
towards which they originally produced hypersensitivity, regardless of whether both antibiotics 
were present or only one (Fig. 3; Supplementary Table 4). Resistance against the first drug always 
remained unchanged, when both antibiotics were present (Fig. 3). This demonstrates that the 
secondary adaptive mutations are not subject to the genetic trade-off originally responsible for 
collateral sensitivity, thereby highlighting that this particular evolutionary constraint can be 
overcome. Intriguingly, populations challenged with increasing concentrations of CAR or STR 
alone, showed significant decrease of resistance against GEN or PIT, thus restoring sensitivity 
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against these antibiotics. There was strong variation among lineages selected with PIT, i.e. only 
some lineages were re-sensitized to STR. Selection by GEN, did not re-sensitize against CAR. We 
conclude that P. aeruginosa has the genetic possibility to escape reciprocal collateral-sensitivity 
via rare cost-free resistance mutations. However, adaptation favors different mutational 
trajectories, where re-sensitization readily occurs, as witnessed with the antibiotics STR, CAR and 
PIT in the unbound treatments. The lack of re-sensitization upon selection with GEN indicates that 
the evolutionary stability of reciprocal collateral-sensitivity depends on the order of antibiotics 
during treatment.  
Population genomics 
To identify the genetic changes selected by treatment with the second antibiotic, we sequenced 
whole-genomes of the resistant starting clones and 35 evolved populations using samples from 
the end of the experiments. The samples for sequencing were selected thus: for each antibiotic at 
least all populations derived from one of the four starting clones and, additionally, when there 
were cases of re-sensitization in populations derived from other clones, all populations derived 
from those clones as well. Our analysis of the underlying genetic changes confirmed distinct 
evolutionary trajectories for bound and unbound evolution treatments, and explained the 
observed cases of re-sensitization (Supplementary Data 1).  
 
 
Figure 4. Genome dynamics during unbound treatments. (a-d) Different evolutionary trajectories 
during selection with the second antibiotic. Treatment order is illustrated with ramps. Shapes represent 
mutations in protein coding genes. Blue shading indicates re-sensitization to first antibiotic. 
 
Genomics for the switch from CAR to GEN 
The sequential selection with CAR followed by GEN resulted in a dual-resistant phenotype, which 
was explained by the sequential fixation of apparently cost-free resistance mutations (Fig. 4a). In 
detail, CARR was produced by a combination of mutations in (i) nalC, a TetR family repressor that 
controls expression of the multidrug efflux pump MexAB-OprM18; (ii) ftsI/L, which encode 
penicillin-binding-proteins 19; and (iii) the two-component sensor cpxS, which likely contributes 
to envelope stress response20. The mutation in nalC explains the collateral sensitivity to GEN11. 
Subsequent gain of GENR was achieved by second-site mutations in the NADH-dehydrogenase 
genes nuoD/G (Supplementary Fig. 1), which are important for proton motive force such that 
mutations confer low-level resistance against aminoglycosides21. Alternatively, adaptation 
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occurred by mutation of ptsP, an important regulator for complex group behaviors associated to 
antibiotic resistance, such as biofilm formation 22. Further mutational trajectories towards GENR 
involved changes in two-component sensors, as previously described11,23. The diversity of 
mutational trajectories explained the observed rapid biomass increases during selection with 
GEN (Fig. 2a) and the lack of re-sensitization to CAR (Fig. 3). The genetic mechanism of maintain 
and gain was thus the first puzzle piece to explain the order-dependence in the adaptive responses 
during CAR/GEN cycling. 
Genomics for the switch from GEN to CAR 
When sequential treatments began with GEN followed by CAR, the emergence of CARR was 
associated with re-sensitization to GEN during unbound treatments (Fig. 3). The genomic analyses 
revealed two genetic mechanisms for the re-sensitization. The original resistance to GEN was 
caused by a non-synonymous substitution in the two-component sensor pmrB (Fig. 4c), which 
was also the molecular mechanism for hypersensitivity to CAR11. Evolved re-sensitized bacteria 
had additional mutations in nalC that may increase CAR-efflux via MexAB-OprM18. Mutations in 
nalC were shown to mediate both resistance to CAR and hypersensitivity to GEN11. Thus, re-
sensitization to GEN may be caused by the antagonistic pleiotropy of nalC mutations that 
apparently override the still present pleiotropic pmrB mutation. A similar phenotypic shift was 
caused via a second regulatory pathway controlled by nalD24, which is alternatively mutated in 
re-sensitized populations (Supplementary Fig. 2). A complementary mechanistic explanation for 
re-sensitization against GEN is re-mutation of pmrB. In three cases nalC mutations coincided with 
mutations in pmrB, including two deletions of 17 and 225 base pairs. Whilst the original SNP in 
pmrB alters gene function, the latter deletions may epistatically suppress the expression of the 
original SNP by pseudogenizing the gene (Fig. 4b). Altogether, unbound adaptation against CAR 
was achieved by mutations in the nalC/D-regulation of the MexAB-OprM pump, sometimes in 
combination with follow-up mutations in pmrB, and these mutations re-sensitized cells via 
epistasis. 
Different mutational trajectories occurred when evolution of GENR was constrained by presence 
of CAR (Supplementary Fig. 1), explaining the observed differences in adaptive dynamics between 
bound and unbound evolution. High extinction frequencies indicated a greatly narrowed mutation 
space during bound evolution (Fig. 2b). Dual-resistance was achieved by the combined action of 
mexR and phoQ, an independent regulator of MexAB-OprM18 and a two-component regulator 
involved in aminoglycoside resistance25, respectively. The evolution of a mutS-dependent hyper-
mutator lineage (Supplementary Fig. 1) – an evolutionary strategy of last resort, because of the 
concomitant accumulation of deleterious mutations – highlights the comparatively high 
evolutionary stability of reciprocal collateral sensitivity when antibiotics are switched from GEN 
to CAR.  
Genomics for the switch from PIT to STR 
Cycling with the drug pair STR/PIT was associated with cases of re-sensitization regardless of 
drug order. Genetic analysis revealed that in both switching directions, ancestral resistance 
mutations were directly reverted to ancestral state (Fig. 4cd), indicating a lack of adaptive 
mutations and thus strong evolutionary stability of reciprocal collateral sensitivity for this drug 
pair. Resistance against PIT was mediated by nalC and mpl, a UDP-N-acetylmuramate: L-alanyl-
gamma-D-glutamyl-meso-diaminopimelate ligase involved in peptidoglycan synthesis26, whereby 
the nalC variant most likely accounts for hypersensitivity to STR11. Here, PITR populations adapted 
to STR by gain of mutations in gidB, which is known to contribute to STR resistance in P. 
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aeruginosa and other pathogens11,27 (Fig. 4c, Supplementary Fig. 3). GidB mutations only mildly 
increased resistance and stronger resistance required the mutational reversion of ancestral PITR-
mutations, which occurred in several replicates. Gained STRR is higher after mild STR increases 
than after strong or constrained ones, as indicated by the bar in the light blue in Fig. 3, due to 
reversal of nalC mutations in this treatment group. The mutational reversal also explained the 
observed re-sensitization to PIT (Fig. 3). 
Genomics for the switch from STR to PIT 
Cycling was likewise constrained in the opposite direction, where original STRR was caused by a 
mutation in gidB (Supplementary Fig. 4). Interestingly, the mutation in gidB present in the starting 
clone was not found in ¾ of the sequenced populations, which had subsequently been challenged 
with PIT alone. Whether or not phenotypic re-sensitization occurred in these cases was 
contingent on the subsequently acquired resistance mutations. In spite of the mutational reversal, 
one of the populations showed dual-resistance, as explained by its subsequent fixation of a 
mutation in mexR that confers multidrug-resistance via over-expression of MexAB-OprM. In the 
other two cases, resistance against PIT likely occurred by mutations in cpxS and PA14_41710, and 
these populations were re-sensitized to STR. As expected, gidB mutations were maintained during 
simultaneous selection with both drugs. Further mutations in nalC/D, did not cause re-
sensitization, indicating epistatic interactions between both genes that prevent the expression of 
their commonly associated collateral sensitivity against aminoglycosides11. Overall, cycling 
between STR and PIT is generally stable, as reflected by frequent extinction and cases of re-
sensitization. The observed variation between populations is caused by epistasis.  
Conclusion 
In summary, we experimentally tested the evolutionary stability of reciprocal collateral 
sensitivity in P. aeruginosa. While reciprocal collateral sensitivity between aminoglycosides and 
-lactams generally limited resistance evolution in this pathogen, we observed that treatment 
outcome was contingent on drug order during sequential treatments. Treatments that started 
with aminoglycosides prevented the emergence of multi-drug resistance during subsequent -
lactam treatment. Our genomic analyses explain the underlying genetic mechanisms, namely 
phenotypic re-sensitization due to epistatic interactions between mutations or direct mutational 
reversal (Fig. 4). Conversely, sequential treatments that started with -lactam and then switched 
to aminoglycoside were prone to evolutionary escape. Our results thus point to important 
limitations for the design of cycling treatments. High efficacy can be achieved by starting cycling 
treatments with the aminoglycoside (not the beta-lactam) and terminating therapy after two 
switches. We anticipate that our findings will contribute to the design of evolution-informed 
antibiotic therapy that controls infection and prevents the emergence of multidrug resistance.  
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Methods 
Bacteria and media 
All experiments were performed with the Pseudomonas aeruginosa PA14 lab strain and four 
derived resistant populations11: CAR-10, GEN-4, PIT-1 and STR-2. The resistant populations were 
previously selected for high level resistance against protein synthesis inhibitors from the 
aminoglycoside family; gentamicin (GEN; Carl Roth, Germany; Ref. HN09.1) or streptomycin (STR; 
Sigma-Aldrich, USA; Ref. S6501-5G), or alternatively cell-wall synthesis inhibitors from the β-
lactam family; carbenicillin (CAR; Carl Roth, Germany; Ref. 6344.2) or piperacillin/tazobactam 
(PIT; Sigma-Aldrich, USA; Refs. P8396-1G and T2820-10MG). Tazobactam was supplied at the 
concentration of 1.0 µg/ml. Antibiotic stocks were prepared according to manufacturer 
instructions and frozen in 100µl aliquots. Aliquots were kept frozen at -20˚C for no more than 5 
days, thawed only once and discarded after use. For isolation of clones, bacteria were grown on 
LB plates supplemented with the respective antibiotic at 37˚C overnight. Evolution experiments 
and resistance measurements were performed in liquid M9 minimal media supplemented with 
glucose (2g/l), citrate (0.5g/l) and casamino acids (1g/l). These experiments were conducted in 
randomized 96-well plates, shaken (180rpm double orbital shaking) and incubated at 37˚C in 
plate readers (BioTek Instruments, USA; Ref. EON), which recorded optical densities (OD600) in 15 
min intervals. 
Genetic resistance trade-off 
Previously, we identified reciprocal collateral sensitivity in evolved antibiotic resistant 
populations11. Populations adapted to high concentrations of CAR and PIT had, respectively, 
increased sensitivity against GEN and STR, and vice versa. We confirmed the trade-off for this 
study by re-measuring the hypersensitivity of populations CAR-10, GEN-4, PIT-1 and STR-2 in 
comparison to wildtype PA14 (10 concentrations, 8 replicates). Cultures were grown to 
exponential phase, standardized by OD (OD600=0.08) and diluted 10x into 96-well plates (total 
volume 100µl), yielding initial population sizes of ~106 CFU. Plates were shaken and incubated at 
37˚C for 12 hours. End-point measurements were then used to measure the dose-response 
relationship of each drug using the ‘drc’ package in the R platform 28. 
Experimental evolution 
To test the evolutionary stability of reciprocal collateral sensitivity, we challenged clones from 
previously evolved resistant populations with increasing concentrations of new antibiotics 
against which the resistant populations were hypersensitive: CAR-10 with GEN, GEN-4 with CAR, 
PIT-1 with STR, and STR-2 with PIT. Stability was assessed with 12-day evolution experiments 
with 2% serial transfers every 12 h. Each population was evaluated with 8 replicate populations 
(4 clones x 2 technical replicates) for each of 5 treatment groups: (i) untreated controls; linearly 
increasing concentration of hypersensitive antibiotic to a low level (ii) or high level (iii), without 
maintaining selection for previous resistance (unbound evolution); or linearly increasing 
concentration of hypersensitive antibiotic to a low level (iv) or high level (v), with simultaneous 
selection for previous resistance (bound evolution). Concentration increases were started with 
defined initial inhibition levels of IC50 50% of the starting clone (IC50) and concluded when 
concentrations were above its IC95 (mild increases) or IC95 of the wildtype PA14 lab strain (strong 
increases), as specified in Supplementary Table 1. At the end of the experiment, evolved 
populations were frozen at -80˚C in a 1:10 v/v proportion of sterile DMSO for characterization. 
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Dose-response measurements 
We evaluated whether surviving lineages maintained or lost their ancestral resistance by 
exposing them to 2-fold concentrations of the drug they were challenged during experimental 
evolution and the one they were originally resistant to. Experiments were carried out as explained 
above, and included the starting clone of each evolved population as a control. We calculated the 
difference in resistance by subtracting the area under the dose-response curve of the evolved 
populations from that of the ancestral clones. Positive values indicate that the evolved lineages 
are more resistant than their ancestor, values close to zero suggest the resistance profile is 
equivalent and negative values highlight the loss of resistance. 
DNA Extraction 
We sequenced the genomes of 9 ancestral, and 35 evolved populations using samples from the 
end of the evolution experiments. The evolved populations were split thus: 9 from bound (3 
strong+bound, 6 mild+bound), 16 from unbound evolution (7 strong, 9 mild) and 8 untreated 
controls. Frozen material was thawed and grown in 10ml of M9 minimal medium for 16-20h at 
37˚C with constant shaking. DNA was extracted using a modified CTAB buffer protocol29. All DNA 
samples were sequenced at the Institute for Clinical Microbiology, Kiel University Hospital, using 
Illumina HiSeq paired-end technology30 with an insert size of 150bp and 300x coverage. Overall, 
we found a total of 164 silent and 442 non-silent mutations (missense variants and short INDELS) 
in 63 protein-coding genes, including many previously characterized antibiotic resistance genes 
(Supplementary Data 1). 
Genomic analysis 
For the genomic analysis of P. aeruginosa PA14, we followed an established pipeline31. Briefly, 
reads were trimmed with Trimmomatic32, and quality-filtered with Skewer33. We used the 
published Pseudomonas_aeruginosa_UCBPP_PA14_NC008463 genome available at 
(http://pseudomonas.com/strain/download) for mapping our samples. Mapping was 
performed using bwa and samtools34,35, and manually inspected for low-quality areas using IGV 
(Integrated genome viewer, Broad Institute; www.broadinstitute.org/software/igv/). We used 
MarkDuplicates in Picardtools to remove duplicated regions for single nucleotide polymorphisms 
and structural variants (SNPs and SV). To call SNPs and small SV we employed both heuristic and 
frequentist methods, only for variants above a threshold frequency of 0.1 and base quality above 
20, using respectively VarScan and SNVer36. For larger SVs we employed Pindel and CNVnator 
37,37,38. We used a combination of sources to annotate variants using snpEFF39, DAVID, the 
Pseudomonas database (available online at: http://pseudomonas.com), and information from 
published work. Count statistics and data visualization were carried out in the R platform.  
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Supplementary material 
 
 
 
 
Supplementary Figure 1. Genomics of hypersensitivity reversal. Several populations started 
from distinct clones and challenged against GEN were selected for whole genome sequencing. 
Shown is the functional effect of mutations found in coding regions of the listed genes (vertical 
axis, left side) in the different starting clones (top horizontal axis), and across evolution 
experiments with different antibiotics (bottom horizontal axis). Functional information (right 
side) is inferred from a combined analysis using DAVID, the Pseudomonas database and 
publications. The shape of the point indicates whether it was found in the ancestor or only in the 
evolved population and the different colors highlight the effect of the variants found. The size of 
the points denotes the frequency at which the variant was found in the reads.  
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Supplementary Figure 2. Genomics of hypersensitivity reversal. Several populations started 
from distinct clones and challenged against CAR were selected for whole genome sequencing and 
analyzed as in Fig. S1. 
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Supplementary Figure 3. Genomics of hypersensitivity reversal. Several populations started 
from distinct clones and challenged against STR were selected for whole genome sequencing and 
analyzed as in Fig. S1. 
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Supplementary Figure 4. Genomics of hypersensitivity reversal. Several populations started 
from distinct clones and challenged against PIT were selected for whole genome sequencing and 
analyzed as in Fig. S1. 
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Supplementary Table 1. Antibiotic concentrations for evolution experiment. 
Previously  
evolved  
resistant  
population  
New antibiotic For 
maintenance 
of original 
resistance* 
First dose 
(IC50) 
Final dose 
mild† 
Final dose 
strong§ 
CAR-10 410 ng/ml 
GEN 
570 ng/ml 
GEN 
890 ng/ml 
GEN 
+87 µg/ml  
CAR 
GEN-4 
 
1.0 µg/ml 
CAR 
30 µg/ml 
CAR 
87 µg/ml 
CAR 
+890 ng/ml 
GEN 
PIT-1 2.2 µg/ml 
STR 
8.5 µg/ml 
STR 
21 µg/ml 
STR 
+4 µg/ml  
PIT 
STR-2 0.68 µg/ml 
PIT 
1.8 µg/ml 
PIT 
4 µg/ml  
PIT 
+21 µg/ml  
STR 
† IC95 of hyper-sensitive population specified in column 1, § IC95 of wildtype PA14, * added to 
treatment groups mild+bound, slow+bound. 
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Supplementary Table 2. Extinction events over time for each antibiotic used during 
experimental evolution and treatment (8 starting evolving populations). 
Challenged with  Treatment (n=8) 
Season 
8 16 24 
GEN Strong 0 0 0 
Mild 0 0 0 
Strong & bound 0 0 0 
Mild & bound 0 0 0 
CAR Strong 1 1 1 
Mild 0 0 0 
Strong & bound 5 6 6 
Mild & bound 0 0 0 
STR Strong 5 6 6 
Mild 0 0 0 
Strong & bound 5 6 6 
Mild & bound 3 5 5 
PIT Strong 2 3 3 
Mild 2 2 2 
Strong & bound 6 6 6 
Mild & bound 3 4 4 
 
 
 
Supplementary Table 3. Evaluation of the effect of the pace of drug increase (mild or strong) 
and evolutionary constraint (bound or unbound) on cumulative relative growtha. 
Antibiotic Variable χ2 P  Adjusted P 
GEN Pace 14.7 <0.0001 0.0002 
Bound 158.1 <0.0001 <0.0001 
CAR Pace 18.1 <0.0001 <0.0001 
Bound 53.8 <0.0001 <0.0001 
STR Pace 2.3 0.1313 0.15 
Bound 29.4 <0.0001 <0.0001 
PIT Pace 9.6 0.0022 0.0023 
Bound 0.4 0.52 0.52 
a  Separate GLMs were performed for each antibiotic used during experimental evolution with the 
cumulative relative growth of surviving populations as the response variable, and pace of drug 
concentration increase (strong or mild) and constraint (unbound or bound) as explanatory fixed 
factors.  Starting clonal population was considered as a nested random factor. We used a type-II 
Wald χ2-test to evaluate the effect of these variables. We used the false discovery rate to adjust the 
P values for multiple comparisons. 
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Supplementary Table 4. Evaluation of the changes in resistance against two drugs after 
evolutionary reversal of antibiotic hypersensitivity*.  
Resistant to Challenged with Treatment Number populations P  Adjusted P 
CAR CAR No drug 8 0.92123 0.94485 
Strong 8 0.71558 0.7736 
Strong+bound 8 0.96151 0.96151 
Mild 8 0.514 0.6425 
Mild+bound 8 0.20661 0.29516 
CAR GEN 
 
No drug 8 0.61526 0.72291 
Strong 8 2.00E-05 0.00013 
Strong+bound 8 0.00159 0.00489 
Mild 8 0.00031 0.00124 
Mild+bound 8 0.00044 0.0016 
GEN 
 
CAR 
 
No drug 8 <0.00001 <0.00001 
Strong 7 <0.00001 <0.00001 
Strong+bound 2 0.05758 0.10237 
Mild 8 <0.00001 <0.00001 
Mild+bound 8 <0.00001 <0.00001 
GEN 
 
GEN 
 
No drug 8 0.01936 0.03872 
Strong 7 0.00013 0.00065 
Strong+bound 2 0.47766 0.61634 
Mild 8 <0.00001 <0.00001 
Mild+bound 8 0.00023 0.00102 
PIT 
 
PIT No drug 8 0.36843 0.49124 
Strong 2 0.01071 0.0252 
Strong+bound 2 0.70115 0.7736 
Mild 8 0.26425 0.36448 
Mild+bound 3 0.63255 0.72291 
PIT 
 
STR 
 
No drug 8 0.04131 0.07869 
Strong 2 0.01344 0.0284 
Strong+bound 2 0.01349 0.0284 
Mild 8 0.00058 0.00193 
Mild+bound 3 0.00191 0.00546 
STR 
 
PIT 
 
No drug 8 0.13735 0.21976 
Strong 4 0.00501 0.01252 
Strong+bound 2 0.05886 0.10237 
Mild 6 <0.00001 0.00057 
Mild+bound 4 0.00451 0.01203 
STR 
 
STR 
 
No drug 8 0.0977 0.16283 
Strong 4 0.90519 0.94485 
Strong+bound 2 0.17739 0.2628 
Mild 6 0.58964 0.71472 
Mild+bound 4 0.1627 0.25031 
* P values were obtained from a series of Student’s t-tests per treatment for populations with 
ancestral resistance against a given antibiotic and evaluated against two drugs. We used the false 
discovery rate correction method to adjust P values for multiple comparisons. 
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Supplementary Data 1. Table of all mutated genes per population, antibiotic and treatment. 
Sequenced  
population*  
Treatment 
 Genetic variant§ Resensitization 
against first 
antibiotic 
Freq. Gene Site Length 
CAR-10 (clone 2) ancestor 1 ftsI 5116490 1  
CAR-10 (clone 2) ancestor 1 ftsL 5118028 1  
CAR-10 (clone 2) ancestor 1 nalC 1391016 -558  
CAR-10 (clone 2) ancestor 1 cpxS 1977519 1  
b24_A3 mild 1 ftsI 5116490 1 -  
mild 1 ftsL 5118028 1 -  
mild 1 nalC 1391016 -558 -  
mild 1 cpxS 1977519 1 - 
  mild 0.94 ptsP 393529 1 - 
b24_F2 mild+bound 1 ftsI 5116490 1 -  
mild+bound 1 ftsL 5118028 1 -  
mild+bound 1 nalC 1391016 -558 -  
mild+bound 0.96 cpxS 1977519 1 -  
mild+bound 0.9 nuoG 2593381 1 -  
mild+bound 0.9 nuoG 2593382 1 - 
  mild+bound 0.9 nuoG 2593383 1 - 
b24_C1 strong 1 ftsI 5116490 1 -  
strong 1 ftsL 5118028 1 -  
strong 1 nalC 1391016 -558 -  
strong 1 cpxS 1977519 1 -  
strong 0.98 pmrB 5637059 1 - 
  strong 1 ptsP 393833 1 - 
b24_B2 strong+bound 1 ftsI 5116490 1 -  
strong+bound 1 ftsL 5118028 1 -  
strong+bound 1 nalC 1391016 -558 -  
strong+bound 1 cpxS 1977519 1 -  
strong+bound 0.98 nuoD 2596430 1 - 
  strong+bound 1 parS 3683342 1 - 
GEN-4 (clone 1) ancestor 1 pmrB 5637090 1  
b24_H8 mild 1 pmrB 5637090 1 yes 
  mild 0.35 PA14_41280 3685053 1 yes 
b24_E9 mild+bound 1 pmrB 5637090 1 - 
  mild+bound 0.95 cpxS 1977308 1 - 
GEN-4 (clone 2) ancestor 1 pmrB 5637090 1  
b24_A9 mild 1 pmrB 5637090 1 yes  
mild 0.31 PA14_29760 2577421 1 -  
mild 0.3 PA14_29760 2577418 1 -  
mild 0.26 PA14_29760 2577412 1 -  
mild 0.21 antC 2795876 1 - 
  mild 0.2 nalD 1551588 1 - 
b24_F8 mild+bound 0.99 pmrB 5637090 1 - 
  mild+bound 0.99 mexR 486253 1 - 
b24_C7 strong 1 pmrB 5637090 1 yes  
strong 1 pmrB 5637230 -225 yes 
  strong 0.93 nalC 1390987 -5 yes 
GEN-4 (clone 3) ancestor 1 pmrB 5637090 1  
b24_D9 mild 1 pmrB 5637090 1 yes 
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  mild 0.29 nalD 1551588 -1 yes 
b24_C8 mild+bound 1 pmrB 5637090 1 -  
mild+bound 0.74 mexR 486331 1 - 
  mild+bound 0.95 phoQ 4369873 1 - 
b24_F7 strong 1 pmrB 5637090 1 yes 
  strong 1 nalC 1391237 -200 yes 
b24_H7 strong+bound 1 pmrB 5637090 1 -  
strong+bound 1 lpxO2 4624709 1 -  
strong+bound 1 mutS 1501522 1 -  
strong+bound 0.88 orfH 2030085 1 -  
strong+bound 1 cpxS 1977213 1 -  
strong+bound 1 PA14_29560 2563755 1 -  
strong+bound 1 PA14_54980 4884493 1 -  
strong+bound 1 PA14_66170 5894687 1 -  
strong+bound 0.89 yeaM 4303970 1 -  
strong+bound 0.53 PA14_70740 6299422 1 -  
strong+bound 0.51 PA14_70200 6259755 -1 - 
  strong+bound 0.5 btuC 2298608 1 - 
GEN-4 (clone 4) ancestor 1 pmrB 5637090 1  
b24_G7 mild 1 pmrB 5637090 1 yes  
mild 0.78 pmrB 5637232 -17 yes 
  mild 0.62 nalC 1391004 1 yes 
b24_A8 mild+bound 1 pmrB 5637090 1 -  
mild+bound 0.57 orfM 2039243 -8 - 
  mild+bound 0.64 nalD 1551227 -8 - 
b24_G8 strong 1 pmrB 5637090 1 yes 
  strong 1 nalD 1551588 1 yes 
PIT-1 (clone 1) ancestor 0.8 mpl 1026509 1  
PIT-1 (clone 1) ancestor 1 nalC 1391367 1  
b24_H5 mild 1 PA14_59230 5276901 1 yes  
mild 1 ipk 5510048 1 yes 
  mild 0.66 gidB 6550306 -3 yes 
PIT-1 (clone 3) ancestor 0.87 mpl 1026509 1  
PIT-1 (clone 3) ancestor 0.95 dacC 1046463 -3  
PIT-1 (clone 3) ancestor 1 nalC 1391367 1  
b24_D6 mild 0.89 mpl 1026509 1 -  
mild 0.88 dacC 1046463 -3 -  
mild 1 nalC 1391367 1 - 
  mild 1 gidB 6530122 1 - 
b24_F4 strong 1 gidB 6550306 -3 yes 
  strong 1 ipk 5510095 1 yes 
STR-2 (clone 2) ancestor 1 pcrD 3784765 1  
STR-2 (clone 2) ancestor 0.97 ipk 5510095 1  
STR-2 (clone 2) ancestor 0.75 gidB 6530306 -3  
b24_H11 mild 1 ipk 5510095 1 -  
mild 0.73 gidB 6530306 -3 - 
  mild 0.5 nalC 1391216 -12 - 
b24_E10 strong 1 pmrB 5637090 1 yes  
strong 0.8 cpxS 1977519 1 yes 
  strong 0.78 PA14_23420 2035186 1 yes 
STR-2 (clone 4) ancestor 1 pcrD 3784765 1  
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STR-2 (clone 4) ancestor 1 ipk 5510048 1  
STR-2 (clone 4) ancestor 0.75 gidB 6530306 -3  
b24_G10 mild 0.9 PA14_23430 2037005 1 yes  
mild 1 PA14_41710 3723476 -330 yes  
mild 1 pmrB 5637090 1 yes  
mild 0.49 pcaK 255917 1 yes 
  mild 0.5 pcaK 255918 1 yes 
b24_E12 mild+bound 1 ipk 5510048 1 -  
mild+bound 1 gidB 6530306 -3 -  
mild+bound 0.97 PA14_59230 5276901 1 -  
mild+bound 0.74 pcaK 255918 1 - 
  mild+bound 0.75 pcaK 255917 1 - 
b24_G11 strong 1 ipk 5510048 1 -  
strong 1 mexR 486350 1 - 
  strong 1 PA14_59230 5276901 1 - 
b24_F12 strong+bound 1 ipk 5510048 1 -  
strong+bound 1 gidB 6530306 -3 -  
strong+bound 1 nalD 1551486 1 -  
strong+bound 1 PA14_59230 5276901 1 - 
 strong+bound 0.67 clpA 2618923 1  
* All samples from plate B, season 24; § Dark shading denotes ancestral mutations, light shading 
represents their maintenance in evolved populations. Freq., frequency. 
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One-sentence summary 
Antibiotics that induce physiological hysteresis reduce selection for drug resistance in 
sequential treatment protocols 
 
Abstract 
Antibiotic resistance can be mediated by inducible changes in cellular physiology. Surprisingly, 
such physiological effects are not part of the current concepts on the evolution of drug resistance. 
By combining experimental evolution, mathematical modelling, genomics, and functional 
genetics, we specifically tested whether bacterial evolution under sequential antibiotic therapy is 
shaped by negative hysteresis, which we here define as the survival-reducing physiological 
change induced by an earlier applied antibiotic. We demonstrate that sequential protocols with 
high frequencies of these physiological constraints impede resistance evolution, because selection 
favors an escape from negative hysteresis over resistance gains. Conversely, sequential protocols 
with little negative hysteresis enhance drug resistance. Our findings highlight the interplay 
between inducible physiological effects and resistance evolution and point to new ways of 
optimizing antibiotic therapy. 
Main text 
Natural environments are often temporally dynamic. They produce continuously changing 
selective constraints that are a particular challenge for organisms to adapt to (1). Similar dynamic 
conditions may be applied in our health system to limit the alarming ability of pathogens for 
resistance evolution. Antibiotic resistance is a global threat (2) and quickly growing by the 
emergence of new resistance mechanisms (3, 4). Cycling treatments may be one option to counter 
emerging resistance (5–8), for example when they exploit evolved collateral sensitivities, where 
the evolution of resistance against a first drug increases sensitivity to a second drug (9, 10). We 
here report a new approach for sequential drug treatments based on antibiotic-induced 
physiological constraints. Our approach takes advantage of hysteresis, which we here define as 
the change in physiology induced by a particular antibiotic that then alters susceptibility of an 
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individual cell to a second antibiotic, thus emphasizing the importance of prior experience for the 
physiological state of a particular cell (11). Negative hysteresis increases while positive hysteresis 
decreases susceptibility to the second drug, potentially reducing or enhancing bacterial survival 
upon drug change, respectively. The general phenomenon was already described in 1962 by Plotz 
and Davis in an attempt to explain the synergistic interaction between two simultaneously applied 
drugs. Short pre-treatments of Escherichia coli with penicillin caused transient damage to the cell 
wall that increased streptomycin uptake, leading to faster killing (12). Hysteresis has not yet been 
applied to drug cycling. Here, we specifically tested the potential of negative hysteresis to increase 
efficacy of cycling treatments using the human pathogen Pseudomonas aeruginosa as a model. 
 
 
Hysteresis depends on the order of drug switches 
We first characterized the hysteresis landscape (Fig. 1) of P. aeruginosa for three distinct and 
clinically relevant bactericidal antibiotics: the fluoroquinolone ciprofloxacin (CIP), the 
aminoglycoside gentamicin (GEN), and the beta-lactam carbenicillin (CAR) (13). As described for 
E. coli, we now found for P. aeruginosa that short pre-treatments with non-lethal concentrations 
of the beta-lactam increased killing by the aminoglycoside (i.e., negative hysteresis for CAR 
followed by GEN; Fig. 1B), while the reverse order slightly inhibited bactericidal activity (i.e., 
positive hysteresis; Fig. 1C; Fig. S1). We further identified a new hysteresis interaction between 
the aminoglycoside and the fluoroquinolone, GEN and CIP, two drugs with strong antagonistic 
interaction when simultaneously applied (Fig. S2). Pre-treatment with GEN caused positive, while 
the reverse direction negative hysteresis (Fig. 1C, Fig. S1). These results highlight that the sign of 
hysteresis can depend on drug order and that hysteresis and drug interaction are not necessarily 
linked, as originally assumed by Plotz and Davis (12).  
 
Fig. 1. Short antibiotic exposures affect killing by other 
antibiotics. (A) Schematic of time-kill experiment with 15 min 
pre-treatments. (B) Pre-treatments with non-lethal 
concentrations of ciprofloxacin or carbenicillin accelerate 
bactericidal activity of gentamicin, shown as concentration of 
viable cells (mean ± SEM, 6 technical replicates). CAR, 
carbenicillin; CIP, ciprofloxacin; GEN, gentamicin. (C) Short pre-
treatments can induce negative or positive hysteresis 
dependent on the direction of switches. 
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Fig. 2. Fast antibiotic cycling can constrain resistance evolution. (A) Schematic of evolution experiment 
with 16 different sequences. (B) The level of negative hysteresis differs between and within treatment 
types. Hys per transfer, cumulative hysteresis factor along treatment divided by number of transfers. (C) 
Evolutionary dynamics, expressed as total growth relative to evolving untreated controls (mean ± CI95; 3-
6 sequences per treatment type and 12 biological replicates per sequence; extinct lineages excluded). (D) 
Variation of extinction frequencies per treatment. Numbers indicate sequence as in (A). 
 
Experimental evolution reveals constrained adaptation under fast sequential protocols 
To assess the potential of hysteresis for cycling therapy, we conducted a high-throughput 
evolution experiment with 190 replicate populations over a total of 96 transfers (~500 
generations). We included three main types of cycling protocols, in order to disentangle the 
influence of hysteresis from the frequency and also temporal regularity of drug switches. Two 
main types were regular but at different switching rates (e.g., fast vs. slow switches; Fig. 2A), while 
the third main type consisted of random drug orders (Fig. 2A). Within each type, several distinct 
sequences were included that varied in hysteresis level (Fig. 2B) and starting drug, while the 
overall proportion of the three antibiotics was equal. Across the 96 transfers, the observed 
evolutionary dynamics consisted of three main phases: an initial increase in growth yield within 
the first 12 transfers, then a phase of gradual improvement until approximately transfer 48, and 
thereafter a phase with little change (Fig. 2C). During the first two phases, fast-regular and 
random sequences led to significantly smaller biomass increases in comparison to the 
monotherapies, whereas slow regular sequences reached almost the high control biomass levels 
already in the second phase (Fig. 2C; statistics sheet 1; figs. S3-6). Some replicate populations went 
extinct and did so significantly more often in the fast-regular protocols (Fig. 2D; statistics sheet 
2). Extinction was also elevated in some random protocols. We conclude that the two treatment 
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types with fast drug changes constrained evolutionary adaptation and increased extinction 
frequencies. 
 
 
Fig. 3. Fast sequential treatments constrain early resistance evolution, due to hysteresis and evolved 
tolerance. (A) Resistance profiles of 320 clones isolated after transfer 12 from 16 populations; the clones 
are indicated by bars within the boxes for a particular treatment. (B) Resistance profiles of 320 clones 
isolated from the same populations after transfer 48. (C) Within-population diversity as determined by 
hierarchical clustering of resistance profiles at the same early and late time points. Different colors denote 
the distinct types per population. (D) Growth rate under drug-free conditions for the same two time points. 
Low growth combined with no resistance indicates tolerance (see #12 early time point). (E) Multidrug 
resistance (MDR) across sequences, inferred from an expansion of the initial analysis with a total of 880 
isolates (mean ± SEM, n = 3-6 populations, 5-20 clones per population). (F) The experienced degree of 
negative hysteresis is significantly correlated with MDR levels after transfer 12. (G) A mathematical model 
tailored to our experimental design predicts that fast cycling leads to reduced population diversity in the 
presence (+hys) but not absence (-hys) of hysteresis. 
 
Hysteresis reduces population diversity in fast cycling 
We next assessed in more detail the evolved changes by characterizing 20 bacterial isolates of one 
representative population from each of the 16 treatments at two time points, defining the 
approximate end of the early (transfer 12) and the middle phases (transfer 48). For the resulting 
640 isolates, we determined antibiotic resistance profiles and growth under drug-free conditions. 
In agreement with the recorded evolutionary dynamics (Fig. 2C), mean resistance varied 
substantially among sequences at the early time point (Fig. 3A), and less so at the later time point, 
at which resistance had generally increased (Fig. 3B). Surprisingly, we found significantly fewer 
resistance types (13) in populations from fast than slow-regular sequences (Fig. 3C; figs. S7, S8; 
statistics sheet 3). Populations from fast-regular sequences were mostly dominated by a single 
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type, whereas populations from slow-regular sequences were divided into 3-4 types. The 
presence of such sub-populations was validated with a complete repetition of the measurements 
(14) (Fig. S9; statistics sheet 4). Moreover, whole-genome sequencing of a representative subset 
of the isolates confirmed that the sub-populations were genetically distinct (Table S1). These 
results contrast with expectations from population genetic theory, because fast switching should 
have rather prevented competitive exclusion and, instead, caused oscillation of multiple types 
parallel to antibiotic exposure. To assess these dynamics in more detail, we developed and 
analyzed a mathematical model tailored to the design of the evolution experiment (13). Under 
standard conditions, the model captured the expected clonal interference and coexistence of 
several types under fast cycling conditions (Fig. 3G). Importantly, when we added hysteresis 
effects to the model, then we found increased selection pressure and a reduction of diversity, 
especially for the fast treatments (Fig. 3G; figs. S10-S13). These observations suggest that 
hysteresis acts as a strong selective constraint during drug cycling and influences diversity within 
the evolving populations. 
Hysteresis is a main determinant of evolved multidrug resistance 
We next asked whether differences in hysteresis levels are associated with variation in evolved 
drug resistance and other phenotypic traits. Resistance varied among and also within the main 
treatment types, most strongly at the early time point (Fig. 3A). Intriguingly, populations treated 
with sequence #12 had zero resistance at transfer 12 (Fig. 3A), and similar success was achieved 
by sequences #5 and #15, in which resistance only increased marginally. To validate the variation 
of drug resistance, we used a larger sample of isolates (240 additional isolates across replicates) 
to calculate a score for multidrug resistance, MDR (13). MDR was significantly lower after fast-
cycling than after slow-cycling (statistics sheet 5), yet the best and the worst cycling treatments 
were random sequences (Fig. 3E), suggesting that next to treatment type, the exact drug order 
and thus possibly the cumulative level of negative hysteresis is crucial. The highest cumulative 
level of negative hysteresis is achieved by sequence 12 (Fig. 2B), in which mean MDR was not 
significantly different from zero (measurements based on all surviving populations; statistics 
sheet 6). Indeed, hysteresis levels were significantly correlated to evolved MDR (Fig. 3F; statistics 
sheet 7), with the lowest resistance corresponding to the highest measure of negative hysteresis. 
Evolved MDR was also negatively associated to switching rate, but to lesser degree (Fig. S14). 
Moreover, hysteresis levels but not switching rates were significantly correlated with rates of 
biomass increase (Fig. S14). We conclude that even though switching rate is important, the 
consideration of hysteresis is sufficient to predict treatment efficacy under our experimental 
conditions, and that treatment efficacy is maximized by the abundance of negative hysteresis. 
Interestingly, the mathematical model indicated that negative hysteresis increases selection 
intensity (Fig. S12), yet the observed outcome was not MDR – as would be expected from 
competitive release (15) – but rather a constrained ability to evolve MDR (Fig. 3F). Thus, we 
hypothesized that hysteresis diverts adaptation towards unusual adaptive peaks. The presence of 
an alternative evolutionary response specific against negative hysteresis is indicated by our 
additional analyses of growth rate (13). Almost all drug protocols resulted in reduced growth 
rates under drug-free conditions (Fig. 4D, validated with colony counts, Table S2; statistics sheet 
8), but the three sequences (#5, #12, #15) with high negative hysteresis and almost no evolved 
MDR showed the strongest growth reductions of up to 42% (Fig. 3D). The combination of reduced 
growth under drug-free conditions and high drug susceptibility is indicative of antibiotic 
tolerance (16), which could thus have been favored through selection by negative hysteresis. 
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Fig. 4. Evolutionary adaptation to negative hysteresis. (A) Evolved multidrug resistance of isolates from 
fast, slow and random cycling and constructed mutants with corresponding mutations (mean ± SEM, 6-20 
technical replicates). The top two bars refer to the isolates, the bottom bars to the defined mutant. (B) 
Isolate from #12 with mutation in ispA shows antibiotic tolerance and thus reduced cellular death over time. 
(C) Presence of negative hysteresis in different genotypes. Pre-treatments with CAR (solid lines) inhibited 
subsequent growth in the presence of GEN in wt and mexR T130P, but neither in cpxS T163P nor ispA Y249D 
mutants (mean ± SEM; 6 technical replicates). (D) Confirmation of hysteresis phenotypes as the dynamics 
of dead cells over time by flow-cytometry (mean ± SEM; 3 technical replicates). 
 
Negative hysteresis favors genetic changes mediating tolerance and a novel response 
To further validate the selective impact of negative hysteresis during sequential therapy, we 
characterized the genes that have likely been the targets of selection using whole-genome 
sequencing of 30 phenotyped isolates (Fig. 3), followed by functional genetic analysis in selected 
cases (13). The genomic characterization revealed different sets of mutations to be favored by the 
main treatment types (Table S1; figs. S15, S16). Isolates from the most effective protocols with 
highest cumulative levels of hysteresis (sequences #5, #12, #15) did not have any unique 
mutations in common (Table S1). Yet, the sequenced isolate from protocol #12 harbored a 
mutation that is likely to mediate tolerance. Based on time-kill experiments (17) with this isolate, 
we could indeed confirm antibiotic tolerance, including absence of resistance, decreased growth 
in the absence of drugs combined with reduced killing rates on all three antibiotics relative to the 
ancestor (Fig. 4B; Tables S2, S3). The isolate has two mutations, one leading to an amino acid 
change in ispA (Y249D) and a frame shift in the glycine cleavage gene gcvT2. Because the gcvT2 
mutation occurred across treatment groups (Table S1), we propose that the ispA mutation is the 
adaptive mutation that caused tolerance through reduced growth, most likely due to the toxic 
accumulation of isoprenyl diphosphates, as previously recorded for a ispA E. coli deletion mutant 
(18). In the first stage of the evolution experiment, sequence #12 was enriched for the negative 
hysteresis switch CAR->GEN. A re-assessment of the CAR->GEN hysteresis showed that negative 
hysteresis could no longer be induced in this isolate (figs. 4C, 4D). We conclude that selection by 
negative hysteresis in sequence #12 was countered by the emergence of antibiotic tolerance, 
mediated through a mutation in ispA. 
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One of the other effective protocols, #5, had a mutation in the previously uncharacterized, 
putative two-component sensor cpxS (PA14_22730, Fig. S14), which is related to the E. coli 
envelope stress response system CpxA-CpxR. This stress response system is activated by 
misfolded proteins, as caused by aminoglycosides (19), and involved in intrinsic resistance to 
these drugs in E. coli (20). CpxS mutations were significantly enriched in fast-regular protocols 
(statistics sheet 9), including those with little indication of antibiotic tolerance. Even though it 
may not cause tolerance, this gene could still contribute to the evolutionary response against 
negative hysteresis. To explore this idea, we re-introduced one prevalent cpxS mutation (leading 
to the amino acid substitution T163P) into the ancestral background (13) and compared it to the 
ancestor and also the similarly generated mexR mutant as a control (including a T130P amino acid 
substitution found in an isolate from slow regular sequence #10). MexR regulates the multidrug 
efflux pump MexAB-OprM, which can extrude the three drug classes (21), potentially conferring 
complete resistance. The tested mexR mutation is unlikely favored by negative hysteresis as this 
gene was only mutated under slow-regular conditions (Fig. S15; statistics sheet 9). Our analysis 
now revealed that resistance against CIP and CAR was moderate for the cpxS mutant, but strongly 
increased for the mexR mutant, while neither mutation altered resistance to GEN (figs. 4A, S17). 
Importantly, using two independent methods to assess CAR->GEN hysteresis (13), we 
consistently found that negative hysteresis was abolished in the cpxS mutant, but still present in 
the mexR mutant (figs. 4C, 4D). We conclude that mutations in cpxS were most likely favored in 
fast cycling protocols to counter negative hysteresis, independent of antibiotic tolerance, while 
mexR mutations enhanced antibiotic resistance in slow-regular sequences. 
 
 
 
An independent experimental test validates the importance of negative hysteresis 
Inspired by Lewontin (22), we specifically re-evaluated the influence of hysteresis by repeating 
evolution experiments with the reversed order of drugs for the most effective sequence #12 and 
the least effective sequence #13. The reverse sequences had the same drug proportions and the 
same number of switches as the original sequences (Fig. 5A), but the direction of the transitions 
was opposite. As a consequence, all was equal except that the cumulative level of negative 
hysteresis was decreased by 10% in the first case and increased by 11% in the second case. As 
expected, reversing #12 decreased extinction frequency (Fig. 5B) and significantly increased 
resistance gains (Fig. 5C; statistics sheet 10). Conversely, reversing #13 increased extinction (Fig. 
5B), although resistance was not affected (statistics sheet 10), most likely because only few 
populations survived and could thus be used for resistance analysis. These results clearly 
demonstrate that negative hysteresis can determine the efficacy of fast sequential therapy. 
Fig. 5. Reversal of sequences predictably alters treatment 
efficacy due to changes in hysteresis. (A) Reversal of the first 
12 treatment steps in two sequences changes hysteresis 
characteristics. Neg. hys, cumulative negative hysteresis. (B) 
Change in hysteresis predictably changes extinction 
frequencies. (C) Decreasing hysteresis significantly increases 
resistance in surviving lineages (mean ± SEM, n = 3 antibiotics). 
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Conclusions 
We here report that antibiotics can induce changes in bacterial cellular physiology that increase 
or inhibit the bactericidal activity of other antibiotics and can be exploited by sequential therapy 
to maximize treatment efficacy. Fast changes between antibiotics are key, because they can 
increase the cumulative effect of negative hysteresis, leading in our experiments to a reduction in 
population phenotypic variation, the rate of biomass increase and MDR. We confirm that selection 
by negative hysteresis does not favor resistance mutations but rather mutations that counter the 
inducible physiological effects, such as those here demonstrated for ispA and cpxS. In contrast, we 
also show that slow drug changes enhance resistance evolution and thus target different sets of 
genes. Our findings may explain the limited success of antibiotic cycling in the clinic, where 
antibiotics are usually changed once per month or less often (23). They may also explain the 
results from one of the few clinical tests of fast cycling, published in 1988 and so far widely 
ignored, which demonstrated that the staggered application of drugs four-hours apart causes a 
significant reduction and often full clearance of P. aeruginosa from the lungs of a small cohort of 
cystic fibrosis patients (24). A further exploration of negative hysteresis may help to find new 
ways for improving antibiotic therapy – with the available drugs and thus without the need to 
isolate and characterize new antibiotic substances. 
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Manuscript supplement 
 
Negative hysteresis improves antibiotic cycling efficacy. 
 
 
Materials and methods 
Experimental design  
The objective of this work was to investigate how physiological constraints affect the evolution of 
pathogens during antibiotic sequential therapy. To address this question, we performed parallel 
evolution experiments with different sequential treatments. 
 
Design of antibiotic sequences 
We manually generated three regular sequences with three distinct antibiotics, ciprofloxacin 
(CIP), gentamicin (GEN), and carbenicillin (CAR). Each sequence started with a different 
antibiotic. The regular treatments were carried out at two switching frequencies, yielding 
treatments ##5 -7 with switches every 12h and ##8-10 with switches every 48h. We further 
generated six cycling treatments ##11-16 with random order from atmospheric noise 
(random.org, Randomness and Integrity Services Ltd., Ireland; Random Sequence Generator, 
timestamp 2015-05-31 10:07:29 UTC) and rotated them to obtain two treatments each starting 
either with CIP, GEN or CAR. All sequential treatments contained equal frequencies of CIP, GEN 
and CAR, but differed in their levels of negative hysteresis. Sequences are shown in Fig. 2A and 
the variation in hysteresis in Fig. 2B. Overall, this experimental design allowed us to disentangle 
the influence of hysteresis from starting drug, cycling rate, and switching regularity, which are all 
likely to influence evolutionary adaptation of bacteria to antibiotic sequential therapy. 
 
Strains and media 
All experiments were started with Pseudomonas aeruginosa UCBPP-PA14 (abbreviated ‘PA14’ or 
‘wt’ for wildtype), a pathogen with broad host-range that was originally isolated from a human 
burn wound (25). We grew bacteria in M9-minimal media supplemented with glucose (2g/l), 
citrate (0.5g/l) and casamino acids (1g/l), to which we added antibiotics where required. 
Carbenicillin (CAR; Carl Roth, Germany; Ref. 6344.2) is a beta-lactam antibiotic that inhibits 
transpeptidase-activity during cell wall synthesis. The fluoroquinolone antibiotic ciprofloxacin 
(CIP; Sigma-Aldrich, USA; Ref. 17850-5G-F) inhibits the unwinding of DNA during DNA 
replication. Gentamicin (GEN; Carl Roth, Germany; Ref. HN09.1) is an aminoglycoside antibiotic 
that inhibits translation of protein synthesis but also produces membrane damage. These 
antibiotics are commonly used for clinical treatment of P. aeruginosa. The antibiotics were 
dissolved, and stored according to manufacturer’s recommendations in aliquots for single use. 
Fresh stocks were prepared in fixed intervals. 
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Time-kill experiments and hysteresis measurements 
To measure hysteresis, we performed time-kill experiments with short pre-treatments as 
previously described (12). Bacteria were grown to exponential phase (OD600 = 0.08, 8x107 colony 
forming units (cfu)/ml) and the culture was split into 10 ml cultures and pre-treated with 
antibiotics for 15 min, or not treated. It is important, that these pre-treatments were non-lethal, 
which we confirmed with cfu-counts and by live-dead staining and flow cytometry. Thereafter, 
cells were pelleted by centrifugation (10 min, 4000rpm, 4°C), media discarded and pellets re-
suspended in media containing an antibiotic and incubated at 37°C and orbital shaking. Samples 
were taken in 1h intervals for a total of 6h and plated on LA plates in serial dilutions. Cfus were 
counted after 24h incubation at 37°C. Concentrations were CIP 40 ng/ml, GEN 480 ng/ml, CAR 50 
µg/ml. Time-kill data is shown in figs. 1B, S1 and S11.  
Hysteresis was quantified by subtracting cfu-counts of pre-treated and untreated cultures. Cfu-
counts were corrected for the growth of the untreated cultures during the 15min pre-treatment. 
Hysteresis factors, were defined as the sum of Log10-differences divided by the number of time 
points (average). Calculated hysteresis factors are shown in figs. 1C and S10.  
To quantify the experienced level of hysteresis for the different antibiotic sequences in the 
evolution experiment, we counted the numbers of the six different drug switches (CIP->GEN, CIP-
>CAR, GEN->CIP, GEN->CAR, CAR->CIP and CAR->GEN) up to a particular time point, the obtained 
counts were multiplied with the respective hysteresis factors, and the sum of products calculated, 
which was normalized by dividing by the number of transfers up to that time point. The inferred 
levels of hysteresis per transfer are shown in figs. 2B, 3F, 5A and S14. 
 
Dose-response curves and drug-interaction measurements 
To measure dose-response curves, bacteria were grown to exponential phase (OD600 = 0.08, 8x107 
cfu/ml) and diluted 10-fold into antibiotic containing 96-well plates. Antibiotics were dosed in 
eight linearly increasing concentrations that exceeded the minimal inhibitory concentration 
(MIC). Concentrations were spatially randomized across the plate. Plates were incubated for 12h 
at 37°C and 1350 rpm shaking on microplate shakers (Heidolph Instruments, Germany; Ref. 
Titramax 100, 1mm orbital), after which we measured growth by optical density (OD600). Obtained 
dose response curves were analyzed to obtain standardized concentrations that achieved 75% 
inhibition (IC75) of final yield after subtraction of background OD600. Similarly we obtained 
information on drug interaction, by combining varying proportions of two antibiotics in a 
randomized checkerboard setup. Checkerboard data is shown in Fig. S2. Results based on dose-
response measurements are shown in figs. 3, 4A, 5C, S7A, and S8A, S17. 
 
Main evolution experiment 
The evolution experiment was started from six different starting cultures of P. aeruginosa PA14 
prepared from single colonies (biological replicates). These independent starting cultures were 
used to take account of stochastic influences, which may bias results from evolution experiments 
initiated with only a single clone. The starting cultures were grown to exponential phase (OD600 = 
0.08) and diluted to starting cell densities of 8x105 cells for the first treatment step. Each biological 
replicate was divided into 2 technical replicates, to take account of stochastic variation during the 
experiment, yielding a total of 12 replicates per treatment combination. Antibiotics were dosed to 
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achieve 75% inhibition (IC75) of final yield in this first treatment step and concentrations were 
constant for the whole experiment (CIP 40 ng/ml, GEN 500 ng/ml, CAR 50 µg/ml). Every 12h we 
transferred 2% of the population to fresh media, containing the same or a new antibiotic. In 
permissive conditions, 12h are sufficient to reach carrying capacity, and populations that reach 
carrying capacity grow 5.6 generations between transfers. The experiment was performed in 96-
well plates (Greiner Bio-One, Germany; Ref. 655161) that were incubated in plate readers (BioTek 
Instruments, USA; Ref. EON) with 180rpm double orbital shaking at 37°C for 96 transfers of 12h 
during which we measured OD600 every 15 min. The thus obtained time-series of growth curves 
is a high-resolution image of the evolutionary dynamics. We prepared a fossil record by freezing 
plates to -80°C every 12 transfers after adding the cryo-protectant DMSO at 10% (v/v).  
In this way, we evolved 190 populations: 16 treatments x 12 replicates each, except for the no-
drug reference #4, for which we had only 10 replicates in favor of empty wells in the microtiter 
plates for background subtraction. Treatments were systematically randomized and evenly split 
across two 96-well plates. Material preparation and transfers were done in a sterilized laminar 
flow hood. Treatment IDs were coded to exclude observer bias. 
Before the experiment, we tested for the existence of spatial gradients in the plate readers. We 
discovered a gradient for aminoglycosides (GEN and streptomycin), but none for CIP, CAR or 
growth without antibiotics. The aminoglycoside-caused gradient only occurred in columns 7-12. 
Treatment by GEN was therefore always carried out in the unaffected half of the plate (columns 
1-6). 
As a measure for treatment efficacy we calculated the integral of the growth curve (area-under 
curve, AUC) divided by the integral for the untreated reference evolving in parallel (relative AUC; 
‘Relative biomass’ in Fig. 2C). Low values denote sensitivity to treatment, whilst a value of 1 
represents un-inhibited growth. Relative AUC is more sensitive and reproducible than endpoint 
population sizes or growth rates (6, 15, 26, 27) because it contains information of all growth 
phases. Data is shown in Fig. 2C and Fig. S5. 
To evaluate the rate of the long-term evolutionary adaptive response, we calculated rates of 
biomass increase using a sliding window approach. Rate of biomass increase was defined as the 
X-1, where X is the transfer at which the mean relative AUC of a sliding window of 12 transfers 
reaches 0.75 for the first time. This measure is related to the previously defined ‘rate of 
adaptation’ (28), which was originally defined for constant environments, yet not applicable to 
adaptation in fluctuating environments, in which growth often oscillates in parallel to antibiotic 
switching. Our measure is less biased by such oscillations and thus more broadly applicable, 
including the here used fluctuating environments. Calculated rates of biomass increase are shown 
in Fig. S6. 
Frequencies of population extinction were determined after transfer 96 by counting the cases in 
which no growth was observed after inoculation of drug-free media and incubation for 24h. 
Extinction frequencies are shown in Fig. 2D. 
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Mathematical model 
We developed a deterministic model to explore the ability of different sequences of drugs to limit 
increase of population size by evolution of resistant types. We made use of a modified version of 
a logistic growth model (competition for space) that included mutation,  
 
The equation refers to the typical logistic growth of different bacterial genotypes, with density xi 
and growth rate ri. Each genotype has three growth rates, for each of the possible treatments (CIP, 
GEN and CAR), ri = {riCIP, riGEN, riCAR}. The mutation rate denoted by qji allows the change of 
genotypes j to another genotype i. The carrying capacity is defined by K. To simulate serial 
transfers the mixture of types is diluted by a dilution factor DF at the end of each season. If the 
density of a genotype falls below the cutoff k during dilution, it is lost and can only reappear via 
mutation. Following dilution, treatments can either switch in any of the following directions (CIP-
>GEN, CIP->CAR, GEN->CIP, GEN->CAR, CAR->CIP and CAR->GEN) or be repeated (CIP->CIP, GEN-
>GEN, and CAR->CAR). 
The model was parameterized to fit the conditions in the main evolution experiment. K = 108 cells, 
DF = 50 applied every 12h, k = 10. Population size is K/4 (IC75) directly before the first transfer. 
Using this model, we generated growth dynamics for a simple system with four competing 
genotypes, the non-resistant wt and three mutants. The mutants are individually resistant to CIP, 
GEN, or CAR, and are parameterized according to the measurements of evolved bacterial isolates 
from the mono-treatments ##1-3 (isolates 12-1a-G8-3, 12-1b-B2-8 and 12-1b-E8-3 for CIPR, GENR 
and CARR, respectively; see Fig. 3A for an overview of evolved resistances under monotherapy), 
as indicated in the following table R:  
Growth rate table R 
Genotype CIP GEN CAR 
wt  0.350 0.346 0.316 
CIPR 0.504 0.072 0.145 
GENR 0.443 0.494 0.287 
CARR 0.463 0.234 0.491 
 
Some mutant growth rates were lower than those of the wt on particular antibiotics, denoting 
collateral sensitivity, and consistent with our previous findings (26). Higher mutant growth rates 
denoted resistance and cross-resistance. 
Switches between antibiotics allowed for hysteresis effects, which we included in the model by 
multiplicating the respective growth rates from table R with the corresponding entry from the 
hysteresis landscape table H, experimentally inferred for wt and the individual resistant mutants 
(figs. S10, S11). 
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Hysteresis landscape table H 
 Switch of treatments 
 
CIP-
>CIP 
GEN-
>CIP 
CAR-
>CIP 
CIP-
>GEN 
GEN-
>GEN 
CAR-
>GEN 
CIP-
>CAR 
GEN-
>CAR 
CAR-
>CAR 
wt  1 1.63 1.18 0.15 1 -0.36 1.09 1.15 1 
CIPR 1 1.05 1.26 0.62 1 -0.21 1.47 1.37 1 
GENR 1 0.94 1.14 0.96 1 1.22 1.01 1.12 1 
CARR 1 0.85 1.01 1.05 1 1.42 0.99 0.99 1 
 
Using this model, we generated growth dynamics for mixed populations for the different 
treatment sequences of the evolution experiment (Fig. 2A). We re-modeled the growth dynamics 
with a derivate model, in which matrix H was replaced by multiplication with 1, thereby excluding 
hysteresis effects. From the modeled dynamics we inferred i) the strength of selection, using the 
cell density of the sensitive wt, and ii) the within-population diversity, as calculated from Shannon 
entropy.  
The modeled growth dynamics are shown in Fig. S12 and Fig. S13, inferred strength of selection 
in Fig. S12, and within-population diversity in Fig. 3G. 
 
Resistance measurements for evolved populations. 
Populations were characterized after transfers 12 and 48, because the variation in evolutionary 
dynamics among treatments was most pronounced just before transfer 12 and then gradually 
decreased until they became insignificant after approximately transfer 48 (Fig. 2C). Evolved 
populations were thawed, mixed and plated on LB plates after serial dilution in PBS. Plates were 
incubated for 30h at 37°C to enable appearance of slow-growing colonies. Isolates were picked in 
an unbiased way: before picking, the plate was sectored, and 20 (for the initial screen) or five (for 
the extension of the analysis) colonies were labeled for picking using a randomized scheme. Due 
to the high number of colonies, we restricted resistance measurements to a subset of populations, 
as described below. 
Initial screen: For feasibility, we focused on one population descended from a specific starting 
culture (culture ‘b’), which was selected because it had surviving descendent populations for all 
sequences. We randomly chose one of the two technical replicates per biological replicates for 
strain isolation. The high number of isolates for each population allowed us to assess the 
phenotypic within-population diversity. In brief, we used hierarchical clustering to identify 
phenotypic sub-populations that differed in resistance profiles (see Statistics for details). The 
clustering yielded 1-4 clusters per population, with different frequencies (Fig. 4C). The isolate 
counts for the clusters were used to calculate the total within-population diversity using Shannon 
entropy (‘Shannon diversity’).  
Extension of the analysis: We randomly chose 48 additional populations from the other starting 
cultures (3 per sequence). We avoided to sample descendants from starting culture ‘f’ (extinction 
of all populations from sequence #4) and ‘a’ (generally very high extinction frequencies across 
sequences). Due to extinction and the restriction by starting cultures, we only tested two 
additional populations for sequences #11 and #16, and one additional lineage for #7.  
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We measured antibiotic dose-response curves for a total of 880 evolved isolates on CIP, GEN and 
CAR. Isolates were grown in 2ml M9, diluted to standard cell density (OD600 = 0.08) and added to 
96-well plates containing eight concentrations of antibiotic from 1/8 MIC to 16x MIC. Treatment 
combinations were all randomized systematically. On each plate, we included two controls of the 
ancestral strain P. aeruginosa PA14. Plates were incubated for 12h at 37°C and 1350 rpm shaking 
on microplate shakers (Heidolph Instruments, Germany; Ref. Titramax 100, 1mm orbital), after 
which we measured growth by optical density (OD600). Resistance values were calculated as the 
area between dose-response curves of the isolates and those of the PA14 controls measured on 
the same plate. A resistance value of zero denotes no resistance, negative values denote hyper-
sensitivity and positive values denote resistance. The advantage of this value as compared to MIC 
is that it is a continuous variable rather than an ordinal variable.  
To compare the efficacy of different treatments using a single value we defined multidrug 
resistance scores (MDR) as the sum of resistance values on the three antibiotics. MDR scores 
represent the distance to the sensitive strain in a three-dimensional resistance space with axes 
for CIPR, GENR and CARR. 
Before the assay, we checked for the existence of spatial gradients in the incubators. We found no 
spatial gradients for fluoroquinolones, beta-lactams or growth without antibiotics. However, we 
found a spatial gradient for aminoglycosides. The gradient occurred between different shelves in 
the incubator, but not within one shelf. We controlled for this gradient, by always incubating 
plates of a given antibiotic on the same shelf.  
Resistance data of the initial screen is shown in figs. 3A, 3B, and 3E. Calculated MDR including the 
additional samples from the extension of the analysis is presented in figs. 3E, 3F, and 4A. Diversity 
data is shown in Fig. 3C. 
 
Measurements of growth rates under drug-free conditions 
We measured maximum exponential growth rates of the sub-populations from the initial 
resistance screen under drug-free conditions. For feasibility, growth rates of sub-populations 
were determined with representative isolates (1-4 isolates per population and time point). The 
values reported in Fig. 3D represent the mean of the measured isolates, weighted by the relative 
proportions of the respective sub-populations. Growth rates were calculated from growth curves 
obtained in 96-well plates, using BioTek plate readers. Prior to measurements, we sub-cultured 
the samples in the plate readers for 16h to allow them to adjust to assay conditions. Immediately 
after end of incubation, cultures were diluted 1000x and re-incubated for 24h during which we 
measured OD600 every 15 min (measurements in triplicate). Sample positions were randomized. 
Reference cultures of P. aeruginosa PA14 were included in every run. Maximum exponential 
growth rates were determined using a sliding window approach. We calculated specific growth 
rate k in sliding windows of size 0.5h, yielding hill-shaped curves with two peaks, a first peak for 
growth on glucose and a second peak for growth on citrate (figs. S7 and S8). The growth rates 
reported in Fig. 3D are the maximum values of the first, larger peak. This procedure was found to 
yield more reproducible results than measurements in defined OD600-windows. Prior to the 
experiment, we checked for the existence of spatial gradients, by measuring exponential growth 
rate for PA14. Spatial gradients were small, but we nevertheless created a function to correct 
systematic error. The inferred growth rates are shown in figs. 3D, S7, and S8. 
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Genomics 
We whole-genome sequenced 30 evolved isolates from different sub-populations as identified by 
the resistance measurements of the initial screen. We included all sub-populations for the early 
time point, and the 3 sub-populations of sequence #8 at the late time point. DNA was isolated from 
5ml cultures that were prepared from single colonies with a cetyltrimethylammonium bromide-
based protocol (29). To verify that the colonies had the previously measured resistance profile, 
we repeated resistance measurements on the cultures from which DNA was extracted (Fig. S9). 
Sequencing was performed by the Institute for Clinical Molecular Biology (ICMB) Kiel, using the 
Illumina MiSeq 2x150bp paired-end technology and NexteraXT library preparation.  
Paired reads were filtered with Trimmomatic (30) and mapped against the UCBPP_PA14 reference 
genome (31) with Bowtie2 (32). Variants were called using the function mpileup from SAMtools 
(33) and filtered by Vcftools (MinQ = 40) (34). We subtracted all mutations already present in our 
previously sequenced lab strain (26). Gene annotations were improved by BLASTing genes 
against the better annotated reference genome of P. aeruginosa PAO1. Additional annotation of 
variants was done with customized python scripts. Intergenic regions containing mutations were 
analyzed for the presence of promoter motifs using PePPER (35).  
All intergenic mutations outside of promoter regions were excluded from analyses. Samples 
shared mutations in the genes PA14_61200 and PA14_38000, both annotated ‘hypothetical 
protein’. These mutations were excluded from analyses. The resulting list of variable sites is 
provided in Table S1 and illustrated in Fig. S15 and Fig. S16. 
 
Annotation of gene PA3206 (PA14_22730) as a new two-component sensor “cpxS” 
Mutations in the previously uncharacterized gene PA3206 (PA14_22730) were indicated to 
contribute centrally to the evolutionary response to negative hysteresis (Fig. 4). Therefore, we 
sought to obtain a more detailed understanding of the function of this gene. We started by 
analyzing its genomic context in Pseudomonas aeruginosa. PA3206 is in close proximity to PA3204 
and PA3205 (Fig. S18A), which have recently been annotated “cpxR” and “cpxP”, respectively (36). 
CpxR forms a two-component regulatory system with the sensor CpxA that is negatively regulated 
by CpxP in Escherichia coli (20) (Fig. S18C). In E. coli it is activated by misfolded proteins, as 
generated by aminoglycosides (19), and CpxA-CpxR is involved in intrinsic resistance to these 
drugs (20). The genomic location suggested that PA3206 may be a homolog of cpxA. However, 
sequence identity between CpxA from E. coli MG1655 (NCBI Gene [uid] 948405) and PA3206 from 
PA14 was only 30%. We BLASTED the protein sequence of CpxA from MG1655 against all proteins 
in the NCBI database from P. aeruginosa. Alignments only started at residue 160, indicating 
differences in the N-terminal sensor domain. Indeed, the best hits were ParS, a different two-
component sensor, suggesting that PA3206 is distinct from CpxA. This was confirmed by 
phmmmer (37) analysis (aligning CpxA from MG1655 against P. aeruginosa proteins): the N-
terminal periplasmic sensor domain has different structure, and also differs with respect to 
length, the number of transmembrane domains and the presence of a signal peptide (Fig. S18B 
and S18E). This line of evidence was further confirmed by a phylogenetic sequence comparison 
of PA3206 with all genes that were annotated “cpxA” in the NCBI Gene database (search 
“cpxA[sym]”) using clustal-omega (38). We used protein sequences of the closely related two-
component sensor “EnvZ” as outgroup (Fig. S18D). We conclude that PA3206 is a new gene, which 
we here name “cpxS”. We decided to keep the base-name due to its genomic context. The “S” 
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denotes that it is the sensor-component of a putative envelope stress-system CpxS-CpxR in P. 
aeruginosa. The de-novo mutations in this study targeted the putative periplasmic sensor domain 
(Fig. S14F), which showed very little resemblance to the canonical sensor cpxA in E. coli, 
Salmonella enterica, Yersinia pestis and P. fluorescens (Fig. S18B and S18E), possibly indicating a 
currently unknown sensor function. 
 
Re-construction of mutations 
Slow-regular cycling was associated with mutations in mexR, and fast-regular cycling was 
associated with mutations in cpxS (homolog of PA3206 in reference strain PAO1). For functional 
characterization, we chose one variant of each gene: mutation 486113T>G = mexR c.388T>G 
p.T130P (sequence #10 isolates 12-1b-A2-4; #10-1 in Fig. 5B; and 12-1b-A2-8 ; #10-2 in Fig. 4B) 
and mutation 1977519T>G = cpxS c.487T>G p.T163P (sequence #7 isolates 12-1b-F2-4; #7-1 in 
Fig. 4B; and 12-1b-F2-3; #7-2 in Fig. 4B). The two mutations were individually introduced into 
the genetic background of the ancestral P. aeruginosa PA14 strain using a scar-free recombination 
method (39). The work was performed by V. Trebosc and C. Kemmer from the company BioVersys 
AG (Hochbergerstrasse 60c, CH-4057 Basel, Switzerland). Mutations were confirmed by Sanger 
sequencing.  
 
Measurement of hysteresis in mutants 
Exponential phase cultures were prepared and pre-treated as described in section “Time-kill 
experiments and hysteresis measurements”.  
Growth rate: Cultures were diluted 1:10 into 96-well plates and growth curves in the presence of 
GEN 420 ng/ml (sub-lethal) were acquired with BioTek plate-readers (37°C, 180rpm orbital 
shaking, OD600 every 15 min for 20h). Growth dynamics are shown in Fig. 4C. 
Flow cytometry: Cells were re-suspended in GEN 420 ng/ml (sub-lethal) and incubated at 37°C. 
Samples were taken in hourly intervals and population survival was assessed using Live/Dead 
staining with the fluorescent dyes Propidium iodide 12.5 µg/ml (Sigma-Aldrich, USA; Ref. P4170-
25MG) and Thiazole Orange 0.4 µg/ml (Sigma-Aldrich, USA; Ref. 390062-250MG). For staining, 
cells were diluted 25x and incubated in PBS containing the dyes for 10 minutes. Samples were 
then diluted 40x and the proportion of dead cells was scored by flow cytometry (Guava EasyCyte 
HT Blue-Green, Merck KGaA, Darmstadt, Germany). Thresholds were set using side scatter (SSC = 
4) and 5000 events were acquired for each sample using low flow rate 0.24µl/s. Counting gates 
were set in green and red fluorescence channels. Samples were measured with three technical 
replicates. Flow cytometry data is shown in Fig. 4D. 
 
Measurement of tolerance  
Antibiotic tolerance was assessed for isolate 12-1a-E2-4 (isolated after transfer 12 from sequence 
#12) via minimal duration of killing (MDK), as previously described (17). MDK90 and MDK99 
values were obtained from time-kill experiments with CIP 50 ng/ml, GEN 500 ng/ml and CAR 100 
µg/ml. Time-kill data und calculated MDK-values are presented in Fig. 4B and Table S3, 
respectively. 
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Replay evolution experiment and resistance measurements of evolved populations 
The replay evolution experiment was conducted as described for the main evolution experiment, 
except that it was started from single starting culture of P. aeruginosa PA14 and lasted 12 
transfers only, as we were interested in the clinically relevant phase of the adaptive dynamics. We 
included 12 replicates for each of five treatment groups: untreated references, sequences #12, 
#12rev, #13 and #13rev. Sequences #12 and #13 were the same as the first 12 transfers in the 
main experiment, and sequences #12rev and #13rev were their respective reverse sequences. 
Sequences #12 and #13 were selected for this experiment because they differed in their level of 
hysteresis and produced different levels of MDR in the main evolution experiment. Importantly, 
the sequences individually started and ended with the same antibiotic. 
Frequencies of population extinction were determined after transfer 12 by counting the cases in 
which no growth was observed after inoculation of drug-free media and incubation for 24h. 
Resistance of all surviving evolved populations was measured as described above after sub-
culturing in 5ml M9 (inoculated with 20µl of the frozen populations) and with two technical 
replicates. Resistance was quantified by the fold-changes in IC75. To assess whether reversing drug 
order altered resistance levels, we calculated the relative change in mean resistance for the two 
sequence pairs (fold-IC75FORWARD/fold-IC75REVERSE x 100%). Calculated resistance changes and 
extinction frequencies reported in Fig. 5B and Fig. 5C. 
 
Statistical Analysis 
Data analysis and statistics were performed with the statistics software R (40). Additional 
information of the statistics is provided in the accompanying Excel file, which contains a separate 
sheet for each of the performed statistical analyses. 
Evolutionary dynamics: The efficacy of cycling strategies to constrain adaptation was statistically 
assessed using mixed linear models (GLMM, R package ‘nlme’ (41)) with relative AUC (see 
methods; ‘Relative biomass’ in Fig. 2C) as response variable, sequence and transfer as fixed 
factors, and starting culture and population as random factors nested in treatment. Due to 
extinction and populations that started growing late (putative persisters) relative AUC had a 
bimodal distribution (Fig. S3). We removed bimodality by excluding extinct and persister 
populations from the analysis. Thereby, our analysis is statistically conservative, because 
extinction and persister frequencies were higher in fast-regular and random treatments. We 
divided analysis for three phases of the evolutionary dynamics: ‘early’ = transfers 1-12, ‘mid’ = 
transfers 13-48 and ‘late’ = transfers 49-96. This splitting was necessary because the evolutionary 
dynamics were non-linear. It removed structure from model residuals, which were normally 
distributed (Fig. S4). P-values were obtained from post hoc tests (function ‘glht’ from R package 
multcomp (42)) and corrected for multiple testing using false-discovery rate (FDR).  
Extinction: We tested for significant differences in extinction frequencies between random, fast-
regular and slow-regular cycling using Fisher’s exact test and total counts of extinct and surviving 
populations for the cycling strategies. 
Identification of sub-populations: Sub-populations were identified by hierarchical clustering of the 
resistance profiles of isolates from the same population and time point with the R package pvclust 
(43): method = ‘average’, ‘euclidean’ distances. Different clustering algorithms (‘median’, 
‘ward.D2’) yielded the same clusters. This analysis identified groups of isolates that share dose-
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responses that are correlated between antibiotics. Isolates were added to a new cluster if they had 
a height larger than the threshold of h = 0.2. After applying clustering with this threshold, the 
residual variation in dose-response curves was lower than that of the isogenic strain PA14. 
Population diversity: We tested whether populations from monotherapies, the no-drug reference, 
random, fast-regular, and slow-regular cycling (all pair-wise comparisons) had significantly 
different within-population diversities (Shannon entropy) using GLMM and post-hoc tests. The 
model had Shannon entropy as response variable, sequence as fixed factor and time point as 
nested random factor. We tested whether there were differences in diversity between random 
and fast-regular cycling and between random and slow-regular cycling, using the same model. P-
values were adjusted for multiple testing by FDR. 
Growth rate under drug-free conditions: We tested whether there were significant differences in 
relative exponential growth rates between populations from random and fast-regular cycling, 
slow-regular cycling (all pair-wise comparisons) after transfers 12 and 48 using GLMM and post-
hoc tests. The model had relative exponential growth rate as response variable, sequence as fixed 
factor and population as nested random factor. P-values were adjusted for multiple testing by 
FDR. 
Multidrug resistance: We tested for significant differences in MDR after transfer 12 between 
random, fast-regular and slow-regular sequences using GLMM and post-hoc tests. The model had 
MDR as response variable, sequence as fixed factor and population as nested random factor. P-
values were adjusted for multiple testing by FDR. We also tested whether MDR in sequence #12 
was significantly different from that of the ancestor using GLMM and post-hoc tests. The model 
had resistance as response variable, treatment group (ancestor or sequence #12) and antibiotic 
as fixed factors and population as nested random factor. 
Overrepresentation of mutational targets: We statistically identified genes that were over-
represented among sequenced isolates from slow-regular or fast-regular cycling using Fisher’s 
exact test and counts for presence and absence of mutations in a focal gene from isolates. 
Resistance in re-play evolution: Fold-changes in IC75 were calculated from dose-response curves. 
We tested for significant differences in evolved resistance between sequences 12-12rev and 
sequences 13-13rev using GLMM and post-hoc tests. The model had fold-change IC75 as response 
variable, sequence as fixed factor and antibiotic as random factor.  
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Supplementary Figures 
 
 
Fig. S1. Short antibiotic exposures can inhibit killing by antibiotics in Pseudomonas 
aeruginosa. (A) Time-kill experiment with ciprofloxacin after 15min pre-treatments with non-
lethal concentrations of specified antibiotics. (B) Time-kill experiment with carbenicillin after 
15min pre-treatments with non-lethal concentrations of specified antibiotics. CIP, ciprofloxacin; 
GEN, gentamicin; CAR, carbenicillin; ctrl, control without pre-treatment; n = 6 technical replicates; 
bars represent mean ± SEM. 
 
 
 
 
Fig. S2.  Antagonistic drug-interaction (directional suppression) between ciprofloxacin and 
gentamicin in Pseudomonas aeruginosa. Values denote mean inhibition of growth, as 
determined by measurements of optical density (OD600) after 12h. Concentrations were spatially 
randomized in the checkerboard experiment. n = 3 technical replicates. 
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Fig. S3. Distribution of response variable for GLMM of evolutionary dynamics. Response 
variable relative biomass (relative AUC) showed a bimodal distribution. The bimodality was 
removed by only including survived populations in the statistical analyses. 
 
 
 
 
Fig. S4. QQ-plots of model-residuals from GLMM of evolutionary growth dynamics as 
reported in Fig. 2C and statistics file sheet 1. (A) Pearson model residuals of all treatments for 
early stage (transfers 1-12). (B) Pearson model residuals of all treatments for middle stage 
(transfers 13-48). (C) Pearson model residuals of all treatments for late stage (transfers 49-96). 
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Fig. S5. Variation in adaptive dynamics between sequences. In general, relative biomass 
increased the fastest in monotherapies and slow-regular sequences and less quickly in fast-
regular sequences. There is pronounced variation between random sequences, which includes the 
slowest adaptation. Extinct populations were excluded. Lines show means of surviving 
populations (n = 4-12 biological replicates) and shading denotes ±SEM. 
 
 
 
 
Fig. S6. Variation in the rates of biomass increase among sequences. The rate of biomass 
increase is defined as X-1, where X is the first transfer at which the mean relative biomass in a 
sliding window of 12 transfers increases to 0.75. See methods for details. Extinct populations 
excluded. 
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Fig. S7 Raw data from characterization of population 12-1a-D8 from fast-regular sequence 
#5. (A) Dose-response curves of 20 isolates and 4 ancestral controls. Isolates showed 
homogenous resistance profiles with low-level resistance. (B) Maximum exponential growth rate 
in media without antibiotics is decreased substantially, as determined using a sliding window 
approach. Inlay shows growth curve. Bars represent mean ± SEM, n = 3 technical replicates. (C) 
Dendrogram with results of hierarchical clustering. (D) Evolved genetic changes, as determined 
from whole-genome sequencing. (E) Plot indicating the relative frequency of different sub-
populations. In this case, the clustering analysis identified only a single sub-population. 
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Fig. S8. Raw data from characterization of population 12-1b-A8 from slow-regular 
sequence #9. (A) Dose-response curves of 20 isolates and 4 ancestral controls. Substantial 
between-isolate variation is found for resistance profiles. (B) Maximum exponential growth rate 
in media without antibiotics indicates larger fitness costs in the green sub-population, as 
determined using a sliding window approach. Inlay shows growth curves. Bars represent mean ± 
SEM, n = 3 technical replicates. (C) Dendrogram with results of hierarchical clustering, indicating 
presence of four clusters. (D) Genetic differences of clusters, as determined from whole-genome 
sequencing. (E) Relative frequency of the four sub-populations.  
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Fig. S9. Repeatability of resistance measurements. The measurements of resistance are highly 
reproducible: Linear model: y = f(x) = 0.96063x + 0.01916. R2 = 0.89. P <2.2E-16 (Pearson product-
moment correlation, t = 30.818, n = 120 biological replicates). Blue, linear model; black, diagonal 
with slope 1. 
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Fig. S10. Extension of hysteresis matrix for resistant genotypes from monotherapies. 
Hysteresis factors determined from time-kill experiments for evolved isolates resistant against 
ciprofloxacin, (CIPR), gentamicin (GENR) or carbenicillin (CARR). A superscript R denotes 
resistance against the respective antibiotic. CIP, ciprofloxacin; GEN, gentamicin; CAR, 
carbenicillin. The values are included in the mathematical model as shown in Fig. 3, figs. S12, S13. 
 
 
 
 
Fig. S11. Time-kill data of resistant types used for the calculation of the hysteresis 
landscape of evolved isolates from monotherapies. CIP, ciprofloxacin 40ng/ml; GEN, 
gentamicin 480 ng/ml; CAR, carbenicillin 50 µg/ml; ctrl, control without pre-treatment. 
  
97 
 
 
Fig. S12. Mathematical model predicts strong selection by hysteresis and reduced clonal 
interference in fast sequential treatments. (A) Evolutionary dynamics for fast-regular 
sequence #5 as produced by a deterministic model without hysteresis (- hys) or with hysteresis 
(+ hys). Superscript R, resistant type; wt, wildtype; CIP, ciprofloxacin; CAR, carbenicillin; GEN, 
gentamicin. (B) The strength of selection as inferred from the reduction in wt-cells is strongly 
increased by hysteresis.  
 
 
 
 
 
Fig. S13. Examples of modeled evolutionary dynamics for different cycling strategies. Model 
includes hysteresis. (A) Monotherapy sequence #1.  (B) Fast-regular sequence #5. (C) Slow-
regular sequence #8. (D) Best random sequence #12. (E) Worst random sequence #13. Colors 
denote antibiotics for the schematics and also the respective resistant types. CIP, ciprofloxacin; 
GEN, gentamicin; CAR, carbenicillin. 
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Fig. S14. Correlation between switching rate or hysteresis level with three measures of of 
treatment efficacy. For comparability, the correlations were restricted to all of the cycling 
sequences #5-16, but excluding monotherapies. The major determinants of treatment efficacy are 
indicated across the three rows. Shaded plots show significant Spearman rank sum correlations.  
 
  
99 
 
 
Fig. S15. Genetic basis of adaptation. Overlap of mutational targets among treatment types (as 
in Fig. 2A). Typeface and boldness indicate number of mutations in the gene. Genes with 
annotation “hypothetical protein” excluded. See Table S1 for raw data. 
 
 
 
 
Fig. S16. Schematic of cellular functions targeted by adaptive evolution. Resistance is mostly 
achieved by mutations in two-component regulators or through mutations in transcriptional 
regulators that control efflux pumps of different substrate specificities. FQ, fluoroquinolones; AG, 
aminoglycosides; BL, beta-lactams; PMF, proton motive force. Further details in Table S1 and Fig. 
S15. 
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Fig. S17. Dose response curves of evolved lineages #7-1, #7-2, #10-1, #10-2 and mutants 
cpxS T163P, mexR T130P as shown in Fig. 4B. CIP, ciprofloxacin; CAR, carbenicillin; GEN, 
gentamicin; wt, wildtype; mean ± SEM, n = 6-20 replicates. 
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Fig. S18. Annotation of PA3206 (PA14_22730) as a new two-component sensor called cpxS. 
(A) Genomic context of cpxA in Escherichia coli K12 MG1655 and PA3206 (PA14_22730) in 
Pseudomonas aeruginosa PA14, suggesting that PA14_22730 may be a homolog of cpxA, because 
of proximity to cpxR and a small periplasmic repressor protein resembling cpxP (36). (B) Protein 
domain structure of E. coli CpxA and P. aeruginosa PA3206, as predicted by phmmer. The proteins 
differ in length, their periplasmic sensor domain, and the number of transmembrane domains. (C) 
Schematic of the function and regulation of the two-component regulatory system CpxAR in E. coli 
(20). In E. coli, the envelope stress response system CpxA-CpxR is activated by misfolded proteins, 
as generated by aminoglycosides (19), and CpxA-CpxR is involved in intrinsic resistance to these 
drugs (20). (D) Phylogenetic tree of CpxA inferred from protein sequences using clustal-omega. 
Protein sequences of the two-component sensor EnvZ serves as outgroup. (E) Alignment of E. coli 
CpxA against all proteins from P. aeruginosa using phmmer shows very low coverage for the 
periplasmic sensor domain. In consideration of these differences, the structural variation, and the 
similarity to other two-component sensors, PA14_22730 is unlikely a true homolog of cpxA. (F) 
Mutational targets found in the evolved, genome-sequenced isolates are located in the putative 
sensor domain of PA3206 (indicated by stars, while colors denote the treatment types). Because 
similar levels of sequence identity exist to other two-component systems, but the genomic context 
indicates interaction with cpxR, we here name this P. aeruginosa gene “cpxS”, the “S” denoting that 
it is the sensor component of a putative envelope stress-system CpxS-CpxR in P. aeruginosa.  
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Fig. S19. Verification that hysteresis was triggered in the evolution experiment. Exponential 
growth rate of populations in slow-regular cycling between transfers 12 and 48. CIP, 
ciprofloxacin; GEN, gentamicin; CAR, carbenicillin. As predicted by the hysteresis landscape in Fig. 
1C, previous exposure to either CAR or CIP transiently inhibited growth rates on GEN (i.e., 
negative hysteresis ‘neg. hys.’, indicated by downwards arrows). The growth rates returned to 
baseline levels, after one transfer. Conversely, previous exposure to CAR or GEN caused transient 
spikes in growth rates on CIP before returning to baseline levels, which was also predicted from 
the hysteresis landscape, because previous exposures to CAR or GEN protected cells from CIP (i.e., 
positive hysteresis ‘pos. hys.’, indicated by upwards arrows). Previous exposures did not 
consistently affect growth rate on CAR, which agreed with the hysteresis factors that were close 
to 1 for switches to CAR. n = 10-12 biological replicates; bars represent mean ± SEM. Extinct and 
putative persister population excluded.  
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Table S1. Genetic changes compared to ancestral PA14 wt strain from whole-genome resequencing*. 
Treat
ment 
SE
Q 
Isolat
e 
POS REF ALT QUA
L 
Depth Feature ST Gene ID Product Type Mutation 
nucleotide 
Mutation  
amino acid 
Mono 
 
1 12-1a-
G8-3 
 
165
916
8 
G A 222 29 CDS - ywjB hypothetical protein sub_syn c.33G>A p.A11A 
542
818
9 
CT C 214 57 CDS + nfxB transcriptional regulator indel c.161delT p.L54Pfs9 
289
249
8 
C CA 44 16 CDS + gcvT2 glycine cleavage system 
protein 
indel c.589insA p.Y197Ifs232 
12-1a-
G8-5 
282
065
9 
TGCTCGGCGATGT
CTCCGCCACCCGC 
TGC 214 18 CDS + mexS oxidoreductase indel c.689_711del p.L230Rfs216 
2 
 
12-1b-
B2-8 
 
563
766
6 
G A 222 10 CDS + pmrB two-component sensor sub_non
syn 
c.983G>A p.R328H 
534
315
2 
G A 193 9 CDS + PA14_60000 hypothetical protein sub_non
syn 
c.409G>A p.D137N 
3 12-1b-
E8-3 
486
683 
C T 222 13 promote
r 
+ mexR_mexA mexA promoter sub Na Na 
No-
drug 
4 12-1a-
F8-20 
No 
mut. 
- - - - - Na - - - - - 
Fast-
reg. 
5 
 
12-1a-
D8-18 
 
197
744
4 
C T 222 28 CDS - cpxS = 
PA14_22730 
two-component sensor 
(homology to PA3206) 
sub_non
syn 
c.562C>T p.G188S 
624
276
0 
CTTGTCGCCAACC
TTCGGCG 
CCGCCCAGC 107 3 CDS - cycB cytochrome c5 indel c.235_255CTTGT
CGCCAACCTTCG
GCG>CCGCCCAG
C 
p.A79Gfs745 
6 
 
12-1a-
C2-13 
368
340
6 
T C 222 18 CDS + parS two-component sensor sub_non
syn 
c.455T>C p.V152A 
155
114
7 
GTCATGCCCGGAT GT 214 13 CDS - nalD TetR family transcriptional 
regulator 
indel c.461_471del p.H154Lfs89 
104 
 
7 12-1b-
F2-3 
342
117
8 
CGTTCGCACTTGA
GGT 
C 159 7 CDS - mexZ transcriptional regulator 
AmrR 
indel c.329_343del p.YLKCER110_C 
280
099
6 
CGCGCCGATCATG CG 136 5 CDS + catB muconate cycloisomerase I indel c.731_741del p.A244Gfs39 
197
751
9 
T G 86 4 CDS - cpxS = 
PA14_22730 
two-component sensor 
(homology to PA3206) 
sub_non
syn 
c.487T>G p.T163P 
317
569
5 
T TGGCCGA 55 14 promote
r 
- PA14_35700
_PA14_3571
0 
PA14_35700 promoter indel Na Na 
359
310
7 
CC CCCCTCACC 43 5 CDS - PA14_40260 hypothetical protein indel c.2833_2834insC
CTCACC 
p.G946Efs376 
12-1b-
F2-4 
280
099
6 
CGCGCCGATCATG CG 214 17 CDS + catB muconate cycloisomerase I indel c.731_741del p.A244Gfs39 
856
314 
AGCGTCACGCTGG AG 183 8 CDS + PA14_09960 hypothetical protein indel c.375_385del p.S125Rfs53 
197
751
9 
T G 125 5 CDS - cpxS = 
PA14_22730 
two-component sensor 
(homology to PA3206) 
sub_non
syn 
c.487T>G p.T163P 
Slow-
reg. 
8 12-1a-
B8-15 
123
684
1 
T C 222 14 CDS - pepA leucyl aminopeptidase sub_syn c.6T>C p.E2E 
368
334
2 
A C 222 16 CDS + parS two-component sensor sub_non
syn 
c.391A>C p.T131P 
289
249
8 
C CA 78 9 CDS + gcvT2 glycine cleavage system 
protein 
indel c.589insA p.Y197Ifs232 
370
748
4 
G GGTGCTGA 41 10 CDS + nirB assimilatory nitrite 
reductase large subunit 
indel c.1438_1439insG
TGCTGA 
p.V480Gfs359 
12-1a-
B8-18 
368
336
1 
T C 222 13 CDS + parS two-component sensor sub_non
syn 
c.410T>C p.L137P 
341
831
6 
GTAGCCCTCGGCG
CT 
G 123 5 CDS - galU UTP-glucose-1-phosphate 
uridylyltransferase 
indel c.769_782del p.S257Hfs96 
105 
 
341
832
9 
C CCTCGAT 41 2 CDS - galU UTP-glucose-1-phosphate 
uridylyltransferase 
indel c.769_770insCTC
GAT 
p.S257NRG 
48-1a-
B8-
*15 
563
732
0 
G A 222 15 CDS + pmrB two-component sensor sub_non
syn 
c.637G>A p.E213K 
155
122
1 
CACGAA CA 214 23 CDS - nalD TetR family transcriptional 
regulator 
indel c.400_403del p.F134Cfs25 
48-1a-
B8-
*18 
155
106
4 
GATCGAACAGGC G 214 22 CDS - nalD TetR family transcriptional 
regulator 
indel c.547_557del p.R182Pfs61 
48-1a-
B8-
*20 
123
684
1 
T C 177 7 CDS - pepA leucyl aminopeptidase sub_syn c.6T>C p.E2E 
368
334
2 
A C 165 8 CDS + parS two-component sensor sub_non
syn 
c.391A>C p.T131P 
9 12-1b-
A8-2 
486
467 
CGGG CGGGGG 214 16 CDS - mexR multidrug resistance operon 
repressor 
indel c.34insG p.A12Gfs106 
855
966 
C A 179 9 CDS + PA14_09960 hypothetical protein sub_non
syn 
c.25C>A p.R9S 
317
569
5 
T TGGCCGA 68 20 promote
r 
- PA14_35700
_PA14_3571
0 
PA14_35700 promoter indel Na Na 
12-1b-
A8-4 
855
966 
C A 222 19 CDS + PA14_09960 hypothetical protein sub_non
syn 
c.25C>A p.R9S 
12-1b-
A8-7 
394
814 
C T 222 12 CDS + ptsP phosphoenolpyruvate 
phosphotransferase 
sub_non
syn 
c.2045C>T p.P682L 
155
114
6 
GGTCATGCCCGGA
TG 
GG 214 18 CDS - nalD TetR family transcriptional 
regulator 
indel c.460_472del p.H154Pfs12 
317
569
5 
T TGGCCGA 74 15 promote
r 
- PA14_35700
_PA14_3571
0 
PA14_35700 promoter indel Na Na 
535
850
8 
CG C 51 17 CDS + PA14_60140 xerD-like integrase indel c.770delG p.R257Lfs172 
12-1b-
A8-9 
855
966 
C A 217 9 CDS + PA14_09960 hypothetical protein sub_non
syn 
c.25C>A p.R9S 
106 
 
411
666
9 
G T 41 11 CDS - PA14_46270 helicase sub_non
syn 
c.358G>T p.L120R 
411
666
8 
A C 40 11 CDS - PA14_46270 helicase sub_non
syn 
c.359A>C 
10 12-1b-
A2-4 
 
563
770
2 
A C 222 11 CDS + pmrB two-component sensor sub_non
syn 
c.1019A>C p.H340P 
486
113 
T G 221 9 CDS - mexR multidrug resistance operon 
repressor 
sub_non
syn 
c.388T>G p.T130P 
317
569
5 
T TGGCCGA 52 15 promote
r 
- PA14_35700
_PA14_3571
0 
PA14_35700 promoter indel Na Na 
12-1b-
A2-8 
486
113 
T G 222 14 CDS - mexR multidrug resistance operon 
repressor 
sub_non
syn 
c.388T>G p.T130P 
390
652
1 
CCCGCACGAGGCT
G 
C 214 15 CDS - PA14_43870 hypothetical protein indel c.786_798del p.S262Rfs28 
289
249
8 
C CA 76 10 CDS + gcvT2 glycine cleavage system 
protein 
indel c.589insA p.Y197Ifs232 
407
965
1 
G C 46 14 CDS - PA14_45890 RND efflux transporter 
(homology to PA1436, 
muxB) 
sub_syn c.612G>C p.T204T 
Rando
m 
11 12-1b-
C8-*3 
368
408
9 
G A 217 9 CDS + parS two-component sensor sub_non
syn 
c.1138G>A p.D380N 
12-1b-
C8-*4 
123
596
4 
TGGCGGCG TGGCG 214 14 CDS - pepA leucyl aminopeptidase indel c.878_880del p.A294del 
368
408
9 
G A 110 4 CDS + parS two-component sensor sub_non
syn 
c.1138G>A p.D380N 
12 12-1a-
E2-4 
999
954 
A C 222 14 CDS - ispA Geranyltranstransferase 
(isoprenyl biosynthesis) 
sub_non
syn 
c.745A>C p.Y249D 
289
249
8 
C CA 111 11 CDS + gcvT2 glycine cleavage system 
protein 
indel c.589insA p.Y197Ifs232 
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13 12-1b-
G2-16 
155
152
6 
T A 222 11 CDS - nalD TetR family transcriptional 
regulator 
sub_non
syn 
c.94T>A p.S32C 
259
205
0 
AT A 214 16 CDS - nuoG NADH dehydrogenase 
subunit G 
indel c.2134delT p.M712Cfs71 
14 12-1a-
D2-3 
467
880
7 
CGGTCAGTTGCGG
A 
C 165 8 CDS - aotJ arginine/ornithine binding 
protein 
indel c.602_618del p.P203Mfs76 
197
775
8 
CTTTCGT C 45 2 CDS - cpxS = 
PA14_22730 
two-component sensor 
(homology to PA3206) 
indel c.248CTTTCGT>
C 
p.S83Na 
12-1a-
D2-6 
342
111
9 
GTT GT 152 8 CDS - mexZ transcriptional regulator 
AmrR 
indel c.402delT p.Q134Hfs105 
197
775
8 
CTTTCGT C 64 3 CDS - cpxS = 
PA14_22730 
two-component sensor 
(homology to PA3206) 
indel c.248CTTTCGT>
C 
p.S83Na 
12-1a-
D2-7 
197
775
8 
CTTTCGT C 110 4 CDS - cpxS = 
PA14_22730 
two-component sensor 
(homology to PA3206) 
indel c.242_247del p.S83Na 
15 12-1b-
H2-17 
436
987
3 
A C 222 10 CDS - phoQ two-component sensor sub_non
syn 
c.779A>C p.V260G 
588
874
2 
GCGTC GCGTCGTC 214 16 CDS + PA14_66100 hypothetical protein indel c.1040_1041insG
TC 
p.347_348insS 
12-1b-
H2-18 
436
987
3 
A C 222 17 CDS - phoQ two-component sensor sub_non
syn 
c.779A>C p.V260G 
393
300
7 
AGGCGGCAACGGC
GGCAACGGCGGCA
ACGGCGGCAACGG
CGGCA 
AGGCGGCAACGGC
GGCAACGGCGGCA
ACGGCGGCAACGG
CGGCAACGGCGGC
A 
214 9 CDS + PA14_44190 sugar MFS transporter indel c.736_737insAC
GGCGGCA 
p.245_246insT
AA 
393
302
8 
CGGCAACGG CGGCAACGGTGGC
AACGG 
214 9 CDS + PA14_44190 sugar MFS transporter indel c.723_724insTG
GCAACGG 
p.241_242insG
GN 
589
344
5 
GGCGGTCGAGCG GGCG 193 7 CDS - wapH glycosyl transferase family 
protein 
indel c.1002_1009del p.L334Pfs340 
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16 12-1a-
H8-16 
550
556
8 
TGGGCCAGGGCCA
G 
TGGGCCAGGGCCA
GGGCCAG 
193 8 CDS - hemA glutamyl-tRNA reductase 
(tetrapyrrole biosynthesis) 
indel c.1215_1216insG
GCCAG 
p.409_410LA 
*Genetic changes compared to Pseudomonas aeruginosa PA14 wt strain as determined by whole-genome resequencing (Illumina MiSeq2x150bp PE, 
Nextera libraries). Intergenic mutations are listed if they affected promoter regions, which were identified using PePPER. Isolates are coded with AA-BB-
CC-DD: AA, transfer; BB, plate; CC, well; DD, colony. SEQ, sequence of antibiotics from evolution experiment; POS, position in genome; REF, allele in 
reference genome; ALT, alternative allele; QUAL, quality score; ST, strand; CDS, coding sequence; Na, not applicable.
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Table S2. Growth rate as determined from CFU-counts confirmed OD-based measurements. 
Phenotype Strain 
Doubling time 
CFUs (min) 
Fitness cfu 
% 
Relative growth 
rate OD600 
Ancestor PA14 41.5 100 1 
Tolerance 12-1a-E2-4  56.3 73 0.593 
CIPR 12-1a-G8-3  42.1 98 0.977 
GENR 12-1b-B2-8 49.4 84 0.976 
CARR 12-1b-E8-3 39.9 104 1.02 
A superscript R denotes resistance against the respective antibiotic. CIP, ciprofloxacin; GEN, 
gentamicin; CAR, carbenicillin. 
 
 
 
Table S3. Minimum duration for killing of tolerant isolate 12-1a-E2-4 (ispA Y249D). 
 CIP (50 ng/ml) CAR (100 µg/ml) GEN (500 ng/ml) GEN 500 ng/ml 
(pre-treated 
with CAR) 
Strain MDK90 MDK99 MDK90 MDK99 MDK90 MDK99 MDK90 MDK99 
wt 1.23 2.81 5.37 > 6 2.69 3.46 2.05 2.65 
ispA 2.62 > 6 5.85 > 6 > 6 > 6 > 6 > 6 
Time in hours to kill 90% (MDK90) or 99% (MDK99) of the starting cell population. 
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Statistics file 
 
Statistics sheet 1. Evolutionary dynamics. Results of post-hoc pairwise comparisons of main 
evolution treatments*. 
Comparison Estimate Std. error z p 
Early phase (transfers 1-12)     
mono-fast regular 1.13413 0.10973 10.335 <2e-16 
mono-slow regular 0.18123 0.08992 2.016 0.0438 
mono-random 1.74299 0.16655 10.465 <2e-16 
fast regular-slow regular -0.9529 0.1122 -8.493 <2e-16 
fast regular-random -0.52527 0.21391 -2.456 0.0169 
slow regular-random 1.38053 0.173 7.98 2.33E-15 
Middle phase (transfers 13-48)     
mono-fast regular 0.3245 0.11259 2.882 0.007901 
mono-slow regular 0.06362 0.09168 0.694 0.58529 
mono-random 0.66692 0.17155 3.888 0.000607 
fast regular-slow regular -0.26088 0.11437 -2.281 0.033823 
fast regular-random 0.01792 0.21932 0.082 0.934879 
slow regular-random 0.53968 0.17619 3.063 0.006574 
Late phase (transfers 49-96)     
mono-fast regular 0.37051 0.2488 1.489 0.2729 
mono-slow regular 0.03939 0.08272 0.476 0.7607 
mono-random 1.07341 0.41217 2.604 0.0552 
fast regular-slow regular -0.29173 0.25141 -1.16 0.3688 
fast regular-random 0.09809 0.41839 0.234 0.8146 
slow regular-random 0.87646 0.42195 2.077 0.1134 
* Post-hoc pairwise comparisons based on z statistics, following analysis of a general linear mixed model 
(GLMM), including relative biomass (relative AUC) as the response variable and sequence and transfer as 
fixed factors and starting culture and replicate population as nested random factors. All significant p values 
are shown in bold (p values were corrected for multiple testing using false discovery rate). 
 
 
Statistics sheet 2. Extinction events. Fishers’s exact tests*. 
Main treatment type Extinct Growth   
Fast – Slow     
fast regular 11 25 p = 0.01201 odds-ratio = 7.287493 
slow regular 2 34  CI95 = 1.407, 73.282 
Random – Fast      
random 11 25 p = 0.15 odds-ratio = 1.9834 
fast regular 13 59  CI95 = 0.70135, 5.564  
Random – Slow     
random 2 34 p = 0.137 odds-ratio = 0.2696 
slow regular 13 59  CI95 = 0.0279, 1.3024 
*All significant p values are shown in bold. 
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Statistics sheet 3. Diversity. Results of post-hoc pairwise comparisons of main evolution 
treatments*. 
Comparison Estimate Std. error z p 
Early phase (transfers 1-12)     
mono - fast regular 0.10791 0.15178 0.711 0.596391 
nodrug - fast regular -0.05418 0.21465 -0.252 0.80072 
random - fast regular 0.16393 0.13144 1.247 0.424684 
slow regular - fast regular 0.79392 0.15178 5.231 1.69E-06 
nodrug - mono -0.16209 0.21465 -0.755 0.596391 
random - mono 0.05602 0.13144 0.426 0.744392 
slow regular - mono 0.68601 0.15178 4.52 2.06E-05 
random - nodrug 0.21811 0.20078 1.086 0.462246 
slow regular - nodrug 0.8481 0.21465 3.951 0.000194 
slow regular - random 0.62999 0.13144 4.793 8.22E-06 
* Post-hoc pairwise comparisons based on z statistics, following analysis of a general linear mixed model 
(GLMM), including within population diversity (Shannon entropy) as the response variable and sequence 
as fixed factor and transfer as nested random factor. All significant p values are shown in bold (p values 
were corrected for multiple testing using false discovery rate). 
 
Statistics sheet 4. Repeatability of resistance measurements. Pearson’s product-moment 
correlation. 
t = 30.818, df = 118, p-value < 2.2E-16 
CI95 = 0.9192860, 0.9600694 
correlation coefficient = 0.943125 
coefficient of determination R2 = 0.889485 
Formula linear model: y = f(x) = 0.96063x + 0.01916 
 
Statistics sheet 5. Multidrug resistance. Results of post-hoc pairwise comparisons of main 
evolution treatments*. 
Comparison Estimate Std. error z p 
Early phase (after transfer 12)     
fast regular-slow regular -2.0795 0.8207 -2.534 0.0338 
fast regular-random -1.3771 1.4462 -0.952 0.341 
slow regular-random 2.7818 1.3965 1.992 0.0696 
Middle phase (after transfer 48)     
fast regular-slow regular -2.45 1.104 -2.219 0.0795 
fast regular-random -1.606 1.913 -0.84 0.4012 
slow regular-random 3.294 1.913 1.722 0.1275 
* Post-hoc pairwise comparisons based on z statistics, following analysis of a general linear mixed model 
(GLMM), including multidrug resistance (MDR) as the response variable and sequence as fixed factor and 
population as nested random factor. All significant p values are shown in bold (p values were corrected for 
multiple testing using false discovery rate). 
 
 
112 
Statistics sheet 6. Zero resistance sequence 12. Results of post-hoc pairwise comparisons of main 
evolution treatments*. 
Comparison Estimate Std. error z p 
Early phase (after transfer 12)     
sequence 12 - ancestor 0.03068 0.22932 0.134 0.894 
* Post-hoc pairwise comparisons based on z statistics, following analysis of a general linear mixed model 
(GLMM), including relative resistance as the response variable and treatment and antibiotic as fixed factor 
and population as nested random factor. All significant p values are shown in bold. 
 
 
Statistics sheet 7. Cumulative hysteresis influence correlates with MDR. Spearman’s rank 
correlation. 
S = 42, p-value = 0.0007719 
rho = 0.8531469 
coefficient of determination R2 = 0.7036527 (calculated via Pearson correlation) 
 
 
Statistics sheet 8. Growth rate. Dunnett test exponential growth rate*. 
Comparison Estimate Std. error z p 
Early phase (after transfer 12)     
fast regular - ancestor -0.05016 0.051515 -0.974 0.413 
mono - ancestor -0.0055 0.051515 -0.107 0.457 
nodrug - ancestor -0.02229 0.064992 -0.343 0.457 
random - ancestor -0.07863 0.047677 -1.649 0.248 
slow regular - ancestor -0.02872 0.050807 -0.565 0.457 
Middle phase (after transfer 48)     
fast regular - ancestor 0.002714 0.016832 0.161 0.61632 
mono - ancestor -0.02479 0.015288 -1.621 0.13121 
nodrug - ancestor 0.007714 0.026076 0.296 0.61632 
random - ancestor -0.04116 0.012624 -3.261 0.00278 
slow regular - ancestor -0.01089 0.01202 -0.906 0.30429 
* Post-hoc pairwise comparisons based on z statistics, following analysis of a general linear mixed model 
(GLMM), including mean exponential growth rate (k) as the response variable and main treatment type as 
fixed factor and sequence as nested random factor. All significant p values are shown in bold (p values were 
corrected for multiple testing using false discovery rate). 
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Statistics sheet 9. Genes overrepresented among mutated genes after transfer 12. Fishers’s 
exact tests*. 
Gene Present Absent   
cpxS     
fast regular 3 1 p = 0.02479 odds-ratio = 16.67657 
other 3 20  CI95 = 1.004, 1089.336 
mexR     
slow regular 3 5 p = 0.01915 odds-ratio = Inf 
other 0 19  CI95 = 1.137, Inf 
*All significant p values are shown in bold. 
 
 
Statistics sheet 10. Re-play evolution experiment (Lewontin). Results of post-hoc pairwise 
comparisons of main evolution treatments*. 
Comparison Estimate Std. error z p 
Early phase (after transfer 12)     
12rev - 12 <= 0 1.4609 0.5946 2.457 0.014 
13 - 13rev >= 0 -0.3286 0.8258 -0.398 0.655 
* Post-hoc pairwise comparisons based on z statistics, following analysis of a general linear mixed model 
(GLMM), including fold-change IC75 as the response variable and sequence as fixed factor and antibiotic as 
nested random factor. All significant p values are shown in bold. 
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Chapter 4 
Short-Form Paper prepared for Antimicrobial Agents Chemotherapy 
 
Sequential treatment with three β-lactams in Pseudomonas 
aeruginosa and the evolution of resistance 
Roderich Roemhild1,2 and Hinrich Schulenburg1,2 
1Department of Evolutionary Ecology and Genetics, Zoological Institute, CAU Kiel, Kiel, Germany; 
2Max-Planck-Institute for Evolutionary Biology, Plön, Germany 
 
Running title 
Sequential treatment with three β-lactams 
 
Abstract 
Multidrug treatments limit the emergence of resistance. Typically, these treatments involve drugs 
with distinct targets. We here investigate sequential therapy with three β-lactams and thus 
antibiotics with the same mechanism of action. Surprisingly, the tested sequential treatments 
produce high efficacy towards the pathogen Pseudomonas aeruginosa, possibly due to conflicting 
resistance mechanisms against the three drugs. Our findings point to novel treatment options. 
 
Main text 
Antibiotic resistance is a global challenge for chemotherapy. Resistance frequently evolves within 
patients in response to treatment. The emergence of resistance may be delayed by multidrug 
treatments, which limit the amount of beneficial mutations available for pathogen adaptation and 
in the case of sequential application can provide additional evolutionary constraints due to 
collateral sensitivity (1–4) and/or negative physiological responses induced by specific 
antibiotics (5, 6). Conventionally, multidrug treatments would avoid antibiotic from similar 
classes, with the rational of limiting the overlap in the respective sets of resistance mutations, and 
thus the ensuing cross-resistance. Yet, the dire need for new therapy has elicited a re-
consideration of previously avoided treatment options. Dual therapy with antibiotics targeting 
cell-wall synthesis is now being considered (7), and a first trial indicates improved treatment of 
methicillin-resistant S. aureus (MRSA) (8). We here investigated in-vitro the evolutionary adaptive 
response of Pseudomonas aeruginosa to triple -lactam sequential therapy, using serial transfer 
evolutionary experiments (Fig. 1).  
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Figure 1. Evolutionary response to triple sequential therapy with three β-lactams in Pseudomonas 
aeruginosa. (A) Chemical structure of the antibiotics with the shared β-lactam structure highlighted in 
dark. (B) Experimental setup with 16 different treatment protocols belonging to 4 general treatment types. 
Each protocol is evaluated with 12 replicates and drugs are dosed below MIC, at inhibitory concentration of 
75% (IC75). CAR, carbenicillin; CEF, cefsulodin; DOR, doripenem. (C) Treatment type determines treatment 
efficacy, as indicated by significantly higher extinction frequencies in fast-switching protocols. (D) 
Evolutionary growth improvements of surviving cultures during treatment (mean ± CI95; 3-6 sequences 
per treatment type and 12 biological replicates per sequence; extinct lineages excluded). 
 
Replicate cultures of P. aeruginosa PA14 (total = 188, derived from 6 colonies) were treated with 
low dose of bactericidal antibiotics, reducing growth to 25% of untreated controls (IC75, inhibitory 
concentration 75). Every 12h 2% of the cultures were transferred to fresh medium, containing 
either the same or a new antibiotic. The cultures were grown in 96-well plates, incubated in plate 
readers at 37°C and shaking (BioTek Instruments, USA; Ref. EON), with kinetic measurement of 
optical density at 600 nm (OD600) every 15 min for a total of 96 transfers. In this way we 
investigated the dynamics of resistance emergence in response to 16 different treatments, 
belonging to four mayor treatment types: monotherapy, fast-regular, slow-regular and random 
therapy (Fig. 1). The experiment precisely followed a setup that we previously used to test 
sequential treatments with antibiotics from different classes (6), yet in this experiment we used 
three -lactams that individually inhibit the DD-transpeptidase activity in cell-wall synthesis (9): 
carbenicillin (CAR), doripenem (DOR) and cefsulodin (CEF). The antibiotics have the same core 
structure, but differ in their side chains (Fig. 1A), which produces different susceptibilities to 
degradation by the chromosomal AmpC -lactamase of P. aeruginosa: AmpC cannot hydrolyze 
carbapenems like DOR, has low activity against cephalosporins like CEF, yet high activity against 
CAR (10).  
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Experimental cultures showed dichotomy in treatment response, with experimental lineages 
either going extinct (26%, 49/188) or evolving resistance against -lactam treatment (139/188, 
74%). Extinction occurred significantly more often in fast and random protocols (average 42%) 
compared to monotherapy or slow protocols (6%, Fig. 1C, Fisher’s exact tests, p < 0.0003). 
Intriguingly, the total percentage of dead cultures was 2-fold that observed in the previous 
experiment (27/190, 14%) (6), indicating a treatment advantage of converging on a single 
mechanism of action. Cultures that survived treatment rapidly evolved resistance against -
lactam treatment, following saturation dynamics. Within the first 12 transfers fast-regular 
protocols delayed increases in growth compared to all other treatment types (General linear 
mixed model, pairwise post-hoc tests, z > 2.46, p < 0.03, Supplementary Table 1), but thereafter 
there were no significant differences among main treatment types (Fig. 1D). We conclude that fast 
sequential treatments with three β-lactams increase extinction, but only mildly decelerate 
resistance evolution.  
The increased extinction in fast sequential treatments can theoretically be caused by two different 
processes: drug-induced negative physiological responses, or, alternatively, antagonistic 
pleiotropy of resistance mutations (collateral sensitivity within β-lactams). The data presented 
here, indicate that it is the latter. Physiological responses can be excluded in this context, because 
all three drugs are known to elicit a similar response, namely induction of AmpC (10). Likewise 
priming experiments showed no influence on killing rates (data not shown). A first line of 
evidence for the importance of collateral sensitivity is the requirement of several mutations for 
the emergence of triple resistance, demonstrated by the consecutive adaptation to the component 
drugs during triple exposure (Fig. 2A). Emergence of triple resistance in fast protocols occurs by 
sequential acquisition of resistance, first against CAR/CEF (i.e., CARR/CEFR) and later against DOR 
(i.e., DORR; Fig. 2A). The signature for antagonistic pleiotropy is slower growth improvement 
against particular antibiotics in fast-sequential compared to monotherapy, i.e. lower growth after 
a certain number of exposures to a particular antibiotic. This analysis reveals that triple sequential 
exposure accelerates adaptation against the antibiotics CAR and CEF, but delays the emergence of 
Figure 2. Growth dynamics in fast sequential protocols. 
(A) Evolutionary growth improvements for fast protocol #6 
during treatment, in more detail. Means of the 7 surviving 
cultures. Relative growth increases to the antibiotics at 
different rates. This demonstrates the consecutive evolution 
of resistance, and thus coexistence of genetic subpopulations. 
The resulting clonal interference may explain the drop in 
growth on CEF around transfer 50, and the subsequent 
oscillations in CEFR. (B) Mean difference of growth during 
exposures to particular antibiotics in fast sequential 
protocols #5-7, compared to growth in monotherapies after 
the same number of exposures to that drug. X-axis denotes 
exposures to particular antibiotic, and thus goes to 96/3 = 32. 
Triple exposure accelerates adaptation compared to 
monotherapy against CAR and CEF, but slows down 
adaptation against DOR. 
 
 
117 
DORR (Fig. 2B), indicating a genetic trade-off. The trade-off is supported by previous work on 
DORR, which is most commonly achieved by loss-of-function mutations in the porin OprD that 
catalyzes uptake of carbapenems (11). DOR appears to select on a narrow mutation space: In a 
previous experiment, all replicate populations treated with DOR produced resistance 
substitutions in OprD, and no other genes (3). The expression of OprD-mediated DORR depends 
on the activity of AmpC (12), which is often altered by mutations in penicillin binding proteins 
(13, 14) that confer CARR and CEFR (3). Conversely, OprD mutations cause collateral-sensitivity 
against other -lactams, especially CAR (3), which likely explains the increased extinction during 
fast sequential treatments. Altogether, the evolution of triple resistance is limited by the 
requirement of several mutations which involve mostly trade-ups, but also collateral sensitivity 
and epistasis.  
We conclude that triple sequential treatment of P. aeruginosa with -lactams has improved 
efficacy compared to monotherapy, because it elevates extinction. Treatment efficacy is limited 
over time, due to the rapid evolution of resistance. An interesting question for future work will be 
how the evolved resistance mutations affect susceptibility to antibiotics with different 
mechanisms of action. If the mutations do not increase cross-resistance, then triple therapy is a 
promising therapeutic option, because it can be applied with high efficacy while at the same time 
maintaining future treatment options with distinct antibiotic classes. 
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Supplementary Table 1. Results of post-hoc pairwise comparisons of main evolution 
treatments*. 
Comparison z p 
Early phase (transfers 1-12)   
mono-fast regular 2.695 0.0241 
mono-slow regular 0.243 0.9049 
mono-random 0.119 0.9049 
fast regular-slow regular -2.462 0.0276 
fast regular-random -2.650 0.0241 
slow regular-random -0.130 0.9049 
Middle phase (transfers 13-48)   
mono-fast regular 1.039 0.359 
mono-slow regular -1.242 0.359 
mono-random -1.095 0.359 
fast regular-slow regular -2.088 0.137 
fast regular-random -1.999 0.137 
slow regular-random 0.189 0.85 
Late phase (transfers 49-96)   
mono-fast regular 0.051 0.96 
mono-slow regular -0.665 0.641 
mono-random -1.710 0.389 
fast regular-slow regular -0.622 0.641 
fast regular-random -1.515 0.389 
slow regular-random -0.980 0.641 
* Post-hoc pairwise comparisons based on z statistics, following analysis of a general linear mixed 
model (GLMM), including relative growth as a the response variable and sequence and transfer as 
fixed factors and starting culture and replicate population as nested random factors. The defined 
model provided a better fit than a minimal model for all three phases (Likelihood ratio > 168, p < 
0.001). All significant p values are shown in bold (p values were corrected for multiple testing 
using false discovery rate). 
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General discussion 
The discovery of antibiotics in the last century revolutionized medicine and greatly reduced the 
fear of bacterial infections. However, the efficacy of antibiotics is inseparably linked to the 
selection of antibiotic resistance. The irrational use of antibiotics has thus culminated in a global 
pool of evolved resistant bacteria that are now considered the most pressing medical challenge of 
the century (Laxminarayan, 2014; Bundesministerium für Gesundheit, 2017). The antibiotic crisis 
is fueled by evolution, and thus by considering principles from evolutionary ecology we may be 
able to use antibiotics in new ways that inhibit the emergence of resistance (Baym, Stone, & 
Kishony, 2016). Sequential treatments – which I investigated in this dissertation – hold hope, as 
they can dynamically respond to bacterial adaptation or altogether divert adaptive priority away 
from resistance.  
Summary of investigations 
At the start of the project, we searched the literature for principles from evolutionary ecology that 
could limit resistance evolution, when applied in therapy (Chapter 1). We discovered a wealth of 
published data that had disappeared from common knowledge, and were not easily accessible 
because of changes in terminology. The result of our survey is that an integration of temporal 
variation in antibiotic therapy, i.e. sequential treatment protocols, has potential to limit resistance 
evolution. Sequential multidrug treatments may delay resistance emergence compared to 
combination and monotherapy because of selection dynamics that arise from temporal contrasts: 
i) Fluctuating selection increases clonal interference 
ii) Change of antibiotics can potentiate treatment due to cross-stress sensitivity 
iii) Change of antibiotics select for re-sensitization due to collateral sensitivity 
iv) Unpredictable changes limit fitness benefits from genetic and physiological 
correlations 
Most of the proposed ideas had not been tested as for their applicability in therapy or with 
sufficient sample size to reach statistically verifiable conclusions. The aspect that had received 
recent attention, was collateral sensitivity. It was argued in the literature that alternations of 
drugs with reciprocal collateral sensitivity serially re-sensitized bacteria to treatment (Imamovic 
& Sommer, 2013; Pál, Papp, & Lázár, 2015). We tested the evolutionary stability and thus the 
potential applicability of collateral sensitivity cycling in a relevant pathogen (Chapter 2). We 
discovered that, although collateral sensitivity generally constrained adaptation, P. aeruginosa 
could escape the re-sensitization cycle with varying degrees of difficulty. The stability of 
reciprocal collateral sensitivity was limited by switching order, and the total number of switches.  
We next tested how the other predicted parameters (switching rate, cross-stress sensitivity, and 
unpredictability) affected the dynamics of resistance evolution. To this end, we performed a small 
series of five evolution experiments, of which two have been analyzed and are presented as part 
of this dissertation. These two experiments differed in the applied antibiotics, which either had 
the same (Chapter 4) or different mechanisms of action (Chapter 3). Our overall results showed 
that temporal variation could slow down adaptation, however this result could not be generalized 
for all fluctuating treatments but instead depended on the specified sequence characteristics and 
antibiotics.  
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The experiments confirmed the anticipated high potential of P. aeruginosa for resistance 
evolution. Several populations evolved a multidrug resistant phenotype within 60 generations (12 
transfers, 6 days). The rapid adaptation occurred significantly more often in slow antibiotic 
cycling, which is therefore clearly sub-optimal, as additionally indicated by low extinction 
frequencies which were not significantly different from monotherapies.  
 
Figure 1. Fitness landscape in drug environments. Fitness landscapes are a simplified illustration of 
evolution originally introduced by Sewall Wright, 1932. Fitness (height) is a function of the genotype space 
(surface) and adaptation is the probabilistic movement on this surface as consequence of selection (slope). 
The superimposed arrows denote the most probable mutation trajectory (adaptive path) for a given 
antibiotic treatment strategy, that typically proceeds along the steepest slope (strongest selection). Short 
arrows indicate extinction events. In drug environments, a large amount of fitness is resistance (top layer). 
Antibiotic hysteresis adds a second fitness dimension. The low resistance gained during fast switching 
treatment can now be explained by the hill-climbing on the second layer, where fitness increases by 
evolving insensitivity to negative hysteresis. In reality, fitness landscapes are n-dimensional. The most 
important additional layer in this context is physiological growth rate (bottom layer). MDR, multidrug 
resistance; neg. hys., negative hysteresis; R1, R2, resistance against different antibiotics; TOL, antibiotic 
tolerance. 
 
Fast sequential treatments, however, had improved efficacy, with significantly increased 
extinction rates and slower resistance increases. There was variation according to drug order, 
which then was explained by physiological cross-stress interactions induced by particular 
antibiotics, which we call antibiotic hysteresis. Antibiotic hysteresis either protected cells from 
antibiotics (positive hysteresis), potentially buffering collateral sensitivity, or potentiated 
treatment (negative hysteresis). A potential mechanism for positive hysteresis is antibiotic-
specific induction of efflux pumps (Morita, Tomida, & Kawamura, 2014). Negative hysteresis 
occurs between many β-lactam and aminoglycoside antibiotics (recent experiments, data not 
shown), and is explained by β-lactam induced acceleration of aminoglycoside uptake (Plotz & 
Davis, 1962). 
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Hysteresis density in the sequential treatment protocols explained the contrasting adaptive 
responses to fast and slow antibiotic switching. The differences were caused by different adaptive 
priorities in two regimens and a genetic trade-off. The treatment protocols with high densities of 
negative hysteresis selected towards insensitivity to negative hysteresis, which was ultimately 
associated with low resistance or even tolerance. Conversely, evolved genotypes from slow 
switching treatments had multidrug resistance, but maintained sensitivity to negative hysteresis. 
Our findings thereby added a new dimension to fitness landscapes in drug environments (Figure 
1), and the ensuing competition of adaptive priorities between the fitness dimensions explained 
the most probable evolutionary outcome. Altogether, this indicated that the probabilistic 
evolutionary outcome can be modulated by changing hysteresis density. We tested this prediction 
with sequences of identical drug proportions and equal number of switches, but slightly different 
levels of negative hysteresis. Hysteresis effects were direction dependent, and the experimental 
test was performed by reversing two drug protocols and comparing their treatment efficacies. The 
obtained data confirmed that changes in hysteresis predictably altered treatment success and 
evolutionary dynamics. Altogether, negative hysteresis was a potent adaptive constraint for 
resistance evolution in our experiment, and could thus potentially be applied to limit resistance 
emergence during antibiotic therapy. 
In Chapter 4 we the complementary evolutionary dynamics to the experiments in Chapter 3, using 
sequential treatments with three β-lactam antibiotics. These drugs did not display negative 
hysteresis, but rather individually upregulated the expression of an intrinsic resistance 
determinant, the AmpC β-lactamase. Resistance evolution occurred at similar rates in fast, slow 
and random protocols. Surprisingly, we observed increased extinction rates in fast switching 
protocols. Indeed, extinction was generally increased 2-fold compared to the previous experiment 
in Chapter 3. The effect was explained by emergence of a strong genetic trade-off, in the most 
common resistance mechanism to one of the antibiotics, doripenem. Multidrug treatments with 
convergence on one mechanism of action may thus be an underappreciated treatment option. 
Altogether, our results indicate several ways to potentially increase the sustainability of antibiotic 
therapy, which are illustrated in Figure 2.  
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Figure 2. Treatments that impede emergence of multidrug resistance. (A) Collateral sensitivity cycling 
works for a single cycle, when treatment starts with the appropriate antibiotic. Patients receive several 
serial doses of an antibiotic, and treatment is then changed to exploit collateral sensitivity of the most 
common resistance mechanisms. The inversion selects for re-sensitization to the first antibiotic, which 
should be applied for a single dose only. AG, aminoglycoside; BL, β-lactam. (B) Sequential therapy with fast 
switching and antibiotics that have different mechanisms of action. Treatment efficacy is improved by 
antibiotic hysteresis. Two dosing regimens are recommended, serial or spaced administration. Serial 
administration uses three drugs, similar to the performed evolution experiments, with the risk of selecting 
multidrug resistant strains in the long-term. Spaced administration emphasizes negative hysteresis and 
keeps the third drug as backup. (C) Sequential therapy with three β-lactams aims at increased extinction. 
An emergence of β-lactam resistance can be countered by switching to antibiotics of a different class.  
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Applicability of sequential drug treatments 
How applicable are the postulated treatment strategies? Their clinical success is contingent on a 
variety of additional biological factors in vivo. These factors include, among others, differences in 
the environment, growth behavior, host factors, and pathogen population diversity. It is 
increasingly realized that antibiotic susceptibility depends on the physiological and metabolic 
state of the cell (Hughes & Andersson, 2017; Yang, Bening, & Collins, 2017), which may be altered 
in vivo. Growth in biofilms strongly decreases drug penetration and may thus enable persistence 
(Stewart, 2002). The adverse side-effects of antibiotics on bodily functions and the disturbance of 
gut microbiota put pharmacological constraints on multidrug treatments. Biological variation in 
pathogen isolates from the same patient (Wilder, Allada, & Schuster, 2009; Imamovic et al., 2018) 
complicates targeted treatment approaches. An ultimate answer as for the applicability of new 
treatment concepts can therefore only be achieved after thorough tests first in animal models and 
then in clinical trials. Nevertheless, some important indicators emerge from comparison with the 
literature. 
Collateral sensitivity cycling 
Our investigations suggest that the applicability of collateral sensitivity cycling may be limited by 
alternative evolutionary trajectories. Whilst the most common resistance mechanisms may cause 
collateral sensitivity, there are rare cost-free mutations (Kim, Lieberman, & Kishony, 2014; 
Barbosa et al., 2017). Collateral sensitivity cycling may thus restrict the substrate for adaptation, 
but does not serially re-sensitize pathogen populations, as originally postulated (Imamovic & 
Sommer, 2013). Our experiments show that the evolutionary stability of collateral sensitivity 
depends on the starting antibiotic. Aminoglycoside resistant strains were readily re-sensitized by 
selection with β-lactam, but β-lactam resistant populations maintained their original resistance 
when exposed to aminoglycosides. The observed history-dependence has important implications 
for therapy: collateral sensitivity cycling with the tested antibiotics can only be carried out for a 
single cycle (Figure 2A), which should then be concluded with a single dose of the first antibiotic. 
The order effect may be less pronounced with other drug pairs. For instance, Yen and Papin 
recently evaluated cycling with the ciprofloxacin (CIP) and piperacillin (PIP). The authors 
observed that CIPR populations of P. aeruginosa became re-sensitized by extended PIP selection, 
and vice-versa (Yen & Papin, 2017). CIP and PIP showed asymmetric collateral sensitivity, so that 
the re-sensitization may actually be explained by activity of other factors, e.g. reduced metabolic 
growth rate. 
An additional limitation of collateral sensitivity cycling is the high phenotypic diversity in clinical 
isolates. Replicate isolates from the same patient show pronounced variation with as for their 
resistance profiles (Imamovic et al., 2018). Whilst homogenous populations may predictably 
respond to treatment, it is difficult to anticipate the evolutionary trajectory of such diverse 
populations. Drug treatments will likely rather sort isolates, than steer evolution into exploitable 
trajectories. I conclude that the applicability of collateral sensitivity cycling is questionable 
because of the discussed limitations.  
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Multi-target sequential therapy 
In contrast, there are good indications for the applicability of faster sequential treatments with 
antibiotics of different classes. Previous work highlights that daily drug alternation can, with 
certain pairs of antibiotics, slow down the emergence of dual resistance (Perron, Gonzalez, & 
Buckling, 2007; Kim et al., 2014; Roemhild et al., 2015; Yoshida et al., 2017) and even cause 
extinction at sub-lethal dosage (Roemhild et al., 2015). Furthermore, sequential treatment 
showed increased potency in the treatment of biofilms (Rojo-Molinero et al., 2016), which 
resemble the lifestyle of many pathogens in vivo. The mechanistic explanation for the efficacy of 
fast switching treatments is unclear, although there are indications for drug-class specificity. For 
example, a fraction of drug pairs from a larger set suppressed the evolution of dual resistance in 
E. coli and all drug pairs that did so, included polymyxin (Yoshida et al., 2017). In alternating 
treatments of P. aeruginosa, exposure to cell-wall-targeting antibiotics slowed down growth 
increases on antibiotics with different targets (Roemhild et al., 2015). Several authors connected 
the efficacy of sequential treatments to collateral sensitivity and thus a property of selected 
genetic variants. Whilst this was a good predictor in a large data set (Yoshida et al., 2017), it was 
a poor predictor for other data sets (Kim et al., 2014; Roemhild et al., 2015). This variation 
suggests that additional factors contribute to the efficacy of fast sequential treatments. These may 
include fitness costs (Andersson & Levin, 1999), and epistasis (Weinreich et al., 2006); but also 
more immediate post-antibiotic effects (MacKenzie & Gould, 1993; Srimani et al., 2017), and 
antibiotic hysteresis. 
Although collateral sensitivity may generally limit resistance evolution by narrowing down the 
number of potential adaptive mutations, it does not explain, why fast switching inhibited 
resistance increases compared to slower switching. A decelerating effect caused by collateral 
sensitivity should theoretically increase with the frequency of resistant variants and thus interval 
length. Therefore, maximum inhibition is expected for slow switching. Yoshida et al. tested 4 drug 
pairs with three switching rates. If there were differences by switching rate, then they occurred 
in the opposite direction: resistance gains were lower for fast compared to slow cycling in two 
pairs (chloramphenicol/polymyxin, chloramphenicol/nitrofurantoin), but not in the other two 
(kanamycin/polymyxin, kanamycin/nalidixic acid). The four pairs differed with respect to their 
collateral sensitivity properties (Yoshida et al., 2017), which did not explain the observed 
differences. A more probable explanation – in line with my experimental findings in Chapter 3, – 
is drug-specific antibiotic hysteresis. Antibiotic hysteresis was cryptic in the experimental setup 
of Yoshida et al., because the authors did not measure growth rate or population size, but only 
increases of the MIC (minimal inhibitory concentration).  
Hysteresis may be an alternative explanation for the observed extinction during alternations of 
cefsulodin/gentamicin and doripenem/ciprofloxacin in P. aeruginosa (Roemhild et al., 2015), as 
indicated by two lines of evidence: antibiotic hysteresis is common with β-lactams (recent 
experiments; data not shown); collateral sensitivity is weak in these drug pairs, due to generally 
small effect size and sign-variation between alternative mutations (Roemhild et al., 2015; Barbosa 
et al., 2017).  
Kim et al. observed only mildly increased efficacy of drug alternation compared to monotherapy, 
along with high overlap in the selected mutation spectra (Kim et al., 2014). The small effect size 
may be a byproduct of the experimental procedure that excluded hysteresis effects, because 
bacteria were frozen and thawed at every transfer (Kim et al., 2014). Hysteresis effects are stable 
for several hours during antibiotic stress (Plotz & Davis, 1962), yet they rapidly disappear when 
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bacteria are in permissive conditions, typically lasting for ~1 generation (recent experiments, 
data not shown). Altogether, antibiotic hysteresis may substantially contribute to the decelerating 
effect of multi-target sequential treatments. To ensure immediate and long-term treatment 
benefits from antibiotic hysteresis, sequential therapy should avoid gaps during sequential drug 
exposures (Figure 2B overlapping concentrations). 
Intriguingly, the clinical applicability of negative hysteresis has been tested, unknowingly, in the 
treatment of chronic lung infections with P. aeruginosa in cystic fibrosis patients (Guggenbichler 
et al., 1988). Sequential dosing with a 4h gap (so called spaced administration) increased 
bactericidal effect 10-100x and delayed post-antibiotic regrowth compared to simultaneous 
dosing (combination treatment). Spaced administration enabled eradication of P. aeruginosa from 
the lungs, sometimes for up to a year, which was not achieved by combination treatments. Patient 
well-being improved during therapy and the authors did not notice unusual adverse effects 
(Guggenbichler et al., 1988). The clinical pharmacodynamics had good overlap to preliminary in 
vitro experiments (König et al., 1986). The used antibiotics were very similar and sometimes 
identical to those applied in the experiments of Chapter 3 and negative hysteresis was recently 
confirmed for these drugs in our lab (data not shown), indicating that the observed treatment 
efficacy was caused by antibiotic hysteresis. Nevertheless, additional research into the 
mechanism, generality, and specificity of hysteresis effects will help to further elucidate the 
applicability of spaced administration, especially in the treatment of infections by other 
pathogens. 
Single-target sequential therapy 
Sequential therapy with several β-lactams is a mostly unexplored treatment option. The strength 
of this approach is the elevated extinction probability (Chapter 4) that was achieved without 
selecting for broad multidrug resistance and therefore without the risk of restricting future 
treatment options. Emerging resistance against β-lactams may be countered by switching 
treatment (Figure 2) to drugs of a different class. Dual therapy with vancomycin and the β-lactam 
flucloxacillin has recently been successfully tested in the treatment of methicillin resistant 
Staphylococcus aureus (MRSA), in a multicenter clinical trial (Davis et al., 2016), which has elicited 
a reconsideration of β-lactam combinations for the treatment of refractory bacteremia (Bartash 
& Nori, 2017). Although the sequential dosing of several β-lactams has not been tested clinically, 
it may be comparatively easily implemented. The approach does not rely on antibiotic hysteresis, 
and therefore treatments do not need to ensure overlapping concentration windows. 
 
Outlook 
Solid in vivo data is required to justify the application of novel treatment strategies. Treatments 
with immediate benefits may altogether be more applicable because they improve treatment 
efficacy without the requirement for prior resistance emergence. Fast switching treatments with 
antibiotics of different classes may have potential for clinical application, because they are 
supported by independent in vitro studies. Their success in comparison to more slowly switching 
treatments, may largely be explained by antibiotic hysteresis, although this has thus far been 
concealed by experimental setups. It is important to recall that resistance increases were only 
inhibited with particular antibiotic pairs. Alternations of other drug pairs had only minor effects 
on adaptation rates and dual resistance evolved quickly (Kim et al., 2014; Yoshida et al., 2017). 
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Accurate prediction of the efficacy of drug pairs is thus vitally important, because failures will 
result in a multidrug resistant phenotype, rather obstructing therapy.  
Mathematical models can contribute to a better understanding of the evolutionary dynamics 
(Wahl & Krakauer, 2000; Traulsen & Hauert, 2009; Song et al., 2015) and may ultimately enable 
the quantitative prediction of treatment outcomes (Friedman, Higgins, & Gore, 2017). In Chapter 
3, we applied evolutionary models to investigate unexpected system behaviors. We had 
empirically observed low isolate diversity after fast switching treatments, which was opposite to 
our expectations. To gain a better understanding of the evolutionary dynamics during sequential 
treatments, we developed a deterministic mathematical model with evolving populations 
composed of mixture of different genotypes (drug-susceptible or various resistant genotypes). 
The genotypes were defined by growth rates, resistance, collateral sensitivity and response to 
antibiotic hysteresis. Intriguingly, this simple model connected the observed diversity to the 
activity of antibiotic hysteresis. Furthermore, the deterministic dynamics were sufficient to 
predict the evolved resistance levels (Chapter 3). Although, deterministic models are helpful, they 
do not reflect the stochastic nature of evolution, which is amplified by bottlenecks in serial 
transfer experiments (Wahl, Gerrish, & Saika-Voivod, 2002). Individual-based models with finite 
population size are a more appropriate representation, and can help to quantitatively assess the 
probability of populations ending in distinct pre-defined states, e.g. resistance against single or 
multiple antibiotics, and even antibiotic tolerance. Stochastic models may thus help to identify 
treatments with a high probability of favorable evolutionary outcomes.  
 
A cellular perspective 
The insights gained in this dissertation highlight the importance of physiological balance and thus 
homeostasis for bacterial evolution. Antibiotic priming was able to induce hypersensitivity to 
other antibiotics. Targeting the expression of intrinsic resistance determinants is key for the 
treatment of already resistant pathogens, which is becoming increasingly important due to the 
alarming spread of resistance. A promising research frontier may thus be the investigation of the 
regulation of intrinsic resistance determinants in pathogens. This research will help to understand 
the molecular mechanisms for antibiotic hysteresis and collateral sensitivity. Genomic data and 
literature suggest that in P. aeruginosa collateral sensitivity is caused by deviation from the 
natural balance in efflux pump expression. The expression of efflux systems is tightly 
interconnected; overproduction of certain pumps causes down-regulation of others (Li, Elkins, & 
Zgurskaya, 2016). Furthermore, their regulation is dependent on AmpC (Masuda et al., 2001), 
another important resistant determinant. Existing literature is a piecework of case studies, and a 
systems biology approach may help to understand these complex regulatory modules in their 
entirety. Thus, we may also begin to better understand the natural function of efflux pumps in the 
ecology of bacteria.  
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List of abbreviations 
 
CAR   carbenicillin 
CIP   ciprofloxacin 
CEF   cefsulodin 
CF   cystic fibrosis 
cfu  colony forming units 
CI95  confidence interval 95% 
CTAB  cetyl trimethyl ammonium bromide 
DMSO  dimethyl sulfoxid 
DNA   deoxyribonucleic acid 
DOR   doripenem 
GEN   gentamicin 
IC75   inhibitory concentration 75 
MIC   minimal inhibitory concentration 
MDR   multidrug resistance 
ppGpp   alarmone guanosin-3′5′-bispyrophosphat 
PIT   piperacillin and tazobactam 
RNA   ribonucleic acid 
SEM  standard error of the mean 
SNP   single nucleotide polymorphism 
STR   streptomycin 
TOL   antibiotic tolerance 
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Special devices, materials and chemicals 
 
Plate readers  BioTek Instruments, USA; Ref. EON 
Microplate Shakers  Heidolph Instruments, Germany; Ref. Titramax 100, 1mm orbital 
Flow Cytometer Guava EasyCyte HT Blue-Green, Merck KGaA, Darmstadt, Germany  
   40mW 532nm green laser, 75 mW 488 nm blue laser 
Climate chamber  for incubation agar plates 35°C, 60% relative humidity 
 
96-well plates (Greiner Bio-One, Germany; Ref. 655161) 
Optically clear, sterile sealing foil (Sarstedt, Germany; Ref. 95.1994) 
Freezing foil AlumasealCS, DMSO-resistant (Sigma-Aldrich, USA; Ref. Z722642-50EA) 
 
 
Table 1. Chemicals relevant to doctoral thesis. 
Name Chemical Stock 
mg/ml 
Solvent Storage Order 
information 
Typical working 
concentration 
CAR Carbenicillin 
disodium salt 
50 50% 
Ethanol 
prepare 
fresh 
Roth 
Ref. 6344.2 
IC75 = 50 µg/ml 
CIP Ciprofloxacin 25 0.1M HCl -20°C Sigma-Aldrich 
Ref. 17850-5G-F 
IC75 = 40 ng/ml  
CEF Cefsulodin 
sodium salt 
20 water -20°C, 
light 
sensitive 
Roth  
Ref. 4014.2-
250MG 
IC75 = 0.4 µg/ml 
DOR Doripenem 
monohydrate 
25 water -20°C Sigma-Aldrich  
Ref. 32138-25MG 
IC75 = 30 ng/ml 
GEN Gentamicin 
solution 
50 comes in 
solution 
4°C Roth;  
Ref. HN09.1 
IC75 = 480 ng/ml 
PIP Piperacillin 
sodium salt 
50 water prepare 
fresh 
Sigma-Aldrich  
Ref. P8396-1G 
IC75 = 1.2 µg/ml 
TAZ Tazobactam 
sodium salt 
10 water 4°C Sigma-Aldrich 
Ref. T2820-10MG 
4 µg/ml 
STR Streptomycin 
sulfate salt 
25 water -20°C Sigma-Aldrich 
Ref. S6501-5G 
IC75 = 11 µg/ml 
PI Propidium 
iodide 
1.25 water -20°C Sigma-Aldrich 
Ref. P4170-25MG 
12.5 µg/ml 
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Minimal medium M9, defined growth medium for P. aeruginosa with glucose (2g/l), citrate 
(0.5g/l) and casamino acids (1g/l), prepared from two separately autoclaved stocks (Parts A, B), 
sterile-filtered glucose and casamino acids, and autoclaved deionized water.  
- Part A (50x) per liter 350g K2HPO4, 100g KH2PO4  
- Part B (50x) per liter 29.4g Na3(citrate) x 2 H2O, 50g (NH4)2SO4, 5g/l MgSO4 x 7 H2O 
- Glucose (100x), 50ml water, 10g D(+)-glucose monohydrate (Merck; Ref. 1.08342.1000) 
- Casamino acids (100x), 50ml water, 5g casamino hydrolysate (Roth; Ref. AE41.1) 
 
Lysogeny broth (LB), Lennox 5 g/l NaCl (Roth; Ref. X964.2) 
Lysogeny broth agar (LA plates), Lennox 5 g/l NaCl, 1.5% Agar-Agar (Roth; Ref. X965.3) 
Saline, 0.85% NaCl 
PBS, phosphate buffered saline, per liter 8.77g NaCl, 2.24g KCl, 0.69g NaH2PO4 x H2O, 0.89g 
Na2HPO4 x 2H2O, set to pH 7.0 
 
Cfu-counting: LA plates, samples spread by glass beads (~20 per plate) 
Freezing bacteria: -80°C in 10% DMSO (v/v) 
Polymerase Chain Reaction (PCR): Phusion polymerase (Thermo Fisher; F530S) 
DNA isolation: CTAB protocol, as modified by Carola Petersen 
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